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CARDIOVASCULAR DISEASES – HEALTH AND ECONOMIC BURDEN IN DEVELOPED 
COUNTRIES 
Cardiovascular diseases (CVD) comprise disorders that affect the heart, blood vessels or 
both. Some of the most common CVD disorders are coronary heart disease ((CHD) i.e. 
stable angina and acute coronary syndrome (ACS)), cerebrovascular disease (i.e. transient 
ischemic attack and stroke), peripheral arterial disease, rheumatic heart disease, 
congenital heart disease, heart failure (HF), venous thromboembolism (VTE) (1).  
CVD had a leading position in contribution to global disease burden among the non-
communicable diseases in the last couple of decades. In 2008, 17 million persons died 
from CVD worldwide. However, in some developed countries, a declining trend of CVD 
mortality rates is observed in recent years. In the Netherlands, CVD are now the second 
largest cause of death accounting for 29% of total deaths after cancer being the first with 
a toll of 33% of total deaths (1). This significant drop in CVD mortality, reaching almost 
50% in both men and women in the Netherlands, might be explained by the advances in 
both treatment and CVD prevention strategies (2-4). Nevertheless, hospital admissions 
due to CVD do not seem to follow the mortality trend and remain high (5). Moreover, 
patients who experience non-fatal CVD events are severely affected with disability and 
impairment of health-related quality of life (HRQoL). For example HRQol of patients after a 
major stroke were on average half of perfect health (6). Given that this estimate is 
positioned approximately only in the middle of the scale, the burden of major stroke on 
patient’s HRQoL is undisputable. Although there is significant variation on the level of 
HRQoL across CVD disorders and across severity levels it consistently indicates 
impairment. 
CVD do not only account for a major share of overall morbidity and mortality worldwide, 
but also significantly contribute to global healthcare expenditures. Some of the major 
drivers of resources used within the healthcare system are the costs of hospitalizations, 
long-term management and rehabilitation care due to CVD. From a broader societal 
viewpoint, next to healthcare costs accounting for approximately two thirds of total 
economic burden due to CVD, one third of costs can be attributed to the productivity loss 
costs associated with the CVD patients being absent from work and the costs of informal 
care of these patients (7,8). In the Netherlands, economic burden of CVD led to healthcare 
expenditures of €5.5 billion annually, while in the whole European Union it mounted to 
€105 billion (7,8). 
CARDIOVASCULAR DISEASES PREVENTION – RISK PREDICTION APPROACH 
The most recent European guidelines on CVD prevention recommend the combination of 




focuses on promoting lifestyle and environmental changes in the population at large (i.e. 
the public health/population-based approach) while an alternative approach aims to 
modify risk factors only in individuals identified to be at a high risk (i.e. the high-risk 
approach). Although the large-size benefits may be reached by applying the population 
prevention approach, the benefits that can be achieved with individual risk assessment 
should not be disregarded. Furthermore, implementing individual risk assessment to 
identify high-risk individuals remains a recommended strategy in regular clinical practise 
(9). 
Nowadays risk assessment tools are derived using data from decades-long studies 
designed to follow large cohorts for a sufficient length of time and for which both patient 
characteristics (i.e. risk factor characteristics) and outcomes are known over time. For 
example, studies based on the Framingham population were among the first ones to find 
the association between a number of, often correlated, modifiable and/or non-modifiable 
risk factors and the onset of CVD (10)(11). Elevated blood pressure (BP), cholesterol or 
glucose levels and smoking have been identified as some of the major modifiable risk 
factors, and age, gender and genetic predisposition are some of the non-modifiable risk 
factors, whose conjoint influence can lead to CVD. 
The aforementioned types of observations have set the grounds for the development of 
various multivariable risk prediction models that attempt to translate this conjoint impact 
of various risk factors on the onset of CVD into a mathematical relation. Numerous 
differences exist between the various proposed CVD risk prediction models. These models 
often differ in the specific risk factors they comprise, the underlying study populations 
(different geographical regions, baseline CVD risks) as well as whether they reflect the risk 
of overall CVD or one of its specific CVD forms (e.g. myocardial infarction, stroke etc.). 
Moreover, they give predictions over different time horizons (e.g. 1-4 years (12), 10 years 
(13) or 30 years (14)), for different clinical endpoints (e.g. fatal (13) or overall CVD (12)) 
and for primary or secondary CVD events (12).  
Because of the aforementioned differences across risk models, the choice and consequent 
utilization of a model for projecting CVD risk in a certain setting is not straightforward. The 
choice of a model might need to be made with respect to specific characteristics of the 
population of interest (e.g. middle-aged or elderly patients, or diabetics), or with respect 
to the need to estimate CVD risk over a specific time-horizon. An example of a model for 
CVD risk assessment in European populations is the SCORE model developed on data from 
12 European cohorts (9,13). The high- and low-risk region-specific multivariable risk 
functions of the SCORE model estimate the 10-year risk of a fatal CVD by accounting for 
age, gender, level of SBP, level of cholesterol and prevalence of smoking. Thus, if the 10-
year risk of a fatal CVD needs to be estimated in individuals from a certain European 
setting, the choice of the SCORE model risk function should be made carefully with respect 





prediction in a specific setting needs to be assessed, and if needed, it can be enhanced by 
various adjustments and validation methods.  
PHARMACOLOGICAL INTERVENTIONS TO PREVENT CARDIOVASCULAR DISEASES 
When it comes to implementing prevention strategies to reduce the overall CVD risk by 
identifying individuals at risk with the use of a suitable CVD risk prediction model (9), 
various national and international guidelines give different recommendations on the CVD 
risk threshold above which pharmacotherapy should be introduced in addition to lifestyle 
changes (15).  
In the Netherlands, cardiology guidelines recommend pharmacotherapy to prevent CVD 
for patients at a 10-year CVD mortality or morbidity risk of 20% or exceptionally at lower 
levels of risk if accompanied with other comorbidities (e.g. diabetes or rheumatoid 
arthritis) or previous CVD (16). Prevention strategies can include antihypertensive 
treatment and/or statins, if high CVD risk is accompanied with systolic blood pressure 
(SBP) greater than 140 mmHg and/or low-density lipoprotein (LDL) greater than 2.5mmol/l 
(16). In patients with a medical history of previous CVD events and elevated SBP and/or 
LDL levels, immediate pharmacotherapy is recommended due to the relatively high risk of 
recurrent CVD events (16).  
Moreover, in the presence of certain individual risk factors, such as atrial fibrillation (AF) 
or diabetes, pharmacological interventions additional to the ones previously mentioned 
may be indicated. For example, atrial fibrillation (AF) is considered to be an independent 
risk factor leading to an even 5-fold increased risk of stroke (17). To prevent stroke in 
patients with AF and minimum one stroke risk factor (i.e. congestive HF or left ventricular 
dysfunction, Hypertension, Age≥75 (doubled risk), Diabetes, Stroke (doubled)-Vascular 
disease, Age 65–74, Sex category (female) [CHA2DS2-VASc] ≥ 1), antithrombotic preventive 
treatment is recommended (17). Yet, this preventive strategy does not apply to patients 
younger than 65 years with an AF diagnosis and being female as the only risk factor. 
Furthermore, once the criteria are satisfied for a patient to receive pharmacotherapy for 
CVD prevention, a choice of the most suitable treatment option needs to be made. From 
the healthcare perspective, this choice should consider both treatment effectiveness in 
modifying the risk factors of interest and its safety profile. For example, to prevent stroke 
in patients with AF, guidelines generally recommend the use of vitamin K-anticoagulants 
(VKAs) or novel oral anticoagulants (NOACs)(17). However, these medicines differ in their 
effectiveness to protect against stroke and other thromboembolic events as well as in the 
safety profile reflected by the incidence of major bleeding events (18).  
Finally, next to considering the health-related aspects of choosing a certain 
pharmacological treatment, the economic consequences of that decision should not be 




consequences of applying pharmacological interventions to prevent CVD should be 
assessed in a formal way through pharmacoeconomic analyses.  
CHALLENGES IN PHARMACOECONOMICS OF CARDIOVASCULAR DISEASES 
PREVENTION  
A number of governmental institutions worldwide request sound pharmacoeconomic 
evidence to aid health policy and reimbursement decisions regarding newly introduced 
interventions (19). Commonly, country-specific guidelines are available to assist analysts in 
conducting coherent pharmacoeconomic analyses for reimbursement purposes. Yet, when 
such analyses on pharmacological interventions to prevent CVD are needed, numerous 
methodological challenges can be encountered whose solutions are not explicitly 
discussed in the aforementioned guidelines.  
To compare different pharmacological interventions in CVD prevention, numerous health 
and economic evidence are needed. In ideal circumstances, evidence on long-term 
treatment effectiveness of specific interventions (i.e. hard clinical endpoints, such as CVD 
morbidity and mortality), HRQoL values collected alongside clinical trial and all the 
relevant up-to-date country-specific costs would be available for such an analysis (Figure 
1A). However, pragmatic pharmacoeconomic analysis needs to consider the use of less 
perfect evidence, as often this evidence is not available at the time when the 
pharmacoeconomic analysis is done (Figure 1B). Firstly, if the pharmacoeconomic analysis 
investigates the use of a new pharmacological intervention that is directed to modifying a 
certain risk factor, such an analysis would commonly have access only to short-term 
(intermediate) treatment effectiveness evidence. This is particularly the case when 
collecting pharmacological efficacy data from a relatively healthy population (commonly 
indicated for primary CVD prevention) where conducting a clinical trial to provide hard-
clinical endpoints evidence would be too lengthy and costly. For example, the evidence on 
effectiveness of different antihypertensive medicines would only indicate the change in 
systolic and/or diastolic BP (SBP and/or DBP) when examined in patients with mild 
hypertension and mild to moderate CVD risk. In case treatment evidence (short or long 
term) is available from more than one study, analysts might consider the evidence 
synthesis of all the relevant data (20). As long-term evidence is generally lacking, it is 
necessary to apply a CVD risk prediction model to translate short-term treatment 
effectiveness to long-term consequences. Notably, given the previously mentioned 
differences across CVD risk prediction models, model choice and its application in 
pharmacoeconomic analysis is not straightforward (21). Finally, in case health outcomes of 
analysis will be expressed in terms of quality-adjusted life-years (QALYs) gained, all the 
available HRQoL evidence reflecting preferences for living in a certain state of CVD might 





less rigorous approach even if a couple of values are available in the literature. Yet, this 
should not be a random process. One may consider a value that is close to analysis’s 
setting, what seems reasonable, but still it is not robust. Therefore, further effort should 








Figure 1 Evidence availability in ideal (A) and pragmatic (B) pharmacoeconomic analysis of 
pharmacological interventions in CVD prevention. 
HRQoL, health-related quality of life; CVD, cardiovascular diseases. 
Embedding and integrating the concepts of evidence synthesis and prediction/simulation 
in economic evaluation is one of the key challenges in providing reliable 
pharmacoeconomic evidence on interventions for CVD prevention. Moreover, the 
dynamic world of new pharmacological interventions for prevention and/or treatment of 
CVD, and changes in country-specific health-related economic factors urge for new 
pharmacoeconomic analysis accounting for those changes. Specifically, the introduction of 
NOACs to the Dutch market for the prevention of stroke in non-valvular AF, and treatment 
and prevention of VTE, requires sound pharmacoeconomic evidence to support 
reimbursement decisions. This evidence should account for all the specificities of the 
Dutch health system and indicate whether there is an additional value associated with the 
use of NOACs compared to the standard treatment with VKAs. Notably, such analyses 
should adequately consider core issues such as dealing with uncertainty and discounting in 
secondary prevention within the context of changing Dutch health-care with increasing 
roles for patient access schemes (such as price-volume arrangements), clinical guidelines-




AIMS AND OUTLINE OF THIS THESIS 
Part I of this thesis addresses some of the challenging issues on simulating and 
synthesizing health and economic evidence in primary CVD prevention. Here, one of the 
issues concerns the application of CVD risk prediction models in pharmacoeconomic 
analysis to project changes in CVD incidence based on changes in risk factor levels 
observed in short-term randomised clinical trials. In order to assess the adequacy of 
incorporating risk prediction models in available pharmacoeconomic analysis for primary 
CVD prevention interventions in high income countries, specify and propose methods for 
enhancing the robustness of such studies, a systematic literature review is described in 
Chapter 2. Based on the knowledge and caveats derived in this review, an attempt was 
made to design a simplified model of primary CVD prevention with antihypertensives 
using surrogate endpoints on lowering SBP projected to hard CVD endpoints. This 
modelling approach is described in Chapter 3. The aforementioned model was informed 
with various published Dutch cost estimates such as cost of HF, angina, stroke, etc. Annex 
1 provides an up-to-date estimate of hospital costs associated with HF in the Netherlands. 
Next, Chapter 4 describes an evidence synthesis of instrument-specific preference-based 
HRQoL values in CHD and its underlying disease-forms (i.e. stable angina, ACS) while 
accounting for study-level characteristics (i.e. covariates) and relevant correlations 
between those values. This study aims to further enhance the robustness of HRQoL values 
used to inform cost-utility analyses on interventions in CHD prevention and/or treatment. 
Part II of this thesis describes a number of pharmacoeconomic findings in secondary CVD 
prevention. In particular, this part of the thesis focuses on the health and economic 
findings associated with the use of VKAs and NOACs such as apixaban and dabigatran, for 
the prevention of CVDs in the Dutch setting. Chapter 5 describes a budget impact analysis 
of increasing market-share scenarios of patient self-testing and patient self-management 
in patients on long-term indication for anticoagulation with VKAs. In Chapter 6, the cost-
effectiveness of using apixaban compared to VKA was evaluated for the prevention of 
stroke in non-valvular AF in the Netherlands. Furthermore, Chapter 7 focuses on the cost-
effectiveness of another NOAC, dabigatran, for treatment and secondary prevention of 
VTE. 
Finally, in Chapter 8 the main findings of this thesis are summarized and discussed in the 
context of current knowledge and practice, and some recommendations for future 
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Background: Long-term trials on the effectiveness of pharmacological treatment for 
primary cardiovascular disease prevention are scant. Risk prediction models are used as a 
tool to project changes in cardiovascular disease incidence due to changes on risk factor 
levels observed in short-term randomised clinical trials. In this article, we summarize the 
literature on the application of these risk models in pharmacoeconomic studies for 
primary cardiovascular disease prevention interventions in high income countries. 
Methods and results: We systematically reviewed the available literature on the 
application of cardiovascular disease risk models in pharmacoeconomic studies and 
assessed the quality of incorporation of risk models in these studies. Quality assessment 
indicated the distance between the characteristics of populations of the risk model and 
the studies reviewed, the frequent disagreement between risk model- and study- time 
horizons and the lack of proper consideration of the uncertainty surrounding risk 
predictions. 
Conclusion: Given that utilizing a risk model to project the effect of a pharmacological 
intervention to cardiovascular events provides an estimate of the intervention's clinical 
and economical impact, consideration should be paid to the agreement between the 
study and risk model populations as well as the level of uncertainty that these predictions 
add to the outcome of a decision-analytic model. In the absence of hard endpoint trials, 
the value of risk models to model pharmacological efficacy in primary cardiovascular 








Cardiovascular disease (CVD) accounts for a major share of overall morbidity and mortality 
in the Western world (1,2). Furthermore, due to the high inpatient costs of most common 
CVDs, it is the most significant contributor of health care expenditures, e.g. treatment 
costs of CVD in European Union comprise 12% of all health care costs (€105 billion)(3). 
Given the health and economic burden of CVD, its primary prevention is of high 
importance to society. 
The onset of CVD has been associated with a number of, often correlated, risk factors. 
Elevated blood pressure (BP), cholesterol or glucose levels, smoking and age have been 
identified as the most important of them, whose conjoint influence can lead to CVD. 
Based on these observations, during the last 25 years, different multivariable risk 
prediction models have been developed, to assist identification of patients at risk of CVD 
in clinical practice (4-23). These models have been generally based on large cohorts that 
are being followed for a sufficient length of time and for which both risk factors and 
outcomes are known over time. The models often differ in the risk factors they comprise 
and the underlying study populations, as well as the definition of the CVD risk studied. 
Furthermore, they make predictions for different time horizons and for different clinical 
CVD-specific endpoints. 
The utilization of CVD risk prediction models in the economic evaluation of 
pharmacological primary prevention has already been established in various studies 
(24,25). Their value stems from the fact that there is limited evidence on the long-term 
benefits of the drugs used in CVD prevention. Therefore, these models provide a linkage 
between the treatment effectiveness on intermediate endpoints, observed in short-term 
randomised-clinical trials (RCTs) (e.g. change in cholesterol, BP), and the long-term 
benefits of treatment (e.g. reduced number of CVD events). Furthermore, prediction of 
the number of CVD events avoided due to treatment also offers a way to estimate the 
future financial savings on these events. 
In this article, we systematically summarize the available literature on the application of 
CVD risk prediction models in pharmacoeconomic studies that explore interventions for 
primary CVD prevention in high income countries. 
METHODS 
Pharmacoeconomic studies of different primary CVD prevention strategies were 
systematically reviewed using the PubMed database and NHS Economic Evaluation 
Database. We used the following keywords: "risk assessment" or "risk prediction model" 
or "risk model" or "risk function" or "risk equation" or "risk factor" or "risk score" and 
"cardiovascular diseases" or "cardiovascular" or "coronary heart disease" and "cost-




effectiveness" or "cost-utility" or "economic evaluation" or "decision model". The search 
was limited to studies published until December 2011. 
Studies were included in the reviewing process if they: 
1) were strictly classifiable in one of the pharmacoeconomic categories of cost-
effectiveness analysis (CEA), cost-utility analysis (CUA) or cost-benefit analysis 
(CBA); 
2) were written in English and published in peer-reviewed journals; 
3) presented a decision-analytic model that has utilized a risk prediction model; 
and 
4) explored pharmacological, primary prevention of overall CVD, or some of its 
constituents, in populations with no prior CVD events or diabetes.  
Hence, we excluded studies exploring either secondary, or primary combined with 
secondary CVD prevention, or studies where CVD was considered as comorbidity to an 
underlying disease (e.g. HIV/AIDS or diabetes).  
Editorials, letters, clinical conference abstracts and reviews were excluded. Finally, we 
focused only on pharmacoeconomic studies in high income countries (defined according 
to their gross national income per capita (26). All abstracts retrieved from the electronic 
databases were independently screened and reviewed by two team members (JS and PP). 
Disagreements were resolved through discussions.  
The appropriateness of the application of the CVD risk models in the pharmacoeconomic 
analyses was evaluated using a set of the criteria similar to that proposed by Grieve et 
al.(24). These criteria relate to:  
1) the agreement between the time horizons of the risk model and the decision-
analytic model; 
2) the comparability between the study population and the risk model 
population; 
3) whether the risk model comprises the key risk variable influenced through 
pharmacological intervention;  
4) the availability of evidence on prediction accuracy in the study population; 
and 
5) the approach followed in incorporating the uncertainty related to CVD risk 
projection into the overall decision-analytic model uncertainty(25,27). 
RESULTS 
Through our search strategy, we retrieved 810 studies. The flow chart of the literature 
search is presented in Figure 1. After implementing all the inclusion criteria, our search 
highlighted 12 relevant studies. Of the 12 studies included, four referred to the United 
States (US)(28-31), two to the United Kingdom (UK)(32,33), two to Sweden (34,35), and 
2 
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27 
one to each of Germany (36), Greece (37), Canada (38), and Japan (39). The main 
characteristics of the pharmacoeconomic studies are summarized in Table 1, while 
information regarding the utilization of CVD risk models and their incorporation in the 
decision-analytic models is summarized in Table 2. A more detailed description of the 
reviewed studies can be found in the appendix.  
 
 
Figure 1 Search results and culling process of retrieving pharmacoeconomic studies of 
pharmacological interventions for primary CVD prevention in high income countries that utilized 
published CVD risk prediction models. 
CVD, cardiovascular diseases 
 
Summarizing the CVD risk models 
The majority of the studies reviewed have utilized CVD risk prediction models based on a 
Framingham population. We encountered five Framingham risk prediction models 
projecting different endpoints for various time horizons (4,5,10,16,22). Such widespread 
application of the Framingham risk models is not surprising. These risk models are widely 
used in clinical guidelines (40,41) and are validated in not only Caucasian- and African- 
American but also in some European and Asian populations, to accurately predict CVD risk 
in asymptomatic patients (42). They comprise a variety of easily obtained and clinically 
relevant risk factors (43). Furthermore, their advantage, which facilitates their 
applicability, is that they are developed on a general population. 
The risk prediction models developed by Anderson et al.(4) were used in five studies 
(28,29,32-34) and their adjusted form in one (39), while another Framingham model 




(34) utilized a different risk model (16) that was also developed on data from the 
Framingham population. Pignone et al. (28) used two Framingham based risk models for 
stroke (10,22) next to the one from Anderson et al. (4). The CHD Policy Model (44) was 
also designed using Framingham data (45).  
Out of 12 studies, three utilized CVD risk models that were not developed on a 
Framingham population. Specifically, Maniadakis et al. (37) utilized a risk model by Glynn 
et al.(11), which was developed on two RCTs populations (46,47). These RCTs investigated 
the effects of aspirin and beta-carotene in male, and the effects of aspirin and vitamin E in 
female health professionals, on prevention of CVD and cancer. The Cardiovascular Disease 
Life Expectancy (CVDLE) Model (48) used by Grover et al.(38) was based on a logistic 
regression function developed on the Lipid Research Clinic (LRC) cohort (49,50). This 
cohort consisted of patients older than 30 years, from 10 clinics in North America that 
were followed for more than 12 years. Lofroth et al.(35) developed separate risk 
equations for myocardial infarction (MI) and stroke that utilized data from two Swedish 
hospital registers and from the Swedish Nora study (35,51). 
Critical assessment of the risk models 
Time horizon  
Five of the reviewed studies (28,29,33,34,39) utilized the CVD risk prediction functions of 
Anderson et al.(4) to estimate annual transition probabilities for Markov models with 
lifetime horizons. However, these risk models are designed to predict a cumulative CVD 
risk in a 4-12 years time horizon. This discrepancy evokes two concerns. The first relates to 
the method the authors used to transform the cumulative risk to annual probabilities and 
the second considers the extrapolation of these probabilities to periods beyond the risk 
model's time horizon. Pignone et al. (28) and Ernshaw et al.(29) assumed an underlying 
exponential distribution to obtain annual CVD probabilities for estimating the Markov 
models. Saito et al.(39) neither reported their method of obtaining annual CHD 
probabilities nor their assumptions related to extrapolating them to a lifetime horizon. 
The risk models by Anderson et al.(5) also provide cumulative CHD risk predictions for 4-
12 years. Brennan et al. applied this risk model annually and for a time horizon of 5 
years.(36) This application is also of concern given that this risk model in quite short 
horizons cannot specify the exact time of onset of the events.(5)  
The CHD Policy Model (44) used by Lazar et al.(31) and Pletcher et al.(30) is a Markov 
model with a 30-year time horizon, where the age- and gender- specific CHD risk is based 
on logistic regression models that are estimated using longitudinal Framingham data(45). 
This approach, although reducing the problems related to the translation or the 
extrapolation of the risk, suffers from the need of long follow-up periods and a large 
cohort size. 
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Johannesson (34) applied a previously published Markov model based on a risk model by 
Kannel et al.(16) This risk model predicts the 8-year CHD and stroke risk. However, his 
decision-analytic model is run for a lifetime horizon. The 8-year cumulative risks are 
transformed into annual probabilities but no exact information is given on how this 
transformation takes place.  
A risk model developed by Glynn et al.(11) that predicts a 5-year CVD risk, was used in the 
model of Maniadakis et al. (37) assuming a lifetime horizon. Maniadakis et al. (37) noted 
that they transformed 5-year probabilities into annual ones, but without reporting the 
method for that or for extrapolating them through lifetime. 
Finally, the CVDLE Model (46) was utilized in a study by Grover et al.(38,48) Even though 
this model is run through a lifetime, it utilizes logistic regression functions developed on 
the LRC cohort (47,51), which gives 10-year predictions. In the article where the original 
model was published (48), the authors assumed equal annual risks. To obtain these annual 
risks they have falsely divided the 10-year risk by 10. This generally results in an 
underestimation of the annual risk (52). 
Population characteristics  
Predictions of CVD risk in decision-analytic modelling can be biased due to differences 
between the risk model and the study populations. Such differences appear more 
frequently when the risk model is estimated using a RCT population. These risk models 
usually overestimate the CVD risk and therefore application of them in a general 
population is not recommended, at least not without proper validation (24). Furthermore, 
significant differences in the socio-economic and educational status between populations 
could lead to considerable prediction discrepancies (43).  
In order to compare these populations in the reviewed studies we evaluated the 
differences in the risk factor levels between the study and the risk model populations. In 
the CUA by Pignone et al. (28), the study population had lower levels of risk factors 
compared with the Framingham one. Therefore, applying the risk model by Anderson et 
al. in this study population might lead to a risk overestimation (4). Risk factors of the study 
cohort in the analysis by Ernshaw et al. (29) were comparable with the Framingham 
population, for the corresponding age and gender. In the study of Brennan et al. (36), 
specific risk factor characteristics of the populations investigated were not provided, 
which hindered us from making any comparisons. Population characteristics in the study 
by Caro et al.(32) were comparable with the ones in Framingham. In the studies by 
Montgomery et al. (33) and Lofroth et al.(35) different strata of risk profiles were 
assumed; therefore, the appropriateness of the risk models for extreme risk factor strata 
would be questionable. Saito et al. (39) did not fully report risk factor characteristics (e.g. 
smoking, left ventricular hypertrophy), thus complicating the comparison. However, the 
model they used has been adjusted to the studied population. Risk factor levels of the 




Maniadakis et al.(37) studied a population with risk factor levels that were slightly 
elevated compared with those in the risk model study. Another discrepancy was that the 
risk model used was based on a population of health care professionals from two RCTs, 
which was not representative of the general population. Grover et al.(38) populated the 
CVDLE Model (46) with risk factor levels from a Canadian population that was comparable 
with the risk model’s population. With respect to the CHD Policy Model (44), given that it 
was calibrated to reproduce USA data on the distribution of the risk factors and CHD 
events, its utilization in the studies by Lazar et al.(31) and Pletcher et al.(30) concerning 
USA population older than 35 years, seems appropriate.  
Key risk variable  
The assessment of the long-term effectiveness of a change in a risk factor level can be 
most clearly observed through a risk model that comprises the risk variable of concern 
(24). The majority of the studies reviewed, investigated either the influence of 
antihypertensives on systolic BP (SBP) and/or diastolic BP (DBP) levels (37,39) or the 
influence of statins on cholesterol levels (30,31,38). In cases where there was no risk 
factor that could be modifiable through a certain treatment, such as for aspirin, a relative 
risk reduction of that treatment, observed through RCTs was modelled to lead to a risk 
reduction (28,29). The same method was also implemented in studies investigating 
treatments for obesity that in general lead to a change in body mass index (32,36). Finally, 
in three studies, although the risk model used could accommodate the effect of statin or 
antihypertensive treatment through cholesterol or BP reductions, the authors 
incorporated it as a multiplicative effect on the CVD risk, drawn from published RCTs (33-
35). The drawback of such method is the potential bias of the risk prediction due to 
differences between the RCT population and the population studied. 
Validation of the risk prediction model  
When making the decision to apply a risk model to a certain population, one should first 
consider the existing evidence of its performance in this population. A necessity for using 
the externally validated risk model is even more pronounced in the case of geographically 
or racially diverse populations (53). Additionally, the time when validation took place is of 
significant importance, given the recent decline in CVD mortality in the western world.(54) 
The Framingham based risk models (4) were found to generally overestimate the CVD risk 
in a variety of European populations (55-57). Given this evidence, the use of Framingham 
in a German setting, as used in the study by Brennan et al.(36), seems questionable. A 
similar overestimation of CHD risk based on the Framingham study (5) was observed for 
British men (55), which questions its utilization in the studies by Montgomery et al.(33) 
and Caro et al. (32). On the contrary, even though Framingham based risk models were 
not validated for a Japanese setting, utilization after adjustment for the Japanese 
population, as done by Saito et al.(39), seems appropriate (4).  
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Maniadakis et al.(37) used a risk model by Glynn et al.(11) that has not been validated for 
a Greek setting. The risk model utilized by Grover et al.(38) has been recently shown to 
accurately predict the 10-year CVD risk for a Canadian setting (58). Finally, the risk models 
developed by Lofroth et al. were not validated for a Swedish setting, although the model 
assumes the age- and sex- specific incidence of MI and stroke in Sweden (35). 
Sensitivity analysis  
Nowadays, it is almost a compulsory requirement from pharmacoeconomic analyses to 
provide an insight into uncertainties surrounding the model inputs as well as the structure 
and the assumptions related to the model (25,27). In the reviewed studies, however, the 
risk prediction uncertainty was rarely incorporated. Specifically, only one study has 
incorporated the uncertainty of the risk model parameters in the probabilistic sensitivity 
analysis (PSA). We considered that a major drawback for the studies lacking incorporation 
of the risk model uncertainty in the PSA, since this uncertainty can be responsible for a 
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Table 2 Study design of economic evaluations on cardiovascular diseases (CVD) primary prevention 
with pharmacological treatment. Studies utilizing risk prediction models. 
CVD, cardiovascular diseases; PSA, probabilistic sensitivity analysis; CHD, coronary heart disease; LRC, Lipid 
Research Clinic follow-up cohort   
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Glynn et al. 
equation(11) 
5-years No No 





model based on 
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4-12 years Yes No 












This systematic review of pharmacoeconomic analyses of primary CVD prevention 
strategies in high income countries identified 12 studies that have used published CVD risk 
prediction models. The majority of these prediction models were based on a Framingham 
population and focused on the CHD and stroke risk. The studies demonstrated the 
usefulness of projecting intermediate effectiveness endpoints to long term, health and 
cost related, benefits. However, after assessing the quality of incorporation of these risk 
models in pharmacoeconomic analyses we identified a distance between the populations 
of the risk model and the study population, a frequent disagreement between risk model- 
and study- time horizons and a lack of proper consideration of the uncertainty 
surrounding the prediction of the risk. 
In order for a risk model to be able to predict accurately the CVD events of a study 
population, there must be a relative agreement between the study and the risk model 
populations with respect to the main CVD risk factors (24). In the reviewed studies, this 
criterion was generally met. However, characteristics that have been earlier identified as 
influential on CVD risk and relate to temporal, regional, demographic and socio-economic 
characteristics have not been adequately assessed in the reviewed studies. For example, 
the Framingham population, which was widely used among the reviewed studies, has 
been earlier found to overestimate CVD risk in the western world, especially in lower 
socio-economic populations (55,59,60). Similar problems can be encountered when the 
risk model is based on special populations, such as populations from RCTs. One such 
example is that of Glynn et al. where the risk model population consisted of health care 
providers, who cannot be considered as representative of the general population (11). 
Pharmacoeconomic analyses generally require the estimation of both costs and effects for 
a lifetime horizon. In this review, most studies were characterized by a disagreement 
between the risk model and the decision-analytic model horizons. Specifically, risk models 
provided a considerably smaller time horizon, forcing the authors to project the estimated 
risks for time horizons for which the risk models were not validated. However, increasingly 
more risk predicting models that are developed on cohorts with longer follow up times are 
becoming available. The risk model by Pencina et al., which is based on the Framingham 
population and can estimate a 30-year CVD risk, might be a valid tool for a more accurate 
estimation of lifetime risk, which is necessary for pharmacoeconomic analyses (19). One 
other such long-term risk model is the QRISK2 model (12), developed using general 
practitioner collected data from the UK, which can be utilized for the estimation of 
lifetime CHD and stroke risk in the general population. 
The usage of a CVD risk model to project the effect of a pharmacological intervention from 
risk factors to CVD events provides an estimate of the intervention's clinical and 
2 
Systematic review application of cardiovascular risk prediction models in pharmacoeconomics 
 
37 
economical impact. However, this projection introduces an additional uncertainty level 
associated with the accuracy of the CVD prediction on the specific population. Although 
pharmacoeconomic evaluations require this uncertainty to be studied together with the 
overall model uncertainty, this has been rarely observed in our review. The means of 
incorporation of this uncertainty has been described in detail in the literature and involve 
the consideration of the level of uncertainty and correlation of the parameters of the risk 
model (27).  
Concluding, we provide some suggestions with respect to the appropriate use of a CVD 
risk model in pharmacoeconomic analysis. First, incorporating a risk model into a 
pharmacoeconomic analysis must be done after the compatibility of the risk model and 
the study populations has been thoroughly investigated. Additionally, the study should 
report the method used for the translation of cumulative risks to short-term probabilities 
and should clearly describe the method behind extrapolating this risk to a lifetime horizon. 
Finally, the uncertainty introduced due to CVD risk prediction should be incorporated in a 
transparent way in the estimation of the overall uncertainty of the decision-analytic 
model, as this prediction parameter is one of the main contributors of uncertainty. 
Appendix 
General description of selected studies 
Pignone et al.(28) performed a cost-utility (CUA) of the use of aspirin for primary 
prevention compared to no intervention in 65-year-old women in a USA setting. For this 
purpose, they developed a Markov model that incorporated disease-specific health states 
and health states related to adverse effects of aspirin. The cardiovascular diseases (CVD) 
risk prediction models used were based on the Framingham Heart Study (4,10,22). The 
cost-effectiveness (CE) of aspirin treatment was modelled in a lifetime horizon. The 
authors concluded that preventive use of aspirin is beneficial in women with a higher risk 
for ischemic stroke but potentially harmful for women with a relatively low stroke risk. 
A CUA was conducted by Ernshaw et al.(29) to compare aspirin alone or in combination 
with a proton-pump inhibitor (PPI) with no treatment, in primary CVD prevention. The 
authors used a Markov model similar to the one of Pignone et al. (28) However, their 
pharmacoeconomic study was focused on a population of 45-year-old men. The CVD risk 
prediction was based on the Framingham Heart Study. Results were explored in time 
horizons of 5, 10, 25 years and lifetime. Higher incremental cost-utility ratios were 
observed for shorter time horizons. The authors concluded that CVD prevention with 
aspirin alone in 45-year-old men was less costly and more effective than no treatment.  
Brennan et al.(36) investigated the cost-utility of sibutramine combined with diet and 
lifestyle advice in obese patients, in comparison with a non-pharmacological intervention. 
They constructed a decision tree model where they modelled weight loss after one year of 




were used to translate weight loss into coronary heart disease (CHD) risk reduction. Their 
conclusion was that, for German, obese patients, sibutramine is more cost-effective 
against non-pharmacological interventions.  
Caro et al.(32) explored the cost-utility of adding rimonabant to exercise and diet, 
compared to exercise and diet alone, in obese patients with and without diabetes. Since 
our focus is on primary prevention in non-diabetic populations, we incorporated in our 
review only the part that applies to non-diabetic patients. The authors designed a one-
month cycle Markov model with three CVD-related health states and a lifetime horizon. 
Framingham risk models (4) were used for calculating the primary CVD risk, as a composite 
of the risk for CHD and stroke. Given that those models do not incorporate body mass 
index (BMI) as a risk factor, the authors incorporated in the estimation of the risk of CHD 
an additional risk for patients with high BMI (62).The authors concluded that adding 
rimonabant to exercise and diet seems to be cost-effective. 
Pletcher et al.(30) explored the cost-utility of statin treatment adherent to the Adult 
Treatment Panel III (ATP III) guidelines (63) against various other risk- and aged- based 
statin treatment strategies. For this purpose, they utilized an updated version of the, 
previously published, CHD Policy Model (44). This is a Markov model based on a USA 
population older than 35 years of age. Risk functions for incident CHD and non-CHD 
related death were based on longitudinal data from the Framingham Heart Study (45). The 
cost-utility estimates were calculated for a 30-year time horizon. The main effect of statin 
use was the reduction of low-density lipoprotein (LDL), with a subsequent estimated 
effect on CHD risk reduction. Pletcher et al.(30) concluded that lipid-lowering strategies 
adherent to the ATP III guidelines are relatively more cost-effective compared to other 
risk- and age- guided alternatives. 
A CUA by Lazar et al.(31) assessed primary prevention with low-cost generic statins 
compared with no intervention and examined under which circumstances their 
application is cost-effective. For this purpose, they utilized the CHD Policy Model (44). 
Lazar et al. (31) incorporated statin-induced diabetes as an additional possible adverse 
effect to statin treatment, next to myopathy and hepatitis. Statin induced diabetes was 
directly incorporated in the model, given that it is considered as one of the CHD risk 
factors. Lazar et al. (31) concluded that statin use in people with even modestly elevated 
LDL or any CHD risk factor could be considered as a cost-effective option. 
Johannesson conducted a study to estimate the 5-year coronary risk level at which statin 
application is considered to be cost-effective in Sweden (34). He utilized a previously 
published Markov model for cost-effectiveness analysis (CEA) in cardiovascular prevention 
(64). In this model, transition probabilities to each of the CHD states were estimated 
through logistic risk models from a study based on the Framingham population (16). In 
order to assess the coronary risk level at which statin use was cost-effective, the author 
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varied the CHD risk level until the cost per QALY reached a certain willingness-to-pay 
threshold.  
Montgomery et al. explored the cost-utility of an antihypertensive intervention compared 
with no intervention in cohorts of 20 different strata of age, gender and high or low CVD 
risk (33). They used a Markov model in which CVD-related transition probabilities were 
estimated through a Framingham Heart study (4). The authors modified the estimated 
baseline CVD risk depending on the probability of successful systolic blood pressure (SBP) 
control. According to Montgomery et al. (33), estimates of cost-utility ratios were higher 
for low-risk women compared with men, while high-risk patients had more favourable 
cost-utility ratios than low-risk patients. 
A CUA of hypertension treatment among combinations of different angiotensin-receptor 
blockers (ARBs) and hydrochlorothiazide (HCTZ) in a Greek setting was performed by 
Maniadakis et al. (37). The authors designed a Markov model with eight CVD-specific 
health states for a lifetime horizon. The risk models developed by Glynn et al., in 
combination with gender- and disease-specific incidence rates were utilized to model 
transitions between CVD states (11). The authors concluded that application of irbesartan 
in combination with HCTZ was the most favourable compared with the other ARBs. 
Grover et al. performed a CEA of antihypertensive and lipid-lowering treatment as 
recommended by the 2003 Canadian Working Group guidelines, in comparison with no 
treatment (38). They utilized the Cardiovascular Disease Life Expectancy (CVDLE) Model 
(48). Probabilities of CVD events in this model were based on logistic regression functions 
developed using data from the Lipid Research Clinic cohort (LRC)(49,50). The authors 
concluded that lipid-lowering and antihypertensive therapies in accordance with the 
Canadian guidelines are cost-effective in most of the age-gender groups of patients.  
A CEA in a Japanese setting concerning different antihypertensive drug regimes was 
conducted by Saito et al.(39). The authors utilized a Markov model in which a hypothetical 
cohort of 55-year old patients with essential hypertension was followed lifelong and 
incidence of CHD and stroke was monitored (65). Transition probabilities to CHD states 
were calculated through adjusted Framingham risk models (4). These risk models were 
adjusted to a Japanese setting under the assumption that the incidence of CHD in Japan is 
20% of that in USA. Saito et al. did not observe any relative advantage in terms of costs 
and expected survival among the applied drug regimes.  
Lofroth et al. performed a CUA of primary CVD prevention through a combination of 
antihypertensive, lipid-lowering or smoking cessation interventions, with the aim of 
optimal resource allocation within the Swedish health care system (35). The authors 
designed a Markov model with disease-specific health states reflecting myocardial 
infarction (MI) and stroke. The model was run through a lifetime horizon. In order to 
calculate the risk of MI and stroke, the authors developed risk functions that were based 




Cause of Death Register (51). The authors based the 1-year risk for MI and stroke on a 
combination of the annual age- and gender- specific incidence and a number of risk 
factors (cholesterol, blood pressure, smoking). The study displayed that resources in the 
studied regions are inefficiently allocated and should be primarily reallocated towards 
smoking cessation interventions and lipid-lowering therapies. 
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Background: In the Netherlands, antihypertensive treatment for patients with mild 
hypertension is recommended if the 10-year cardiovascular disease (CVD) risk exceeds 
20%. Recent evidence suggests that lifelong CVD risk estimates might be more informative 
than 10-year ones. In addition, the cost of antihypertensive treatment in the Netherlands 
has declined over the last decade. The aim of this study is to estimate the cost-
effectiveness of lowering systolic blood pressure (SBP) in patients ineligible for treatment, 
both in a 10-year and in a lifetime horizon.  
Methods: A Markov model was developed to assess the cost-effectiveness of SBP 
reduction compared to no reduction in patients with mild hypertension and low CVD risk. 
Modified SCORE risk estimates were used to predict fatal and non-fatal CVD events. We 
analyzed scenarios for different age groups, genders and SBP reductions. Specifically, SBP 
reductions due to hydrochlorothiazide (HCT) 25mg and hypothetical reductions with 
HCT/Losartan combination were assumed. Parameter uncertainty was assessed through a 
probabilistic sensitivity analysis. 
Results: In a 10-year horizon, in scenarios of SBP reduction with HCT 25mg, the 
incremental cost-effectiveness ratio (ICER) estimates for men varied across different ages 
in the range of €6,032 to €58,217 per life year gained (LYG), while for women ICER 
estimates were in the range of €12,345 to €361,064 per LYG. In a lifetime horizon, the 
cost-effectiveness estimates were favorable for both genders. In scenarios of hypothetical 
SBP reductions, more favorable ICER estimates compared to no reduction were found. A 
large uncertainty around the cost-effectiveness estimates was observed among all 
scenarios. 
Conclusions: Larger SBP reductions were found to be cost-effective in both a 10-year and 
lifetime horizon. These findings might call for more aggressive SBP reductions in patients 
with mild hypertension. Yet, a high level of uncertainty surrounds these cost-effectiveness 
estimates since they are based on CVD risk prediction modelling. 
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Cardiovascular disease (CVD) is the largest cause of morbidity and a major cause of 
premature death and reduced quality of life in Europe. At the same time, CVD is the most 
significant contributor to health care expenditures; treatment costs of CVD in EU comprise 
12% of all health-care costs (€ 105 billion)(1), while in the Netherlands they reach 8% of 
the total health-care budget (€ 5.5 billion)(2). Due to the fact that people with moderate 
or high hypertension (>160mmHg), previous CVD events or diabetes mellitus (DM) are 
generally considered to be at higher risk for CVD, preventive treatment in these groups is 
rather straightforward and common (3,4). The question arises when considering 
preventive treatment in patients with mild hypertension (140-160 mmHg), no prior CVD 
events or DM, and overall low CVD risk (4), given the economic implications and ethical 
considerations of such a decision. Currently, national guidelines recommend lifestyle 
changes as a first step in lowering blood pressure in this patient population (5). Failure of 
this intervention should be followed initially with diuretic treatment (e.g. 
hydrochlorothiazide (HCT)) and if necessary combinations of diuretic and Angiotensin 
converting enzyme inhibitor (ACEi) or Angiotensin receptor blocker (ARB) (5). In parallel, 
the cost of these antihypertensive agents has declined considerably the last years in the 
Netherlands, primarily due to generic introduction (6), causing a reduction on the cost of 
treating patients with hypertension. Guideline recommendations on preventive treatment 
of CVD in people with neither prior events nor DM necessitate the estimation of a patient-
specific risk for fatal or non-fatal CVD (3-5,7-9). Several studies have focused on identifying 
and correcting for risk modifiers (e.g. reducing systolic blood pressure (SBP) or cholesterol 
level) that can be beneficial for cardiovascular risk reduction (10-15). Considering the 
overall prevalence of hypertension and the fact that elevated SBP is a major 
cardiovascular risk factor, considerable health and economic benefits are expected from 
its control (16-19). 
The effective control of SBP through antihypertensive medication has been established 
through numerous clinical trials (20). However, the effectiveness of these drugs often 
varies across trials. Under these circumstances, the proper consideration of the exact long 
term health and economic consequences of SBP reduction in patients with mild 
hypertension and no prior CVD events requires evidence-synthesized estimates of SBP 
reduction (e.g. through meta-analysis and mixed-treatment comparisons)(21,22). Such 
estimates are currently available only for older antihypertensive agents, such as diuretics 
(20) but not for newer antihypertensive agents such as ACEis and ARBs. 
The aim of this study is to estimate the health effects and economic consequences of SBP 
reduction through antihypertensive treatment in patients with mild hypertension but with 
no history of CVD or diabetes. SBP reduction was used as a surrogate endpoint that was 




the impact of such an intervention in the Dutch setting, we utilized a CVD risk calculation 
model recently validated for this population; i.e. the low-risk version of SCORE (23,24). 
Furthermore, we applied cost estimates for cardiovascular complications as well as drug 
costs reflecting the Dutch situation. We investigated the cost-effectiveness (CE) of 
different scenarios of SBP reductions achieved by antihypertensive treatment in different 
age groups of men and women, in comparison to no treatment, both in a 10-year and in a 
lifetime horizon.  
METHODS 
Model structure 
A Markov model was developed to compare the long-term costs and health benefits of 
primary CVD prevention through SBP reduction. The model included five health states: 
baseline (healthy with mild hypertension but no CVD history), acute non-fatal CVD, stable 
non-fatal CVD, fatal CVD and non-CVD related death (Figure 1). Patients remained in the 
baseline state until a fatal or non-fatal CVD event occurred or they died due to other, non-
CVD related, causes. From the acute CVD state at the end of one cycle, patients could 
move to a stable non-fatal CVD state, experience a subsequent, fatal or non-fatal, CVD 
event or die from other causes. From the stable CVD state, patients could experience a 
subsequent fatal or non-fatal CVD event or die from other causes. The model allows for 
multiple recurrent non-fatal CVD events to occur with a restriction to one event per cycle. 
Transition probabilities between health states were modelled through reparametrizing the 
10-year risks of CVD mortality and morbidity and non-CVD related mortality into 
respective one-year probabilities as given in the Appendix. 
The simulations were run using two time horizons: 10-year and lifetime, both applying 
cycles of one year in the Markov model. All patients were assumed to be dead by the age 
of 100 years. The model was developed using the statistical software R (version 3.0.2)(25). 
 
 
Figure 1 Markov model on the progression of CVD in patients with mild hypertension. 
CVD, cardiovascular disease 
3 




The Markov model was applied in a set of different scenarios separately for men and 
women, where the population analyzed varied with respect to its age (age groups: 40, 50, 
60, 65), baseline SBP (hypertensive groups of SBP at 140 mmHg, 150 mmHg, 160 mmHg) 
and level of SBP reduction achieved by the treatment. For the base-case analysis, 
antihypertensive treatment with HCT 25 mg was assumed. According to a recent meta-
analysis, SBP reduction achieved through HCT 25 mg, in a similar population, was 
estimated on average to be 11.3 mmHg (20). In the absence of evidence-synthesized 
estimates on SBP reduction achieved by combinations of HCT and ACEis or ARBs, 
hypothetical scenarios of SBP reductions (20 and 30 mmHg) achieved with a fixed-dose 
combination of HCT 12.5 mg/Losartan 50 mg were assumed. All comparisons were made 
against a no treatment alternative. Additionally, a scenario analysis focusing on male and 
female smokers, examined the cost-effectiveness of a 10-year treatment with HCT 25mg 
against no treatment in this patient population.  
It was assumed that antihypertensive medication was the sole cause of SBP reduction. 
Additionally, SBP reduction was assumed to be instant and remain constant throughout 
the time horizon. Also, every patient with elevated SBP was immediately diagnosed and 
treated (in the treatment scenario) or left untreated (in the no treatment scenario). 
Finally, the base-case scenario was adjusted to incorporate patients’ adherence to HCT. 
Adherence was defined as the percentage of prescribed   dosage taken over a one year 
period, and was assumed to be 78.6% (26). Assuming that poorly adherent patients would 
have lower benefits from the treatment with HCT, the level of adherence was modelled 
through a reduction in the antihypertensive effect of HCT (i.e. 11.3 × 0.786 = 8.8818) and 
drug treatment related costs (i.e. drug costs and pharmacy fee)(27)(28,29). All the patients 
in the treatment alternative were assumed to be fully persistent with the treatment. 
Transition probabilities: CVD mortality risks 
In order to calculate the probability of a fatal CVD event, the updated SCORE model for 
low-risk regions was utilized (23) (personal communication: Fitzgerald T, Department of 
Epidemiology & Public Health/Statistics, University College Cork). The low-risk SCORE 
model has been shown to produce better prediction estimates for the Dutch population in 
comparison to both the high-risk SCORE and the so-called SCORE-NL models (3,24). The 
SCORE model only gives the 10-year cumulative probability of a fatal CVD event. However, 
due to the use of 1-year-cycles in our model, annual transition probabilities were needed. 
Annual transition probabilities were obtained for every time point and for each of the 
scenarios by estimating the age- and SBP- specific CVD event probability conditional on 
the patient’s survival up to this time point (30). In other words, one’s probability to have 
an event in a certain year is dependent on whether the patient has survived until that year 




transforming the SCORE cumulative probabilities to annual probabilities is provided in the 
Appendix. 
The explanatory covariates used in the estimation of fatal CVD risk through the SCORE 
model are age, gender, level of SBP, level of cholesterol and prevalence of smoking. 
Therefore, age-specific prevalence of smoking and cholesterol levels that were 
representative of the Dutch population were used (Table 1)(31,32). These baseline patient 
characteristics were updated through the time horizon observed in order to account for 
the time dependent change in the risk of CVD events. Finally, it was assumed that patients 
with a non-fatal CVD event were at least as likely to experience a subsequent event as 
patients with no CVD history.  
Transition probabilities: CVD morbidity risks 
Given that the SCORE model only estimates the probability of a fatal CVD event, a 
functional form linking the annual risk of mortality to the annual risk of morbidity and 
mortality was estimated using the risk estimates presented by the Dutch College of 
General Practitioners (NHG)(9).  
)0003055.0()0202491.0()2767607.0(
001.0867.1083.7 2 ++−= xxy , 
where y represents the annual overall risk of morbidity and mortality and x the annual 
mortality risk. In order to obtain annual probabilities for non-fatal CVD events, the annual 
probability of a fatal CVD event was subtracted from the respective estimated overall CVD 
probability. 
Transition probabilities: non-CVD mortality 
The transition probabilities representing the annual risk of death from non-CVD causes 
were estimated using 2010 Dutch population data (33-35). In particular, the non-CVD 
related probabilities of death were estimated by subtracting the number of CVD deaths 
from the total number of deaths in 5-year age groups and dividing them by the total 
number of people in the same age groups. Since 5-year interval probabilities were 
calculated, it was further assumed that these probabilities are representative for a person 
of average age within each group. However, in the Markov model one-year cycles were 
applied, hence estimates of age-dependent annual probabilities were necessary. 
Therefore, the estimates of non-CVD related annual probabilities of death from the age of 
40 until 100 were extrapolated and interpolated using non-linear regression modelling 
(36). 
Finally, in order to account for the increased risk of death in patients experiencing non-
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Table 1 Age-stratified baseline patient characteristics in Dutch population. 
Ag
e 
SBP (mmHg)a32 Cholesterol 
(mmol/l)32 
Smoking31 (%) SBP (mmHg) a32 Cholesterol 
(mmol/l)32 
Smoking31 (%) 
 Men Women 
40 126.10 5.41 36.3 115.10 5.05 27.4 
50 131.67 5.57 33.9 123.16 5.52 28.8 
60 138.87 5.55 29.3 131.13 5.77 24.3 
65 141.66 5.50 24.1 134.99 5.79 19.3 
70 144.44 5.45 18.9 138.86 5.81 14.3 
80 147.04 5.35 16.1 143.37 5.76 11.1 
90 148.26 5.26 16.1 145.69 5.71 11.1 
10
0 
148.26 5.26 16.1 145.69 5.71 11.1 
aAge-stratified patient levels of SBP are used only for the purpose of model validation. 
SBP, systolic blood pressure. 
Costs 
The definition of CVD in the SCORE risk model comprises a variety of CVD outcomes. That 
wide range of outcomes within the CVD definition complicates assigning accurate cost 
estimates to the overall CVD. To overcome this, the cost of CVD was assumed to be a 
composite of the costs related to acute myocardial infarction (AMI), unstable angina, 
heart failure (HF) and stroke, as these are cumulatively responsible for the majority of CVD 
events. Therefore, Dutch estimates of incidence for each of the outcomes were used to 
weight the overall CVD cost estimate (40,41). Unit cost estimates from previous costing 
studies conducted in The Netherlands were updated to the year 2013 using the Dutch 
inflation index (Table 2)(27,42-45). A distinction was made between the acute costs of the 
first year after the event and the cumulative cost of health resources used in subsequent 
years. Finally, an additional cost for a fatal CVD event was assumed (27). 
The drug prices applied referred to the cheapest generic alternatives available on the 
market and were defined as price per guideline-proposed dosing regimen (Table 2)(46). In 
the first year of treatment, patients were assumed to visit the general practitioner (GP) 
twice, and to subsequently refill their prescription by phone, every three months. In order 
to establish and monitor the appropriateness of the antihypertensive treatment dosage 
applied, four laboratory tests estimating the glomerular filtration rate and level of 
potassium in the blood were added to the first year treatment costs (47)(5). In the 
subsequent years, the monitoring of treatment dosage was assumed to consist of one GP 
visit and laboratory test per year. It was assumed that the patient will visit a Dutch 
pharmacy for every refill, hence a pharmacist fee would apply (48). The patients were 
assumed to take the same antihypertensive drug according to the proposed dosing 
regimen throughout the year until they experienced an event. 
Cost-effectiveness 
The costs of antihypertensive treatment and cardiovascular events were aggregated 




treatment costs, as well as costs related to non-fatal and fatal CVD events. Costs of a no 
treatment alternative consisted only of costs related to CVD events.  
As a measure of effectiveness, the life-years gained (LYG) that were obtained by the SBP 
lowering strategy were utilized. Initially, the life years lost (LYL) for every SBP, age and 
gender scenario due to the CVD mortality were estimated. The LYG were defined as the 
difference in LYL between the no treatment alternative, where patients were assumed to 
remain with a certain baseline SBP level, and the treatment alternative, where patients 
were assumed to achieve a reduction of SBP. 
The CE of SBP lowering was expressed through the incremental cost-effectiveness ratio 
(ICER). The ICER thus reflects the additional cost, which, by choosing a treatment 
alternative, is imposed over the no treatment alternative in order to gain one year of life. 
Future costs and benefits were discounted by 4% and 1.5% annually according to the 
Dutch guidelines for pharmacoeconomic research (49). The CE analysis was performed 
from a healthcare perspective and only direct pharmacy and medical costs associated with 
CVD events were considered.  
Validation 
We validated the performance of our Markov model by comparing the model’s estimate 
of life expectancy (LE) for an average Dutch patient of age 40, 50, 60 and 65, to the 
respective life tables from the Dutch Bureau of Statistics (Table 3)(50). A general 
agreement between the observed and modeled LE was observed, although the model 
slightly overestimated the LE for both genders. These differences can be attributed to a 
number of factors such as the uncertainty on average SBP, cholesterol and smoking levels, 
the inability of SCORE to predict life-long estimates and the differences between the 
SCORE and the current Dutch population.  
Probabilistic sensitivity analysis 
Simultaneously incorporating the uncertainty around all parameters in the CE analysis was 
done through a probabilistic sensitivity analysis (PSA) with 10,000 iterations for each 
estimation. Key input parameters in the deterministic analysis that were assumed to be 
random variables were: the antihypertensive effect of HCT on SBP, the level of population 
adherence to HCT treatment, the covariate estimates of the SCORE model, the incidence 
rates and cost estimates of CVD, the costs of pharmacy, GP fees and laboratory tests, and 
the probability of non-CVD death. When cost estimates were available only as single point 
estimates, they were assumed to follow a log-normal distribution with a coefficient of 
variation equal to 0.25. In order to capture the uncertainty around the parameters of the 
SCORE model the Cholesky decomposition on the variance-covariance matrix of the SCORE 
regression model was used (personal communication: Fitzgerald T, Department of 
Epidemiology & Public Health/Statistics, University College Cork). Through this technique, 
correlated random draws can be generated from the parameters’ multivariate normal 
3 
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distribution (30,51). A beta distribution was assigned to the CVD specific incidence rates, a 
log-normal distribution to the cost estimates and a normal distribution to the rest of 
varied parameters (Table 2). 
Results from the PSA are presented through cost-effectiveness acceptability curves (CEAC) 
and 95% confidence interval (CI) estimates around the incremental effects and the 
incremental costs. The CEAC assesses the probability that the estimated ICER is under a 
certain willingness to pay (WTP) threshold. Finally, in order to approximate the 
contribution of the individual parameters to the overall uncertainty of the model the 
Analysis of Covariance (ANCOVA) method was used. This method links the proportion of 
the variance in the PSA-simulated incremental effects and incremental costs to the 
variation of the model input parameters.(30) When the impact of each parameter on 
overall model variation was examined, the impact of the antihypertensive effect of HCT 
and the level of adherence with HCT was separately assessed, while all SCORE parameters, 
CVD related costs, incidence rates of separate CVD events, costs of pharmacy fees, GP 
related fees and laboratory tests, and the probability of death due to non-CVD causes 
were assessed jointly. 
Table 2 Key parameters and corresponding distributions for deterministic and probabilistic analyses.  
Parameter Men Women Distribution 
 First year Subsequent 
years 
First year Subsequent 
years 
 
Cardiovascular complication (2013, €) 
































Estimated CVDa 19,252 2,533 17,128 2,772  
Death27 2,976 (8.00, 0.02) 2,976 (8.00, 0.02) Log-normal 
(μ,σ) 
Incidence (per 100,000 person-years)   
Stoke41 182 (12,324 , 6,727,241) 116 (7,818 , 6,731,747) Beta (p,q) 
Myocardial infarction40 212.2 (481 ,226,219) 212.2 (481 ,226,219) Beta (p,q) 
Heart failure40 66.4 (154 , 231,846) 66.4 (154 , 231,846) Beta (p,q) 
Unstable angina 171.8 (390 , 226,610) 171.8 (390 , 226,610) Beta (p,q) 
Meta-analyzed estimate of 
SBP reduction due to HCT 
25 mg20  
11.3 mmHg (11.3 , 0.86) Normal 
(μ,σ) 





Parameter Men Women Distribution 
 First year Subsequent 
years 
First year Subsequent 
years 
 
Annual drug costs (2013, €)  





General practitioner visit48 31 (3.39, 0.25) Log-normal 
(μ,σ) 
Laboratory test47 2 (0.55, 0.25) Log-normal 
(μ,σ) 




6 (1.84, 0.25) Log-normal 
(μ,σ) 
Additional pharmacy fee 
for the first drug issuing48 
4 (1.24, 0.25) Log-normal 
(μ,σ) 
Discount rate (costs)49  4% Fixed 
Healthy life expectancy 50 Life-table Fixed 
Probability of non-CVD 
death33-35 
Derived from cited sources Normal 
(μ,σ) 
Discount rate (health)49  1.5% Fixed 
a Based on the assumption that the cost of CVD will be a composite of the costs related to stroke, MI, HF and 
unstable angina whose contribution to the estimated CVD costs is calculated according to their annual incidence 
in The Netherlands.  
CVD, cardiovascular diseases; HCT, hydrochlorothiazide; N/A, not available; SBP, systolic blood pressure. 
 
Table 3 Predicted life expectancy for an average Dutch patient of different age groups. 
Gender Age Dutch Bureau of Statistics50   (LE) Model prediction (LE) 
Man 40 40.31 40.60 
 50 30.85 31.20 
 60 22.03 22.52 
 65 17.95 18.58 
Woman 40 43.98 44.97 
 50 34.45 35.43 
 60 25.47 26.42 
 65 21.19 22.19 
LE, life expectancy. 
RESULTS 
Base-case scenario 
A 60 year-old man with baseline SBP equal to 160 mmHg was estimated to be in a 10-year 
risk of 5.2% for a fatal and 5.1% for a non-fatal CVD event. The corresponding 10-year risk 
of a fatal and a non-fatal CVD event after treatment with HCT dropped to 4.4% and 4.6% 
respectively, resulting in 0.0847 LYG. For a 60 year-old woman with the same SBP level, a 
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10-year risk of 2.1% for a fatal and 2.9% for a non-fatal CVD event was estimated. After 
HCT treatment the estimated 10-year fatal and non-fatal CVD risks were 1.8% and 2.6% 
respectively. Treatment with HCT was estimated to result in 0.0413 LYG in a 10-year time 
horizon.  
In a lifetime horizon, the fatal CVD risk for a 60 year-old man with baseline SBP equal to 
160 mmHg was estimated at 22.9% and the non-fatal CVD risk at 17.1%. The 
corresponding fatal risk after HCT treatment was estimated at 20%, while the non-fatal 
CVD risk was estimated at 15.7%. This resulted to an estimated 0.2874 LYG. A woman with 
similar characteristics was estimated to have a lifelong fatal CVD risk of 20.2% while the 
non-fatal CVD risk was estimated at 15.9%. After HCT treatment these estimated risks 
dropped to 17.7% and 14.6% respectively. This reduction resulted to an estimated 0.3197 
LYG. 
Figure 2 presents the distribution of costs for a 10-year and a lifetime horizon for a 60-
year-old man and a 60-year-old woman with baseline SBP of 160 mmHg. The total costs 
for a man with the aforementioned characteristics who was assumed not to receive 
antihypertensive treatment, were €2,014 in a 10-year and €5,608 in a lifetime horizon. 
When assuming that this person is treated with HCT 25mg, the total costs in a 10-year and 
a lifetime horizon raised to €2,604 and €6,496, respectively. For a woman with similar 
characteristics, assumed not to be receiving treatment, the costs in a 10-year and a 
lifetime horizon were €1,210 and €5,443, respectively. Applying antihypertensive 
treatment with HCT 25 mg in a woman with these characteristics resulted in 10-year and 
lifetime costs of €1,938 and €6,553, respectively. It can be observed that the pharmacy fee 
and the cost of GP visit bear most of the antihypertensive treatment related costs, while 
non-fatal CVD events are responsible for the vast majority of medical costs. 
The estimated ICERs after 10-year treatment with HCT in men  were in a range from 
€6,032/LYG (65-year old men with a baseline SBP of 160 mmHg) to €58,217/LYG (40-year 
old men with a baseline SBP of 140 mmHg); the estimated ICERs for women were in a 
range from €12,345/LYG (65-year old women with a baseline SBP of 160 mmHg) to 
€361,064/LYG (40-year old women with a baseline SBP of 140 mmHg). In a lifetime 
horizon the estimated ICERs for men were in a range from € 3,076/LYG (65-year old men 
with a baseline SBP of 160 mmHg) to €4,221/LYG (65-year old men with a baseline SBP of 
140 mmHg); while for women were in a range from €3,074/LYG (40-year old women with 
a baseline SBP of 160 mmHg) to €4,645/LYG (65-year old women with a baseline SBP of 
140 mmHg). 
The estimated, per patient, 10-year and lifetime costs and LYL for the treatment scenario 
which assumed treatment with a fixed-dose combination of HCT 12.5mg/Losartan 50mg 
as well as for the no treatment alternative, for different gender, age and SBP reduction 




The ICERs for all the SBP reduction scenarios in a 10-year and a lifetime horizon, compared 
to no reduction are presented in Figure 3. In general, the ICERs indicate that SBP reduction 
would be more cost-effective and even cost-saving in older men and for greater SBP 
reductions. In a 10-year horizon the estimated ICERs were significantly more favorable in 
men, while this difference between genders in a lifetime horizon was less pronounced. 
Treatment vs. no treatment in male and female smokers scenario 
Table 4 presents the estimated 10-year fatal and non-fatal CVD risks in a 60 year-old man 
and woman with baseline SBP equal to 160 mmHg and the corresponding risk levels after 
treatment with HCT 25mg. Applying HCT in male smokers in a 10-year time horizon was 
associated with ICERs in a range from €2,727/LYG (65-year old men with a baseline SBP of 
160 mmHg) to €37,964/LYG (40-year old men with a baseline SBP of 140 mmHg); the 
estimated ICERs for women were in a range from €6,161/LYG (65-year old women with a 
baseline SBP of 160 mmHg) to €229,456/LYG (40-year old women with a baseline SBP of 
140 mmHg). 
Table 4 Estimated 10-year fatal and non-fatal CVD risks in a 60 year-old man and woman with 
baseline SBP equal to 160 mmHg and the corresponding risk levels after treatment with HCT 25mg. 
 Risk (%) with no treatment at a baseline 
SBP=160mmHg 
Risk (%) after treatment with HCT 25mg  
 Man 
Fatal CVD 8.3 7.1 
Non-fatal CVD 7.3 6.5 
 Woman 
Fatal CVD 3.6 3.1 








Figure 2 Allocation of overall medical costs in a treatment and no treatment alternative. 
A: Allocation of the total cost in the treatment (left) and no-treatment (right) alternative in the scenario of a 60-
year-old man in a 10-year time horizon with baseline SBP of 160 mmHg receiving HCT 25 mg  as an 
antihypertensive treatment. 
B: Allocation of the total cost in the treatment (left) and no-treatment (right) alternative in the scenario of a 60-
year-old woman in a 10-year time horizon with baseline SBP of 160 mmHg receiving HCT 25 mg  as an 
antihypertensive treatment. 
C: Allocation of the total cost in the treatment (left) and no-treatment (right) alternative in the scenario of a 60-
year-old man in a lifetime horizon with baseline SBP of 160 mmHg receiving HCT 25 mg  as an antihypertensive 
treatment. 
D: Allocation of the total cost in the treatment (left) and no-treatment (right) alternative in the scenario of a 60-
year-old woman in a lifetime horizon with baseline SBP of 160 mmHg receiving HCT 25 mg  as an 
antihypertensive treatment. 
SBP, systolic blood pressure; HCT, hydrochlorothiazide; CVD, cardiovascular disease; GP, general practitioner 
Probabilistic sensitivity analysis (PSA) 
Application of multivariate PSA to the base-case scenario revealed a wide uncertainty 
range around the incremental costs and incremental effects (Figure 4). This uncertainty 
was found to be greater in scenarios with higher baseline SBP levels. In Figure 5, the 




presented for a 60-year-old man and a 60-year-old woman with  baseline SBP levels of 
160, 150 and 140 mmHg assuming to be treated with HCT 25 mg, in a 10-year and a 
lifetime horizon. In a 10-year time horizon, in men, the probabilities that the SBP 
reduction from baseline SBP of 160, 150 and 140 mmHg due to HCT 25mg would be below 
the WTP of €20,000/LYG were 0.8012, 0.7469 and 0.6818, respectively (Figure 4 A). In a 
lifetime horizon the corresponding probabilities were 0.9618, 0.9510 and 0.9324 (Figure 4 
C). In a 10-year time horizon, in women, the corresponding probabilities were 0.5786, 
0.4855 and 0.3972 (Figure 4 B), while in a lifetime horizon these probabilities were 0.9865, 
0.9821 and 0.9719 (Figure 4 D). 
The results of ANCOVA, applied for a 60 year-old man whose SBP was lowered due to 
treatment with HCT 25mg from a baseline SBP of 160 mmHg in a 10-year time horizon, 
clearly indicate that the parameters of the SCORE model have the most significant 
contribution to the uncertainty around the incremental effects and incremental cost 
estimates, being responsible for 75.7% and 46% of the variance of the respective PSA 
simulations respectively (Figure 6). 
DISCUSSION 
In the present analysis, both the long-term health benefits and the economic 
consequences of SBP reduction in a Dutch population with mild hypertension were 
estimated. In the base-case scenario, where SBP reduction was assumed to be achieved 
through antihypertensive treatment with HCT, significant health and economic benefits 
were observed in all scenarios for both genders in a lifetime horizon. However, ICER 
estimates for HCT treatment compared to no treatment in a 10-year horizon found SBP 
reductions to be more favorable when targeted to older patients and yet more in men 
than in women. In the hypothetical SBP reduction scenarios achieved through fixed-dose 
combination HCT 12.5mg/Losartan 50mg, the long-term health and economic benefits 
estimated were greater than in the base-case scenario for both a 10-year and a lifetime 
horizon. Thus, the CE estimates across all scenarios were highly influenced by the model’s 
time horizon. 
In the scenario comparing a 10-year treatment with HCT 25mg vs. no treatment in male 
and female smokers, the estimated ICERs were more favorable than the ICERs estimated 
in the base-case scenario in patients with comparable age-, gender- characteristics but 
with the prevalence of smoking representative for Dutch population.  
The aforementioned results reflect the higher levels of CVD risk estimated for male and 
female smokers (Table 4) compared to patients with similar characteristics but with 
average smoking prevalence, as well as the greater benefits of risk reduction in smoking 
patient population. 
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The impact of the model parameters’ uncertainty on the ICER estimates was assessed 
through a PSA. The results of the PSA show that although the deterministic approach is 
likely to favor the CE of SBP reduction, the leap from the reduction of a risk factor to that 
of CVD risk is surrounded by a significant amount of prediction uncertainty.  
Our findings, in terms of both health and economic benefits of SBP reduction are similar to 
the results of other studies investigating the CE of SBP reduction in low CVD risk patients, 
both in a 10-year and in a lifetime horizon (52-57). 
 
Figure 3 Discounted ICER estimates for different scenarios of SBP reductions. 
A: Discounted ICER estimates for different scenarios of SBP reductions in a 10-year time horizon in men aged 40, 
50, 60 and 65, compared to no treatment. 
B: Discounted ICER estimates for different scenarios of SBP reductions in a 10-year time horizon in women aged 
40, 50, 60 and 65, compared to no treatment. 
C: Discounted ICER estimates for different scenarios of SBP reductions in a lifetime horizon in men aged 40, 50, 
60 and 65, compared to no treatment. 
D: Discounted ICER estimates for different scenarios of SBP reductions in a lifetime horizon in women aged 40, 
50, 60 and 65, compared to no treatment. 






10-year time horizon Lifetime horizon 
Figure 4 Uncertainty around the incremental costs and incremental effects.  
Bar plots show the incremental cost and the incremental effect estimates from the deterministic analysis. The 
lines above the bars represent the upper 95% confidence interval limit estimated through a probabilistic 
sensitivity analysis.  
A: Uncertainty around the incremental costs in 60-year-old men for different SBP baseline levels, assumed to be 
treated with hydrochlorothiazide 25 mg.  
B: Uncertainty around the incremental effects in 60-year-old men for different SBP baseline levels, assumed to 
be treated with hydrochlorothiazide 25 mg. 
C: Uncertainty around the incremental costs in 60-year-old women for different SBP baseline levels, assumed to 
be treated with hydrochlorothiazide 25 mg. 
D: Uncertainty around the incremental effects in 60-year-old women for different SBP baseline levels, assumed 
to be treated with hydrochlorothiazide 25 mg. 









Figure 5 Cost-effectiveness acceptability curves. 
Cost-effectiveness acceptability curves show the probabilities that SBP reductions achieved with HCT 25 mg as 
antihypertensive treatment from baseline SBP levels of 160, 150 and 140 mmHg observed in a 10-year and in a 
lifetime horizon, in 60-year-old men A,C and 60-year-old women B,D, are cost-effective at different willingness to 
pay threshold values.  
A: Cost-effectiveness acceptability curves for the treatment with HCT 25 mg assumed in the treatment scenarios 
of 60-year-old men in a 10-year time horizon.  
B: Cost-effectiveness acceptability curves for the treatment with HCT 25 mg assumed in the treatment scenarios 
of 60-year-old women in a 10-year time horizon.  
C: Cost-effectiveness acceptability curves for the treatment with HCT 25 mg assumed in the treatment scenarios 
of 60-year-old men in a lifetime horizon.  
D: Cost-effectiveness acceptability curves for the treatment with HCT 25 mg assumed in the treatment scenarios 
of   60-year-old women in a lifetime horizon.  





Figure 6 ANCOVA analysis of proportion of sum squares for incremental effects and incremental 
costs. 
ANCOVA analysis of proportion of sum squares for incremental effects (left) and incremental costs (right) driven 
by the contribution of the individual model parameter uncertainty. 
ANCOVA, analysis of covariance; CVD, cardiovascular disease; GP, general practitioner; HCT, hydrochlorothiazide. 
 
However, some discrepancies were found in terms of the estimated ICERs. For example, 
through our analysis, it was found that as age increases, lowering of SBP becomes more 
cost-effective when looking in a 10-year time horizon; while the CE of SBP reduction does 
not vary considerably across ages when looking in a lifetime horizon. This is in contrast to 
two other simulation analysis, where middle-aged patients were identified as being those 
mostly benefiting from SBP reductions (52,56). Yet, comparability between studies is 
hampered due to differences regarding the choice of primary CE outcome (QALY)(52,54-
57), and specific assumptions in the model (e.g. differences in baseline patient 
characteristics, modelling of different CVD-related health states, level of SBP reduction 
and country specific cost estimates)(52-57).  
To our knowledge, similar CE studies on the impact of SBP reduction in patients with mild 
hypertension for various age, gender and specific baseline SBP levels and adapted to the 
Dutch situation, have not yet been conducted. From the abundance of different CVD risk 
prediction models (e.g. the Framingham, QRISK, ASSIGN etc.(58-63)), we decided to 
implement the SCORE model (23) given that it has recently been validated for the Dutch 
population.  
We chose to conduct our simulations both in a 10-year and a lifetime horizon. There is a 
variety of reasons for choosing a 10-year time horizon. Firstly, the SCORE model has only 
been validated for 10-year horizons (23). Secondly, if a lifetime horizon is to be applied, 
the CVD risk estimates in the elderly populations might deviate from the CVD risk 
estimated from SCORE as it is validated only for patients under 65 (64,65). Finally, for 
these reasons mentioned above, it can be anticipated that the application of a 10-year 
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horizon is more conservative than a lifetime. However, in order to make a comparison to 
similar studies and to see the influence of its choice on final outcomes, our simulations 
were also conducted in a lifetime horizon.  
In order to examine the uncertainty in the input parameters, multivariate PSA was 
applied. Interval estimates for the scenarios observed revealed a large uncertainty range 
around the expected values from the deterministic analysis regardless of the applied time 
horizon. When investigating the contribution of each of the included parameters to the 
overall uncertainty (ANCOVA), the coefficient estimates of the SCORE model were found 
to have the most impact. This simply suggests that even though a certain risk prediction 
model has been shown to be applicable for a certain population, building decisions upon 
the model should still be made cautiously and being aware of the inevitable uncertainty 
surrounding estimates of effectiveness and CE that are based on long-term projections 
(51). 
As every analysis, ours is also confronted with some limitations. The risk of having a non-
fatal CVD event was obtained through a functional form linking the annual risk of mortality 
to the annual risk of morbidity and mortality. This approach is based on the fact that the 
SCORE model only predicts a CVD mortality risk. Other recent risk prediction models (e.g. 
the Framingham, QRISK, ASSIGN etc.(58-63)) generally provide estimates of an overall CVD 
risk (i.e. CVD morbidity and mortality) with no insight in the fraction of fatal cases. Given 
the requirement of our model to distinguish between fatal and non-fatal CVD events as 
well as the fact that the SCORE model was the only currently validated model in the Dutch 
population, we incorporated it in our analysis for the prediction of CVD mortality together 
with the functional form linking the annual risk of mortality to the annual risk of morbidity 
and mortality. Furthermore, the probability of subsequent non-fatal CVD events was 
assumed to be equal to the probability of a first non-fatal CVD event. This is supported by 
the fact that the SCORE risk model is limited to prediction of first events only and that 
there are no available estimates of risk of subsequent events in the population that the 
SCORE was developed on. Moreover, the fact that the occurrence of a composite CVD 
event was modelled in our analysis hampers the estimation of a subsequent CVD event 
risk. A subsequent CVD event could occur in any CVD form (e.g. stroke, MI) and, therefore, 
the risk of its re-occurrence would be dependent on the specific primary CVD event form. 
Notably, we could expect more cost-effective outcomes if risks of subsequent non-fatal 
events following a first event were naturally assumed to be higher. Therefore, in order to 
alleviate the underestimation of the CVD risk, an increased mortality risk was assumed in 
patients experiencing non-fatal CVD events. Furthermore, the impact of the joint 
interaction of variables SBP and antihypertensive treatment on the risk prediction is not 
accounted for in the SCORE model. Such a limitation of the SCORE model prevents 
modelling the impact of SBP level on risk prediction with and without the use of 




exclusively achieved by specific antihypertensive treatment. In a real life setting, 
differences in persistence to treatment or the presence of other risk factors could 
obviously result in significant discrepancies between real life and the simulated results of 
our analysis. In the base-case scenario, the real life effectiveness of HCT 25mg and 
patients’ adherence to this treatment were incorporated. However, in the absence of 
synthesized evidence on the effectiveness of the HCT 12.5mg/Losartan combination, 
hypothetical SBP reductions of 20 and 30 mmHg were assumed. The latter assumption 
was made in order to incorporate the treatment costs in the overall cost estimate of SBP 
reduction and not to derive an estimate of CE for the combination treatment per se. 
Additionally, an instant, incremental SBP reduction was assumed. In reality, however, this 
is highly unlikely. Moreover, side effects resulting from antihypertensive treatment were 
not incorporated. Societal costs were also not included in the estimations of CE which 
makes our estimates more conservative. However, it could be expected that implementing 
a societal perspective is likely to lead to more favourable ICERs especially at younger 
populations that encounter greater loss of productivity and costs related to it. Finally, it 
should be noted that CVD risk reduction can also be accomplished through dietary 
measures or increased exercise, potentially leading to comparable (or perhaps even more 
favourable) ICERs (55,66). 
Recent evidence suggest that lifelong CVD risk estimates might be more informative than 
10-year ones.(67) However, treatment recommendations by the latest Dutch guidelines 
are based on the levels of patient’s 10-year risks. Specifically, patients can receive 
treatment if their 10-year risk for CVD is more than 20%, or if they have accompanying risk 
factors (5). The cumulative 10-year risk for our patient population was less than 20%, in all 
cases. Hence, if a decision on whether to apply antihypertensive treatment would have 
been made merely in accordance to the guidelines, none of our patients would have 
received treatment. Notably, guideline recommendations are made with respect to CE of 
treatment application. However, due to the recent changes in pharmaceutical policy in the 
Netherlands (e.g. preference policy (6)), the cost of antihypertensive treatment is now 
considerably lower. This might lead to the conclusion that the current recommendations 
limit treatment to a population with a relatively high 10-year risk, whereas favourable CE 
is also likely in groups with lower risks. Furthermore, younger patients, who are currently 
at a relatively low 10-year risk, are likely to experience an increase in risk later in life, due 
to their characteristics. Therefore, especially for this population, early preventive 
treatment is expected to provide significant increases in LE, as illustrated in our model 
when applying the lifetime horizon (67). 
Conclusion 
Even relatively small SBP reductions can lead to significant lifetime health and economic 
benefits. Given that, nowadays, low-cost generic drugs account for the smallest share in 
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the overall medical costs in primary CVD prevention, there are more opportunities for a 
wider and less strict application of CVD prevention strategies. 
SBP reductions in low-risk elderly men were found to be more cost-effective when 
compared to women, in a 10-year time horizon. When employing a lifetime horizon, the 
CE estimates indicated a comparable eligibility of both genders for treatment. However, 
our results clearly indicate that decision-making should highly consider the amount of 
uncertainty surrounding the estimated values of the analysis. 
Appendix  
Detailed description of the process and assumptions on transforming the SCORE 
cumulative risk to annual probabilities 
The SCORE model applies a Weibull proportional hazards model to provide a 10-year 
cumulative risk of CVD mortality. In our analysis we used the coefficients of an updated 
SCORE model for low-risk regions (personal communication: Fitzgerald T, Department of 
Epidemiology & Public Health/Statistics, University College Cork). 
The SCORE risk model included covariate adjustments for a number of risk factors. We 
used Dutch-specific values for these risk factors in order to produce predictions of 10-year 
CVD mortality risk that would correspond to the Dutch population and we consequently 
estimated annual probabilities of CVD mortality. 
Specifically, the underlying baseline 10-year probability of survival without CVD  was 
estimated for different ages and SBP levels after being corrected for the risk factors total 
cholesterol and the prevalence of smoking using Dutch-specific values. 
  = exp(− exp(α
 ∗ (age − 20
(

, ω = exp(β ∗ (sbp − 140
/10 +  β !"#  ∗ (chol − 5
 +  β)"*+  ∗ smoker
 , 
where α, ρ, β , β !"#, β)"*+ are the coefficients of the updated SCORE model; sbp is 
the level of systolic blood pressure investigated (mmHg); chol is the level of total 
cholesterol (mmol/l); smoker stands for the prevalence of current smoking. 
Annual probabilities were obtained for every Markov cycle and for each of the scenarios 
by estimating the age- and SBP- specific CVD event probability conditional on the patient’s 
survival up to this time point. For example, survival in the first year /0 where t=1 from 
the start of the observation is conditional on the patient’s underlying baseline survival . 
Survival probability /0 at the time point t is: /0 = exp1− exp(α
 ∗ (age − 20 + t
(
3, ω = exp(β ∗ (sbp − 140
/10 +  β !"#  ∗ (chol − 5
 +  β)"*+  ∗ smoker
, 
where t stands for the year for which the probability of CVD mortality needs to be 





Process of calculating the annual probability of CVD mortality  
Step 1 
In order to estimate the risk of having a fatal CVD event in the first year of the model 
cycle, calculate  and /0, where t has a value 1. CVD7890:;<0= 9<>? =@:9 A = 1 − (/A ⁄ 
  
Step 2 
Calculating the yearly risks of having a fatal CVD event in the second and the following 
years continues in the following manner:  CVD7890:;<0= 9<>? =@:9 C = 1 − (/C /A⁄ 




Table A.I Estimated 10-year costs of treatmenta assumed with a fixed-dose combination HCT 
12.5mg/Losartan 50 mg and no treatmentb and life years lost (LYL) for different age groups and 
different SBP scenariosc per patient. 
 
Gender Age Baseline 
SBP 
(mmHg) 
10-year cost of   










Men        
 40 160 888 0.14 20 1,706 0.10 
    30 1,674 0.08 
 150 842 0.12 20 1,674 0.08 
       
 50 160 1,364 0.36 20 2,004 0.25 
    30 1,910 0.21 
 150 1,229 0.30 20 1,910 0.21 
       
 60 160 2,014 0.58 20 2,409 0.40 
    30 2,233 0.34 
 150 1,766 0.48 20 2,233 0.34 
       
 65 160 2,261 0.59 20 2,550 0.42 
    30 2,342 0.35 
 150 1,972 0.50 20 2,342 0.35 
       
Women        
 40 160 704 0.02 20 1,595 0.02 
    30 1,590 0.01 
 150 697 0.02 20 1,590 0.01 
       
 50 160 823 0.11 20 1,646 0.08 
    30 1,618 0.06 
 150 783 0.09 20 1,618 0.06 
       
 60 160 1,209 0.28 20 1,868 0.20 
    30 1,785 0.16 
 150 1,090 0.23 20 1,785 0.16 
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Gender Age Baseline 
SBP 
(mmHg) 
10-year cost of   










 65 160 1,482 0.37 20 2,027 0.26 
    30 1,907 0.21 
 150 1,312 0,31 20 1,907 0,21 
aTreatment alternative assumed costs of antihypertensive treatment and costs due to cardiovascular morbidity 
and mortality that in a certain lower degree appears in a treated cohort, 
bNo treatment alternative assumed costs due to cardiovascular morbidity and mortality, 
c Different age-, gender- and SBP reduction related scenarios were assumed  for a treatment and no treatment 
alternative, Treatment with a fixed-dose combination HCT 12,5mg/Losartan 50 mg was assumed to reduce the 
SBP from a baseline SBP of 160 mmHg for either 20 or 30 mmHg; or to reduce the SBP from a baseline SBP of 150 
mmHg for 20 mmHg, No treatment alternative assumed that a patient would remain at a baseline SBP level 
respective to the one assumed in the treatment scenario (160 or 150 mmHg), 
LYL, life years lost; SBP, systolic blood pressure 
 
Table A.II Estimated lifetime costs of treatmenta assumed with a fixed-dose combination HCT 
12.5mg/Losartan 50 mg and no treatmentb and life years lost (LYL) for different age groups and 
different SBP scenariosc per patient. 














Men        
 40 160 6,434 4.33 20 7,532 3.28 
    30 7,096 2.83 
 150 5,959 3.78 20 7,096 2.83 
       
 50 160 6,098 3.43 20 6,875 2.60 
    30 6,431 2.25 
 150 5,593 3.00 20 6,431 2.25 
       
 60 160 5,608 2.54 20 6,040 1.92 
    30 5,601 1.66 
 150 5,092 2.22 20 5,601 1.66 
       
 65 160 5,221 2.09 20 5,508 1.58 
    30 5,086 1.36 
 150 4,721 1.82 20 5,086 1.36 
       
Women        
 40 160 6,524 4.43 20 7,741 3.30 
    30 7,303 2.83 
 150 6,053 3.83 20 7,303 2.83 
       
 50 160 5,974 3.57 20 6,977 2.67 


















 150 5,511 3.10 20 6,556 2.29 
       
 60 160 5,443 2.73 20 6,146 2.05 
    30 5,737 1.76 
 150 4,978 2.37 20 5,737 1.76 
       
 65 160 5,142 2.31 20 5,680 1.73 
    30 5,279 1.49 
 150 4,679 2.01 20 5,279 1.49 
a Treatment alternative assumed costs of antihypertensive treatment and costs due to cardiovascular morbidity 
and mortality that in a certain lower degree appears in a treated cohort, 
bNo treatment alternative assumed costs due to cardiovascular morbidity and mortality, 
c Different age-, gender- and SBP reduction related scenarios were assumed  for a treatment and no treatment 
alternative, Treatment with a fixed-dose combination HCT 12,5mg/Losartan 50 mg was assumed to reduce the 
SBP from a baseline SBP of 160 mmHg for either 20 or 30 mmHg; or to reduce the SBP from a baseline SBP of 150 
mmHg for 20 mmHg, No treatment alternative assumed that a patient would remain at a baseline SBP level 
respective to the one assumed in the treatment scenario (160 or 150 mmHg), 
LYL, life years lost; SBP, systolic blood pressure 
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Background: Acute heart failure (AHF) is frequent, severe and costly, however detailed 
population-based epidemiological data are currently unavailable for the Netherlands. Our 
aim was to characterize the incidence, patient characteristics and outcomes of AHF, and 
estimate associated hospitalizations costs in the Netherlands. 
Methods: Using the 2010 and 2011 National Medical Registration (LMR), we identified all 
patients admitted to hospital with AHF as a primary diagnosis. We extracted hospital data 
on resource use in 2011 associated with AHF, as it provided more contemporary 
information, in order to calculate its cost. Major components of hospital resource use 
included in this estimate were inpatient care, diagnostic procedures and major 
interventions conducted during the hospital stay and autopsy associated with inhospital 
mortality.  
To quantify the cost of inpatient care, we applied four different scenarios. Scenario 1 
assumed the aforementioned cost to be associated only with the cost of stay in general 
wards. Other scenarios (2-4) assumed the cost of stay in emergency wards to contribute 
with 10, 25 and 50% to the cost estimate associated with inpatient care 
Results: Analysis of the data identified 33,973 hospitalizations in Netherlands in 2010 due 
to main diagnosis of AHF. In 2011, the identified number of hospitalizations was 15,731 for 
men and 15,517 for women. The average patient age in AHF in 2011 was 74.4 (±11.8) and 
79 (±11.6) years for men and women, respectively. The most common comorbid 
conditions were atrial fibrillation, old myocardial infarction, diabetes, unspecified 
hypertension, COPD and other diseases of endocardium. The mean hospital length of stay 
was 7.9 days and it was similar for men and women. Finally, the estimated hospital cost of 
AHF in scenario 1 was €3,902 for women and €4,044 for men, while in scenarios 2, 3 and 4 
the cost was even higher reaching up to €8,088 for women and €8,078 in men. 
Conclusions: Our study provides important insights into the characteristics and costs of 
AHF hospitalizations in the Netherlands. Further analysis directed to linking the available 
LMR data with hospital claims data will indicate the cost of medication use and therefore 
provide more comprehensive hospital AHF cost estimates.  
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Heart failure (HF) is a syndrome presented with symptoms and signs caused by cardiac 
dysfunction that commonly affects elderly people (1). In the United States, approximately 
5.8 million people have HF, while in Europe this syndrome affects more than 15 million 
people (2,3). In line with international findings, HF is a highly prevalent condition in the 
Netherlands causing a major health and economic burden to the healthcare system. 
According to the national RIVM-data, an incidence of 37,000 and prevalence of 127,000 
patients was recorded in 2008 (4). In addition, patients with HF may suffer not only from 
different levels of physical activity impairment, but also lower quality of life (QoL) 
compared to the general population. Specifically, two studies assessing the QoL in Dutch 
patients with HF used the EQ-5D instrument (measures an individual’s preference for 
living in HF state compared to other health states) to summarize QoL between values of 
0.47 and 0.77 (5,6). This range in the QoL observed in the two studies may be due to the 
differences in HF severity, time of assessment relative to disease onset and other 
underlying patients’ characteristics (e.g. age, comorbidities or type of treatment). In 
agreement with the high health burden associated with HF, the economic burden to the 
Dutch healthcare system was marked with the cost of €455 million or 0.6% of the total 
healthcare budget in 2007 (4). The major share of expenditures (i.e. 60%) was recorded 
for hospitalizations for HF. Notably, hospitalizations might occur due to the new onset of 
HF (‘de novo’) or deterioration of chronic HF with symptoms that warrant hospitalization. 
Both of the aforementioned presentations of HF can be described as acute heart failure 
(AHF) according to ESC guidelines for the diagnosis and treatment of acute and chronic 
heart failure 2012 (1). Notably, the number of HF hospitalizations in Dutch hospitals 
increased in the period 1998-2010(4). Given such a trend in hospitalizations and the 
indications of higher, both short- and long-term, mortality risk following index 
hospitalization (7), it remains important to have up-to-date information on the incidence 
of AHF.  
In the last decade, there have been major changes in the clinical practice and treatment of 
HF marked with the introduction of new medications and medical devices. These 
treatment innovations are expected to lead to a better survival and shorter length of 
hospital stay (1,8,9). Though clinical trials on new treatments might indicate favorable 
health outcomes in HF patients, the decision on their application in clinical practice are 
also made with respect to the economic consequences associated with their use. 
Importantly, to conduct robust economic analyses on treatment strategies in HF patients, 
analysts should be provided with the most contemporary evidence on both health 
outcomes and costs associated with those strategies. Given that the costs of 




date information on the use of hospital care resources is essential for such evidence, ergo, 
ultimate economic evaluations. 
In this study, we aim to characterize the incidence, patient characteristics and outcomes 
of AHF, and estimate associated hospital costs in the Netherlands. 
METHODS 
Data source  
The National Medical Registration (LMR) for 2010-2011 was used to identify patients who 
were hospitalized for AHF as primary (discharge) diagnosis either due to the new-onset HF 
or decompensation of chronic HF. Hospital data coverage was 87% and 82% in 2010 and 
2011, respectively. LMR provide information on demographic characteristics (e.g. age, 
gender), the main (discharge) diagnosis, secondary (other) diagnoses, date of admission 
and discharge, medical procedures performed during the stay (i.e. surgery, imaging, etc.), 
prior location of patient (own home, hospital, etc.), discharge destination (death, own 
home, another hospital, rehabilitation center, etc.) and characteristics of the hospital (i.e. 
general  or academic hospital). In the LMR dataset, diagnoses are coded using the 
International Classification of Diseases, Ninth Revision (ICD-9). 
Identification of cases 
Cases were selected for our analysis if their discharge diagnosis was coded with one of the 
ICD-9 codes detailed in Table 1. Here the term ‘discharge’ refers to both live discharges 
and deaths. Additionally, patients admitted to hospital in 2009 but discharged in 2010 
were also selected for the analysis. The absolute number of cases (including day 
admissions) was identified for both 2010 and 2011, however, the description of patient 
characteristics and outcomes was provided only for cases observed in 2011 as it provided 
more contemporary information. Specific outcomes described are the length of hospital 
stay, medical procedures performed and patient flow in 2011. When patient 
characteristics, such as the presence of comorbidities and age, were analyzed, recurrent 
cases of HF hospitalizations were excluded. The presence of comorbidities was identified 
by analyzing the secondary diagnosis if reported.  
All the analysis was performed using SPSS version 22. 
Cost estimation 
In this study, a top-down approach was used to estimate the hospital costs associated 
with AHF. In this approach, cost components were valued by identifying age- and gender-
specific resource use from annual AHF cases in 2011. This resulted in estimating hospital 
resource use (e.g. average length of stay) for an average male and female patient. 
Additionally, separate resource use estimates were estimated for different age groups (i.e. 
<70, 70-85 and >86). Hospital resource use components were subgrouped into four 
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categories: inpatient care, diagnostics, interventions and autopsy. Unit costs associated 
with those categories were based on national tariffs or collected from published Dutch 
studies (Table 2)(10-12). All costs were inflated to 2014 levels using the Dutch inflation 
index. 
The LMR provides no information on whether patients were admitted to a general or 
emergency hospital ward. Therefore, we applied four different scenarios to quantify the 
cost of inpatient care. Scenario 1 assumed the cost of inpatient care to be associated only 
with the cost of stay in general wards. Other scenarios (2-4) assumed the cost of stay in 
emergency wards to contribute with 10, 25 and 50% to the cost of inpatient care. 
 
Table 1 Identification of patients hospitalized for heart failure 
Description ICD-9 code 
Hypertensive heart disease malignant with HF  402.01 
Hypertensive heart disease benign with HF  402.11 
Hypertensive heart disease unspecified with HF  402.91 
Hypertensive heart and renal disease malignant with HF  404.01 
Hypertensive heart and renal disease malignant with HF and renal failure  404.03 
Hypertensive heart and renal disease benign with HF  404.11 
Hypertensive heart and renal disease benign with HF and renal failure  404.13 
Hypertensive heart and renal disease unspecified with HF  404.91 
Hypertensive heart and renal disease unspecified with HF and renal failure  404.93 
Congestive HF, unspecified  428.00 
Left HF  428.10 
Systolic HF unspecified  428.20 
Systolic HF acute  428.21 
Systolic HF chronic  428.22 
Systolic HF acute on chronic  428.23 
Diastolic HF unspecified  428.30 
Diastolic HF acute  428.31 
Diastolic HF acute on chronic  428.33 
Combined systolic and diastolic HF unspecified  428.40 
Combined systolic and diastolic HF acute  428.41 
Combined systolic and diastolic HF chronic  428.42 
Combined systolic and diastolic HF acute on chronic  428.43 
HF unspecified  428.90 





Table 2 Cost estimates applied in the analysis. 
Key resource items Unit cost (€, 2014) 
Length of stay in general ward (daily) 469 
Length of stay in emergency ward (daily) 1,524 
Electrocardiography 22 
Echocardiography 53 
Computer tomography scan 202 
Doppler 41 
Catheterisation 815 
ICD implantation 35,893 
PTCA 3,553 
Pacemaker 10,152 
Cost of autopsy 427 
ICD, implantable cardioverter defibrillator; PTCA, Percutaneous transluminal coronary angioplasty  
RESULTS 
In 2010, a total of 33,973 hospitalizations were coded with a main diagnosis of HF at 
discharge in Dutch hospitals. Throughout this period, there was a similar level of 
hospitalization between men and women (i.e. 49.9%:50.1%). In 2011, the identified 
number of hospitalizations was 15,731 for men and 15,517 for women. 
The average patient age in AHF was 74.4 (±11.8) and 79 (±11.6) years for men and women 
respectively. The distribution of patient ages for those hospitalized for AHF is reported in 
Figure 1. The mean number of comorbidities per patient was 2.6 (±2.4). Some of the most 
frequent comorbidities in AHF patients were atrial fibrillation (8.3%), old myocardial 
infarction (4.1%), diabetes mellitus (3.9%), unspecified hypertension (3.8%), COPD (3.3%) 
and other diseases of endocardium (3.2%). 
Figure 2 depicts the patients flow for hospitalizations occurring in 2011. In 95% of the 
cases, home was identified as a prior location of a patient. The majority of hospitalizations 
took place in general hospitals (i.e. 92.6%). Day admissions accounted for 6% of all 
admissions. After the hospitalization, 78.7% of patients returned to home, 11.5% were 
transferred to nursing care or other hospitals and 9.8% died by the end of their hospital 
stay. The mean length of hospital stay was 7.9 (±9) days and it similar for similar for men 
and women (Figure 3). 
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Figure 1 Distribution of hospitalized acute heart failure patients according to their age. 
Hospital costs of AHF 
Inpatient care cost was the largest contributor to the overall AHF cost estimate in both 
women and men at 95% and 88%, respectively (Figure 4). Echocardiography and 
electrocardiography were identified as some of the most frequently used diagnostic 
procedures, while the most common interventions were various catheterizations, 
percutaneous coronary angioplasty, implantable cardioverter defibrillator (ICD) 
implantation. Based on the resource use of the aforementioned categories and their 
respective national cost estimates (Table 2), the estimated hospital cost of AHF in scenario 
1 was €3,902 for women and €4,044 for men (Figure 4). After adjusting for age- and 
gender-specific level of resource use, the estimated cost of hospitalization due to AHF in 
women was in range from €3,623 in women older than 86 years to €4,251 in women 
younger than 70 years (Table 3). In men, the corresponding cost of hospitalization was in 
range from €3,709 (>86 years old) to €4,453 (<70 years old) (Table 3). Scenarios 2, 3 and 4 
assuming the cost of stay in emergency wards to contribute with 10, 25 and 50% to the 
inpatient care cost, are presented in Table 4. At a cost of stay in emergency ward 
contributing with 10% to the total inpatient care cost, the estimated AHF hospital cost was 




inpatient care cost to 50%, resulted in the total AHF hospital costs of €8,088 in women 
and €8,078 in men. 
Figure 2 Patient flow in 2011. 
 
Figure 3 Length of hospital stay (days) related to acute heart failure. 
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Figure 4 The estimated cost of hospital admissions associated acute heart failure for women (left) 
and men (right). Scenario 1. 
 
Table 3 Age- and gender-specific cost of hospitalization (excl. medication use) for AHF. Scenario 1. 
Age group Resource  Women Men 
<70 years Inpatient care €4,251 0.03% € 4,453 0.02% 
Diagnostics 16.72% 19.51% 
Interventions 83.20% 80.42% 
Autopsy 0.05% 0.05% 
71-85 years Inpatient care €4,065 94.62% €4,028 88.56% 
Diagnostics 0.03% 0.03% 
Interventions 5.30% 11.35% 
Autopsy 0.05% 0.06% 
>86 years Inpatient care €3,623 98.74% €3,709 97.77% 
Diagnostics 0.03% 0.05% 
Interventions 1.16% 2.13% 
Autopsy 0.07% 0.06% 
 
Table 4 The estimated cost of hospital admissions associated with AHF. Scenarios assuming the 
emergency ward costs to contribute to the inpatient care cost. 
Scenario Cost of hospitalization (excl. medication use) for AHF (€) 
 Women Men 
2: emergency ward 10% 4,739 4,851 
3: emergency ward 25% 5,995 6,061 
4: emergency ward 50% 8,088 8,078 






In the 2010 and 2011 LMR data and for AHF cases only, there were 33,973 and 31,248 
hospitalizations, respectively. Based on the hospital resource use associated with AHF in 
2011, we estimated the hospital cost of AHF in scenario 1 to be €3,902 for women and 
€4,044 for men. However, this is under the assumption that the resource use of inpatient 
care was associated only with the costs of stay in general hospital wards. In fact, the 
overall hospital cost of AHF rose significantly when the cost of stay in emergency wards 
was assumed to contribute to the cost of inpatient care. In particular, with the 
contribution of emergency wards costs of 50%, the overall hospital cost of AHF would 
double. Furthermore, our findings on the age- and gender-allocation of hospital resources 
indicated lower AHF costs in older patients and in women compared to men. The 
estimated decrease in costs in older age groups was due to lower use of intervention 
resources. 
The absolute number hospitalizations due to AHF decreased in 2011 compared to 2010, 
however, this finding is based on the LMR data with incomplete hospital coverage. 
Therefore, in order to properly assess the most recent trend in AHF hospitalizations, 2012-
2014 Dutch hospital data with complete hospital coverage should be analysed. 
Interestingly, our analysis indicated a relatively low presence of certain comorbidities in 
AHF patients in comparison to other international findings (13). For example, 
hypertension as a secondary diagnosis was reported only in 3.8% of AHF patients in the 
2011 LMR data, while in other studies on AHF patients such as the ADHERE, OPTIME and 
VMAC, the prevalence of hypertension was approximately 70% (13). Failure of some of the 
Dutch hospitals to report secondary diagnoses may be a reason for the aforementioned 
findings.  
Comparison to other studies 
In their report on HF, Koopman et al. indicated a lower number of hospitalizations due to 
HF in the Netherlands in 2010 (i.e. 14,808 men and 15,030 women) in comparison to our 
observations (4). This discrepancy might be due to the possible differences in the data 
coverage at the time of the analysis and cases selection criteria (e.g. the choice of the ICD-
9 codes, inclusion of patients admitted in 2009 but discharged in 2010, or inclusion of 
cases with day admissions). 
A Dutch study reported the cost for HF hospitalisation in the Netherlands in 1999 to be 
€4,795 (14). However, a direct comparison of this cost estimate to our findings is hindered 
given the disparity in reporting hospital resources between the two studies. Moreover, 
changes in clinical practice and introduction of new innovations for the treatment of AHF 
during the last decade may contribute to potential differences in cost estimates. 
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Our analysis is confronted with several limitations that may restrict the interpretation of 
results. One limitation is that the identification of AHF cases in our study relies on 
discharge diagnosis. Specifically, problems with the interpretation of the data may arise if 
incomplete and/or imprecise coding of diagnosis occurs. A couple of studies provided 
evidence of the number of hospital events related to HF to be underestimated when the 
analysis was solely based on hospital discharge codes (15-17). Furthermore, incomplete 
coding might also be the reason for a relatively low prevalence of certain comorbidities 
(e.g. hypertension, diabetes, atrial fibrillation, etc.) in AHF patients that our study 
observed. Another limitation of our study concerns the missing information on medication 
resource use in AHF. This inevitably underestimates the estimated hospital AHF cost. 
Further investigation should be directed to linking the available LMR data with hospital 
claims data. This will indicate the cost of medication use and therefore provide more 
comprehensive hospital AHF cost estimates. Notably, such a complete analysis should 
provide a valid, up-to-date hospital AHF cost estimate that could find its use in economic 
evaluation on HF treatments. 
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Background: There are numerous health-related quality of life (HRQol) measurements 
used in coronary heart disease (CHD) in the literature. However, only values assessed with 
preference-based instruments can be directly applied in a cost-utility analysis (CUA).  
Objective: To summarize and synthesize instrument-specific preference-based values in 
CHD and the underlying forms of CHD, stable angina and post-acute coronary syndrome 
(post-ACS), for developed countries, while accounting for study-level characteristics and 
within-study correlation. 
Methods: A systematic review was conducted to identify studies reporting preference-
based values in CHD. A multivariate meta-analysis was applied to synthesize the HRQoL 
values. Meta-regression analyses examined the effect of study level covariates age, 
publication year, prevalence of diabetes and gender. 
Results: A total of 40 studies providing preference-based values were detected. 
Synthesized estimates of HRQoL in post-ACS ranged from 0.64 (Quality of Well-Being) to 
0.92 (EuroQol European ”tariff”), while in stable angina they ranged from 0.64 (Short form 
6D) to 0.89 (Standard Gamble). Similar findings were observed in estimates applying to 
general CHD. No significant improvement in model fit was found after adjusting for study-
level covariates. Large between-study heterogeneity was observed in all the models 
investigated. 
Conclusions: The main finding of our study is the presence of large heterogeneity both 
within and between instrument-specific HRQoL values. This large between-study 
heterogeneity among instrument-specific HRQoL estimates may be explained by both 
observed and unobserved underlying methodological differences across instruments and 
study-level characteristics. Current economic models in CHD ignore this between-study 
heterogeneity. Multivariate meta-analysis can quantify this heterogeneity and provide 
estimates for CUAs. 
  
4 




A large number of health-related quality of life (HRQoL) measures for patients with 
coronary heart disease (CHD) is available in the literature (1-4). Those measures either 
describe the HRQoL of patients suffering from CHD overall or distinguish across patients 
suffering from one of the underlying forms of CHD, specifically stable angina or post-acute 
coronary syndrome (post-ACS). This interest in estimating the level of HRQoL in CHD is 
mainly due to its increasing economic and clinical burden (5), the number of CHD 
prevention and treatment strategies available, and the necessity to assess the impact of a 
treatment on HRQoL for use as input parameter in cost-utility analyses (CUAs) (6,7).  
From the abundance of HRQoL measurements in CHD, only the preference-based HRQoL 
values can be directly applied in CUA (6,8). These values express the individual’s 
preference for living with CHD compared to other health states on an interval scale where 
the value of zero is assigned to death, and the value of one to full health (7). Their 
application in CUA is essential for the computation of the quality-adjusted life years 
(QALYs) health summary measure (7,9,10). Preference-based values can be generated 
with direct elicitation techniques, such as the time trade-off (TTO), the standard gamble 
(SG) and the rating scale (RS). Another approach is based on preference-based multi-
attribute instruments, such as, the EuroQol 5D (EQ-5D), Short form 6D (SF-6D)) health 
utility index (HUI) and the quality of well-being (QWB) scale (7). Alternatively, in the 
absence of HRQoL values obtained by one of the aforementioned instruments, other 
HRQoL measurements can be mapped onto a preference-based estimate (11-13).  
There is significant variation in the published literature with respect to the preference-
based HRQoL value of patients with CHD (1,14-16). Methodological differences between 
direct preference-based techniques such as the exact specifications of the questions on 
individuals’ preferences, have been shown to have considerable impact on HRQoL values 
(7). Some of the differences in HRQoL values measured with preference-based multi-
attribute instruments reflect the variation across instruments on the sensitivity of 
different health attributes across different severity levels as well as the use of different 
direct valuation techniques (7). Finally, HRQoL values can largely vary due to differences in 
study-level covariates such as patients’ characteristics (e.g. underlying CHD forms, age, 
and comorbidities), types of treatment applied or time points of measuring HRQoL relative 
to the disease onset or treatment initiation. 
All the aforementioned differences in the underlying methodology indicate that the choice 
and interpretation of the HRQoL value to be applied in CUA need to consider the impact of 
both instrument-specific properties sometimes limited to country-specific 
pharmacoeconomic guidelines’ requirements (e.g. the EQ-5D in the UK(8)), and study-level 
covariates for specific HRQoL values. The choice of the instrument can have a significant 




al. compared the outcomes of a CUA on different treatment options for patients with knee 
pain, where HRQoL was measured with both the EQ-5D and SF-6D instruments (17). The 
authors demonstrated that the treatment option that was estimated to be the most 
favourable differed depending on the HRQoL instrument used in the aforementioned 
patient population. Notably, it is this sensitivity of CUA outcomes on the HRQoL values 
(17) that urges for robust estimates of HRQoL. This issue becomes even more complex 
when multiple candidate sources for the HRQoL value exist in the literature. 
Evidence based decision making requires the use of all available relevant evidence for 
decision making through a form of evidence synthesis as such exercise can provide better 
estimates around the mean and variance of HRQoL. Examples of meta-analysis in HRQoL 
can be found in various disease areas (18-20). Those meta-analyses accounted for the 
underlying differences in the instruments by examining their impact on the level of HRQoL 
in a meta-regression framework (19,21), and  by conducting univariate meta-analyses for 
the values measured with each instrument (22). The application of meta-analysis on 
HRQoL values is straightforward when all values are measured with the same instrument. 
However, a number of studies provide multiple and correlated HRQoL values measured in 
the same population but using different instruments. Conducting separate univariate 
meta-analyses for each HRQoL is inappropriate as ignoring the within-study correlation 
might lead to biased mean and standard error (SE) estimates (23,24). Instead, multivariate 
meta-regression analysis is recommended (23,24). Therefore, in this study we aim to 
systematically summarize and synthesize the published preference-based HRQoL values in 
CHD and its underlying disease-forms (i.e. stable angina and post-ACS) for developed 
countries. To account for the underlying differences in the instruments used to measure 
the HRQoL, and the correlation between instrument-specific values both within and 
between studies, the synthesis of HRQoL values is conducted on an instrument-specific 




This study was conducted following the PRISMA guidelines. Relevant studies reporting 
HRQoL in CHD were independently screened and systematically reviewed by two team 
members [JS and PP]. Studies were searched using MEDLINE and EMBASE. The search 
terms used were: (“coronary disease” or “coronary heart disease” or “myocardial 
infarction” or “angina” or “acute coronary syndrome”) and (“utility” or “quality of life” or 
“outcome assessment”) and ("Health Utilities Index" or "quality of well-being" or "rating 
scale" or "standard gamble" or "time trade-off" or "15D" or "SF-6D" or "EQ-5D" or 
"HALex"). The search was limited to studies applying to developed countries published 
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between 1990 and November 2014. By including only studies from developed countries, 
we aimed to limit the variation on HRQoL associated with the relation between socio-
economic status and HRQoL (25). Additionally, the references of the identified articles and 
other systematic reviews were searched for relevant studies not included in the above-
mentioned databases (snowballing). Studies were considered eligible for this analysis if 
they: 1) applied a preference-based instrument of measuring HRQoL (TTO, SG, RS, EQ-5D, 
SF-6D, SF-15D, HUI, QWB and HALex) 2) reported mean preference-based HRQoL values 
measured three months or more after the initiation of CHD-treatment or after the onset 
of CHD, 3) reported standard deviations (SDs) and sample sizes or confidence intervals 
(CIs)/SEs of those measurements. Duplicate studies were excluded as well as editorials, 
letters, clinical conference abstracts, reviews and studies that reported median but not 
mean HRQoL values. Disagreements were resolved through discussion.  
Data were extracted from the eligible studies regarding study origin (authors, publication 
year, country), study design, participants (age, study sample, percentage of men, 
percentage of diabetics, underlying form of CHD) as well as the HRQoL (mean value, SD or 
CI/SE of the mean), type of instrument for measuring HRQoL and correlation coefficients 
between instrument-specific values.  
Assumptions and data adjustments 
We distinguished between two underlying CHD forms: stable angina and post-ACS. The 
stable angina and the post-ACS groups comprised of stable angina patients and patients 
with unstable angina or myocardial infarction, respectively, in whom HRQoL was 
measured at least three months after diagnosis or treatment initiation. Our analysis was 
limited to HRQoL values measured three months after onset of CHD or treatment 
initiation hypothesizing that the impact of the acute disease onset or a treatment effect 
on HRQoL will be stabilized by then. When allocating recorded HRQoL values to underlying 
CHD forms based on the patients’ characteristics reported in the studies, certain 
assumptions were made. If information on patients’ characteristics was insufficient to 
provide their allocation to either stable angina or post-ACS, these HRQoL values were 
analysed as values for general CHD patients. Furthermore, no distinction was made 
between the HRQoL values measured in patient subgroups other than the ones reflecting 
underlying CHD forms (e.g. different treatment or socio-economic subgroups). In cases 
where studies provided HRQoL values in a subgroup classification that was not of interest, 
the HRQoL values across subgroups were synthesized to provide a weighted mean and 
variance estimate for a specific CHD form per study. 
Statistical model 
A multivariate meta-analysis was used to estimate synthesized, instrument-specific HRQoL 
estimates in post-ACS, stable angina and general CHD (23). This approach accounts for the 




different instruments and was extended to a multivariate meta-regression analysis to 
account for the impact of study-level covariates where appropriate. The general structure 
of the model applied is presented below in matrix form. E< =  F<G< + H< + I<  i = 1,…,n                                                       (1) 
Here E<  stands for a vector of size p whose elements comprise the instrument-specific 
HRQoL values for study i, F<  is a matrix of p instruments and k covariates, G<  is the vector 
of regression coefficients of size k, H<  is a vector of random-effects terms of size p and I<  is 
a vector of random sampling errors of size p. We assumed that H<~MVN(0, N
, where  
 N =  O PAC ⋯ RS(TTU
PAPV⋮ ⋱ ⋮RS(TTU
PAPV ⋯ PVC Y.                                                        (2) 
Here ∆ represents the between-study variance–covariance matrix and its elements are PVC, 
the between-study instrument-specific variance, and RS(TTU
, the between-study 
correlation coefficient assessed when measuring the HRQoL values with Z and Z[ 
instruments. Additionally, it was assumed that I<~MVN(0, \<
, where 
\< =  O ]<A
C ⋯ RTTU]<A]<V⋮ ⋱ ⋮RTTU]<A]<V ⋯ ]<VC Y                                                        (3) 
The matrix \<  is the within-study variance–covariance matrix with elements ]<VC , the 
within-study instrument-specific variance and RTTU , the within-study correlation 
coefficient. 
A common problem in multivariate meta-regression is the presence of missing data for 
variables of interest in eligible studies. In our analysis, missing data were anticipated for 
some of the E<  elements and their corresponding variances, as well as for some within-
study correlation coefficients. Missing values in E<  may occur when HRQoL in a particular 
study was not estimated with all the instruments included in the meta-regression. We 
resolved this by setting the missing values in E<as equal to zero and their corresponding 
variances equal to an arbitrary large number (1,000) (11). In this way the contribution of 
these values to the summarized HRQoL estimate was insignificant. The problem related to 
missing values of RTTU  was resolved by retrieving correlation estimates from a more 
general population without severe comorbidities. Elements of RTTU  that still remained 
missing were assumed to be equal to zero (24). In order to observe the impact of ignoring 
the presence of correlation and to account for possibly different values of correlation 
coefficients, we undertook a sensitivity analysis by assuming correlation coefficients to 
take values of 0 and 0.5 (26). 
In the regression analysis, the covariates incorporated in F<  were examined for their 
statistical significance and their impact on reducing some of the between-study 
heterogeneity on those HRQoL values. There are no guidelines to suggest the minimal 
number of studies per outcome of interest (i.e. an instrument-specific HRQoL value) 
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required for the regression analysis to be plausible in the multivariate setting. For this 
reason, we adopted the guidelines for the univariate setting that suggest a data set 
sample size of approximately 10 measurements may be sufficient for conducting a 
regression analysis with one covariate at a time (26). The regression analysis was limited 
to those outcomes where at least 10 measurements were available. 
In order to indicate the extent of heterogeneity in the true population level of HRQoL that 
is unexplained by study-level covariates and random sampling error in the multivariate 
setting, we calculated the ^_C and ^`C  statistics, recently suggested by Jackson et al (27). We 
used ^`C  to measure the impact heterogeneity for all HRQoL estimates jointly and the ^_C 
statistic to measure the level of heterogeneity both jointly and separately for instrument-
specific HRQoL estimates (27). For the estimation of the ^_C, the aCstatistic was used as a 
basis. In the multivariate setting, the aCstatistic can be interpreted as the ratio of the 
volumes of CIs for summarized estimates under the random effect model and the volumes 
of CIs for summarized estimates under the fixed effects models (27). Under such a 
notation of the aCstatistic, Jackson et al. suggested that the ^_C can be estimated as ^_C = (aC − 1
 aC⁄  (27). Furthermore, the ^`C  statistic, was estimated as ^`C = (bC − 1
 bC⁄ , where the bC statistic represents the ratio of a generalized version of 
Cohran’s Q statistic and its associated degrees of freedom (27).  
The multivariate meta-regression analysis was performed using the package mvmeta (28) 
in the statistical software R (version 2.15.3) (29). 
RESULTS 
Study characteristics 
A total of 40 eligible studies representing over 30,575 patients were identified after the 
inclusion and exclusion criteria were applied (Figure 1). The main characteristics of these 
studies are detailed in Table 1 (1-4,14-16,30-64). The studies were published between 
1991 and 2014, with most of them between 2005 and 2010. Of the 40 studies included, 10 
referred to the UK, 8 to the US, 6 to the multiple country settings, 4 to Germany, 3 to 
Canada and Finland, 2 to Norway and Sweden, and 1 to each of Australia and Korea. 
Various study designs were implemented, ranging from randomised clinical trial to 
different observational study designs. Of the HRQoL values present in those 40 studies, 
31% were observed in patients with stable angina and 29% in patients with post-ACS. The 
remaining 40% of the HRQoL values were associated with patients suffering from any form 
of CHD (including stable angina and post-ACS). The majority of patients were men (71%) 
with an average age of 65.35 years. There was large variation in patients’ characteristics, 
such as the presence and prevalence of various comorbidities (e.g. prevalence of diabetes 
was in range 7-38%), and treatment under evaluation (e.g. surgical procedures, 




reported, the time of HRQoL assessment from disease onset or treatment initiation was 
between 4 months and 10 years.  
The most commonly applied instrument for measuring HRQoL values was the EQ-5D 
(63.5%), while 15D, QWB, SF-6D, HUI, SG, TTO, RS and HALex were less prevalent (7.7, 7.7, 
5.8, 5.8, 3.8, 1.9, 1.9 and 1.9%, respectively). The values measured with the EQ-5D 
instrument varied by the type of TTO “tariffs” utilized (i.e. UK, US, Europe and Korea). The 
scoring of most of the EQ-5D values was based on the UK “tariff” (53%) while US, 
European and Korean “tariff” were less present (19, 8, 8 and 3%, respectively). Three 
studies provided no explicit information on the EQ-5D scoring “tariff” used, however, in 
order to allow for the evidence synthesis these values were grouped together with the UK 
“tariffs”. The values measured with the HUI instrument were presented in the studies as 
both mark 2 (i.e. HUI2) and mark 3 (i.e. HUI3). 
Finally, the correlation coefficients between the instrument-specific HRQoL values, 
necessary for conducting a multivariate meta-analysis on the data set formed, were 
reported in only one of the studies included in the data set (39). Therefore, some of the 
correlation coefficients were retrieved from other studies on cardiovascular patients or 
general populations without severe comorbidities (Table 2)(39,44,65-68). Nevertheless, a 
great number of within the instrument-specific correlation coefficients remained missing. 
Multivariate meta-analysis estimates in post-ACS, stable angina and general CHD  
Table 3 summarizes the instrument-specific estimates synthesized through multivariate 
meta-analysis in the post-ACS, stable angina subgroups and general CHD assessed on the 
full data set. The values for HRQoL in estimates synthesized in post-ACS ranged from 0.64 
(QWB) to 0.92 (EQ-5D European ”tariff”), while in stable angina it ranged from 0.64 (SF-
6D) to 0.89 (SG). In general CHD, the values ranged from 0.60 (HALex) to 0.89 (SG). 
Between-study SDs and variance-covariance matrices for HRQoL in the post-ACS, stable 
angina subgroups and general CHD, when these parameters could be estimated, are 
reported in Tables 4-6. 
In this evidence synthesis, some of the instrument-specific HRQoL values included in the 
data set were present only as single inputs. Notably, the output of the multivariate meta-
analysis in the aforementioned cases reflected the initial instrument-specific HRQoL 
inputs. Because the EQ-5D UK ”tariff” values were the only instrument-specific values 
available as multiple inputs in both post-ACS and stable angina subgroups, a relatively fair 
comparison of the level of summarized HRQoL between the two subgroups would only be 
possible for this instrument-specific subgroup. This comparison indicated slightly lower 
estimates in post-ACS (i.e. 0.76) than the ones in stable angina (i.e. 0.78).  
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Figure 1 PRISMA flow diagram summarizing the study selection process. 
HRQoL, health-related quality of life; SD, standard deviation; SE, standard error; CI, confidence interval. 
 
Large variations are noticeable across instrument-specific estimates of HRQoL in CHD 
presented in Table 3. The highest level of HRQoL was observed for the SG, TTO and 15D 
estimates, which were followed by slightly lower EQ-5D and HUI estimates, while the RS, 
SF-6D, QWB and HALex were the instruments with lowest HRQoL estimates. 
Interestingly, substantial unexplained between-study but within-instrument heterogeneity 
was observed in all the multivariate meta-analysis models with the most excessive levels 
of heterogeneity observed in overall CHD (Table 3). There was a general agreement 
between both ^`C  and ^_C statistics on the level of heterogeneity.  
Regression analysis 
The EQ-5D UK “tariff” values were the only instrument-specific values available with more 
than 10 observations per instrument used and therefore in line with our requirement for 
regression analysis. This led to reducing the analysis from a multivariate to a univariate 
meta-regression where the impact of disease subgroup, age, publication year, and 
prevalence of diabetes and of men was examined on the EQ-5D UK “tariff” values subset. 
Here, increasing age was found to generally reduce the level of HRQoL while prevalence of 
diabetes and higher proportion of men increased its level. The impact of publication year 




significant improvement in the model fit nor did they reduce the between-study 
heterogeneity (Table 7). 
Sensitivity analysis on the correlation coefficients between instrument-specific values was 
undertaken. The result of this sensitivity analysis was that the model was overall robust to 
different values of the correlation coefficients (Table 8). Moreover, the SEs of instrument-
specific estimates were generally insensitive to ignoring the correlation between the 
instrument-specific values or setting the values of correlation coefficients to 0.5.  
DISCUSSION 
This is the first study that systematically summarized and synthesized instrument-specific 
preference-based HRQoL values in CHD and its underlying disease-forms, post-ACS and 
stable angina in developed countries. Pooled mean HRQoL values for patients in post-ACS, 
in stable angina and overall CHD were estimated and a large variation was observed both 
within and between the instrument-specific values. This variation could be explained by 
the large underlying heterogeneity in the study populations, and the observed and 
unobserved variation between the HRQoL instruments. Other factors possibly include the 
impact of treatment applied, initial (acute) disease severity level, national and socio-
economic characteristics, various comorbidities present or the time of assessment. 
Moreover, the fact that direct TTO “tariffs” assessed in general populations for the 
preference-based scoring of the EQ-5D instrument vary across countries (69), suggests 
that variations in the HRQoL values assessed across CHD populations from various national 
or multinational settings could be larger than the ones observed across general 
populations. The variation was larger in overall CHD, which was expected due to variation 
in the patients’ form of underlying CHD across studies. 
Additional arguments emphasize that unobservable differences in cultural or socio-
economic status may also be present in representatives of a general population selected 
for the assessment of tariffs (70). The consequence of this would then be a greater 
underlying variability in HRQoL values in CHD assessed with instruments utilizing those 
tariffs. In essence, the aforementioned concerns may have a direct impact on the 
generalizability of country-specific HRQoL values to various national or multinational 
settings.  
The regression analysis indicated no significant association between available study-level 
covariates and HRQoL estimates. However, the reduction and increase in HRQoL observed 
with advancing age and higher proportion of men, respectively is in line with other 
published information (71). Surprisingly, studies with a higher proportion of patients with 
diabetes had a higher average HRQoL estimate what contrasts the finding by Xie et al. 
(72). This may be due to the missing information of the prevalence of diabetes across the 
studies as well as an example of ecological fallacy. 
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The variation between the instruments in the HRQoL estimates observed in our study is in 
agreement with the findings from other studies that demonstrated the differences across 
instrument-specific HRQoL values (73-75). Similarly to the study by Johnson et al, we 
observed higher levels of HRQoL when summarizing the EQ-5D US “tariffs” compared to 
the UK “tariffs”(69). Additionally, SG values commonly exceed TTO values and RS values, a 
finding that was also confirmed in our study (76,77). Furthermore, our synthesized HUI3 
estimates in CHD were lower compared to the EQ-5D estimates, but similar to the findings 
of O’Brien et al. in patients at increased risk of sudden cardiac death and receiving 
implantable defibrillator therapy(74). In our study, both the summarized and study-level 
SF-6D values were lower than EQ-5D values in CHD what contrasts the observations of 
Brazier et al.(1,57). Differences such as the valuation technique, bounds of scale and 
sensitivity to change after treatment are only some of potential reasons for the variation 
between the instrument-specific HRQoL estimates (73-75).  
For the evidence synthesis we applied multivariate meta-analysis given that when 
information on various instrument-specific values is sparse, it allows for “borrowing of 
strength” from the values available by accounting for the correlation between them 
(23,24). Though such an approach may provide more precise summarized estimates 
(23,24) than a meta-analysis where the correlation is ignored, this did not hold in our 
study due to a high between-study variation. 
Potentials for direct comparisons of our analysis to other synthesized HRQoL values are 
limited due to the lack of studies meta-analysing preference-based values in CHD. A meta-
analysis of 84 studies identified to address HRQoL in cardiac patients by Kinney et al. may 
be one potential comparator to our study (78). Kinney et al. investigated the effect of 
pharmacological, surgical, nursing or other treatment on HRQoL and found a small positive 
effect of treatment (i.e. standardised mean difference (d) = 0.31). Despite certain 
similarity in the patient populations investigated between the two studies can be 
acknowledged, numerous differences such as the study inclusion criteria (i.e. any 
measurement of HRQoL including the ones of single health attributes), choice of study 
effect size (i.e. standardised mean difference), the period of data collection (i.e. 1987-
1991) and the methodology used for conducting meta-analysis (i.e. fixed-effect model) 
hamper adequate comparisons.  
Another comparator to our study may be a review by Dyer et al. on the EQ-5D values in 
cardiovascular disease (CVD). Dyer et al. summarized and stratified the EQ-5D values 
across different CVD subgroups (e.g. ischemic heart disease (IHD) such as 
angina/myocardial infarction/CHD, heart failure etc.) and, when feasible, across three 
severity level categories defined by the percentage of patients in a given group in class 
III/IV of NYHA or CCS class. Their stratification of the EQ-5D values with IHD collected at 
baseline resulted in the range of values from 0.45 for moderate/severe angina to 0.80 for 




due to the high heterogeneity observed (i.e. I2 of 82-96%), but suggested more rigorous 
study inclusion criteria and the possibility to expand their data set with more recent 
publications (i.e. studies published after 2008) as a method to reduce some of the 
heterogeneity observed. However, the more rigorous inclusion criteria that our study 
proposed such as the inclusion of only mean HRQoL values measured in patients in stable 
or post-acute disease state, and incorporating HRQoL values from a wider publication 
range (i.e. 1990-2014) in the data set, did not reduce the high heterogeneity observed 
across studies. Notably, the heterogeneity indices observed in the study by Dyer et al. and 
the ones observed between the EQ-5D values in our study cannot be directly compared. 
Differences between the two data sets and the method for disease stratification (i.e. post-
ACS and stable angina subgroups vs. CCS class categories reported in ICH) are limiting such 
a comparison.  
Our analysis is confronted with certain limitations. The main limitation of our study is that 
we analysed study-level and not patient-level data. Analysing patient-level data might 
provide significant improvements in our analysis. If detailed information on patients 
currently classified to suffer from CHD was available, this would allow for a more accurate 
disease-specific allocation of HRQoL values. Conducting the multivariate meta-analysis on 
such a data set could possibly lead to estimates with lower level of between-study 
heterogeneity. Another limitation of our study was that we conducted the meta-
regression analysis only on the subset of the EQ-5D UK “tariff” values due to a relatively 
small number of studies providing other instrument-specific values. This regression 
analysis was also limited with the respect to the variety of covariates investigated. 
Covariates such as patients’ socioeconomic status, presence of comorbidities other than 
diabetes or the impact of treatment applied were not investigated in the regression 
analysis due to their scarce information across the studies (79). Expectedly, this study was 
confronted with the missing information on within-study correlation coefficients. This was 
solved by retrieving the correlation coefficients reported in other studies on 
cardiovascular patients or general populations. The sensitivity of the study results on the 
correlation coefficients utilized was tested in the sensitivity analysis. Finally, information 
on HRQoL in CHD measured with non-preference-based and disease-specific instruments 
was not included in our analysis.  
Importantly, our study did not aim to investigate what the most appropriate and reliable 
instrument to measure HRQoL in CHD is, but rather to summarize and synthesize all the 
available evidence of preference-based instrument-specific values. The decision on the 
most robust instrument-specific estimate to be applied in a CUA depends not only on the 
appropriateness and reliability of an instrument to measure HRQoL in CHD but also on its 
agreement with instrument-specific values available for other health states modelled in 
the CUA. Furthermore, some decision-makers might argue that considering the previously 
discussed reasons for country- and centre-specific variability in HRQoL values, one should 
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simply choose a single country-specific and CHD-form specific HRQoL value. However, in 
the case where multiple country-specific values exist or even a single such value is 
unavailable, the decision on the most robust value becomes more complex and needs to 
rely on an evidence-synthesis exercise Moreover, although distinguishing between 
underlying CHD-forms seems as more clinically relevant, CUAs in both primary and 
secondary prevention of CHD often model a general CHD health state (80-83). An evidence 
synthesis of all available instrument-specific HRQoL values may again be considered to 
select a robust HRQoL estimate in overall CHD. Such an estimate could then reflect more 
appropriately the complex nature of CHD and its various manifestations. This motivated us 
to consider an evidence-synthesis of HRQoL values in overall CHD in this study. 
Finally, characterizing the between study heterogeneity not only provides a better mean 
estimate for HRQoL values used in CUA but it also provides a better understanding on the 
uncertainty around the HRQoL value and how this translates into uncertainty around the 
CUA outcomes. This uncertainty, as we showed in our study, is considerable and as it is 
mostly found between studies, it is ignored when a single value from an individual study is 
selected. Dias et al proposed that in the presence of between-study heterogeneity, using 
the predictive distribution is the appropriate way to characterize parameter uncertainty 
when embedding synthesized evidence in CUA (84). Researchers using the findings from 
this study for economic evaluation purposes will therefore have to rely in generating 
values that incorporate both within- and between-study standard deviation (predictive 
distribution) provided in the results section of this article. 
Conclusions 
This study represents the first evidence synthesis of instrument-specific preference-based 
HRQoL values in post-ACS, stable angina and CHD in general. Considerable differences in 
mean HRQoL estimates were observed both within and between the instruments. These 
differences characterized by large between-study heterogeneity may be explained by both 
the observed and unobserved methodological differences across instruments and 
underlying study-level characteristics. Current CUAs in CHD ignore this between-study 
study heterogeneity. Therefore, multivariate meta-analysis can facilitate quantifying this 
heterogeneity for HRQoL estimates and offer the means for uncertainty around HRQoL 


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 4 Between-study SDs and variance-covariance matrix in post-ACS model. 
Instrument  SD Variance-Covariance matrix 
  EQ-5D UK EQ-5D US 
EQ-5D UK 0.07 -  
EQ-5D US 0.05 -0.09 - 
ACS, acute coronary syndrome; SD, standard deviation; UK, United Kingdom; US, United States. 
 
Table 5 Between-study SDs and variance-covariance matrix in stable angina model 
Instrument  SD Variance-Covariance matrix  
  EQ-5D UK QWB SF-6D SG 
EQ-5D UK 0.06 -    
QWB 0.01 0.00 -   
SF-6D 0.00 1.00 0.01 -  
SG 0.06 -0.01 0.02 -0.01 - 
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Background:  Patient self-testing and/or patient self-management (PST and/or PSM) might 
provide better coagulation care than monitoring at specialised anticoagulation centres. 
Yet, it remains an underused strategy in the Netherlands. 
Methods: Budget impact analyses of current and new market-share scenarios of PST 
and/or PSM compared to monitoring at specialised centres were performed for a national 
cohort of 260,338 patients requiring long-term anticoagulation testing. A healthcare payer 
perspective and one to five year time horizons were applied. The occurrence of 
thromboembolic and haemorrhagic complications in the aforementioned patient 
population were assessed in a Markov model. Dutch specific costs were applied, next to 
effectiveness data derived from a meta-analysis on self-monitoring of oral anticoagulation. 
Sensitivity and scenario analyses were performed to assess uncertainty on budget impact 
model results. 
Results: Increasing PST and/or PSM usage on a national level from the current 15.4% to 
50% was found to be associated with savings ranging from €8 million following the first 
year to €184 million after 5 years. Further increases in the use of PST and/or PSM 
produced greater savings up to €450 million by 5 years after a complete replacement of 
anticoagulation testing with PST and/or PSM. Sensitivity analyses showed robust cost-
savings, with the extreme of thromboembolic risk being maximally unfavourable for the 
budget impact of PST and/or PSM. Results of a scenario analysis exploring a linear increase 
in the uptake of PST and/or PSM from the current 15.4% to the expected 50% indicated 
savings from €2 million after the first year to €184 million cumulatively after the fifth year. 
Finally, potential unfavourable budget impact was found in scenarios exploring an 
increase in the use of PST alone as well as increase in market shares of PST and/or PSM in 
patients with atrial fibrillation on long-term oral anticoagulation. 
Conclusion: PST and/or PSM was found to be a more favourable alternative to monitoring 
at specialised centres. However, using PoC devices solely for PST resulted in greater 
expenditures compared to testing in anticoagulation clinics. Additionally, our study 








Oral anticoagulation therapy (OAT) with vitamin K antagonists (VKA) has been shown to 
reduce the risks of thromboembolic events in a number of clinical situations (1). In the 
Netherlands, indications for OAT include atrial fibrillation (AF), arterial diseases (e.g., 
cardiomyopathy, coronary syndromes and surgery, vascular surgery, cerebral embolism), 
heart valve replacement and venous thromboembolism (2). Patients with AF represent the 
majority of patients requiring OAT (i.e. 62%). Given the increase in numbers of AF 
patients, it is not surprising that the number of patients requiring OAT has increased as 
well over the past decades in Western countries (2). Furthermore, the population of 
patients in need of OAT is projected to increase further in the coming decades (3,4). This is 
partly due to the aging population in Western countries and the positive association 
between age and the incidence and prevalence of AF (5). 
While warfarin is commonly used worldwide, acenocoumarol and phenprocoumon (to a 
lesser extent) are the VKAs of first choice in the Netherlands. Prophylaxis with VKA is 
considered an effective strategy but it has some shortcomings, including multiple 
interactions with food and other drugs as well as inter-individual and intra-individual 
variability in pharmacodynamics (6,7). As a result, regular monitoring is required to 
maintain the international normalized ratio (INR) within the therapeutic range. INR-testing 
is typically performed at specialised anticoagulation testing centres, adding to the 
cumbersomeness of VKA use for the patients. Notably, Point-of-Care (PoC) devices allow 
for patient self-testing (PST), where trained patients can perform the INR-test but still 
inform his/her healthcare provider for subsequent advice on anticoagulant dosing, or even 
patient self-management (PSM), with trained patients performing the INR testing, 
interpreting the results, and adjusting dosing accordingly. 
In agreement with the increasing number of patients with indications for OAT, the number 
of patients using INR-testing in the Netherlands has increased from approximately 
320,000 in 2002 to 430,000 in 2012 (2). Again, this trend is expected to continue in the 
coming years with the aging population. Also, between 2007 and 2011 annual incidence 
for AF has steadily increased from under 40,000 in 2008 to 56,000 in 2012 (2). 
These figures, however, may still underrepresent the actual number of patients in need of 
OAT as many eligible patients do not receive anticoagulation because of concerns of the 
patients or concerns of their physicians of being outside the INR range (8-12). PoC testing 
may also address this issue. As supported by international findings (13,14), PST and/or 
PSM can lead to better coagulation care in the Netherlands compared to regular 
monitoring in specialized anticoagulation centres (2). This may be due in part to the 
convenience of use, resulting in more frequent testing, which is associated with greater 
time in therapeutic range (TTR) (15). Also, findings from meta-analytical studies suggest 




reduced risks of thromboembolic events and all-cause mortality (13). Finally, it has been 
reported that the patient empowerment inherent in PoC-strategies in itself already 
directly reduces the risks of complications and death even in the absence of any 
measurable increase in the quality of anticoagulation control (16). Despite these positive 
results, PST and/or PSM remains an underused strategy in the Netherlands. 
Eligible patients for PST and/or PSM include all those on long-term OAT (regardless of 
indication), who have passed the required training. To date, the estimated number of 
patients on long-term OAT in the Netherlands is approaching 260,338. In the current 
situation, 15.4% of this population utilizes PST and/or PSM (2). In this study, we will assess 
the budget impact of the current situation and new scenarios where PST and/or PSM 
represents 50%, 75% and 100% of INR monitoring in the Netherlands.  
METHODS 
A budget impact analysis (BIA) was performed, using a patient cohort approach. Patients 
in the cohort exit the model after death, but no new patients enter the model (closed 
model). The perspective of the study is that of a healthcare payer. In the present analysis, 
the patient cohort includes all patients, who require anticoagulation monitoring for OAT 
for any clinical indication.  
The design and reporting of study outcomes followed the recommendations of 
International Society for Pharmacoeconomics and Outcomes Research for BIAs (ISPOR) 
Task Force (17)(18). 
Model structure 
Patients indicated for OAT are at risk of haemorrhagic and thromboembolic events. To 
incorporate the course of disease in the BIA, a Markov model was developed. This model 
includes the following health states: no complications, thromboembolic complications, 
haemorrhagic complications, and death (Figure 1). A cycle length of one year was used. 
The cumulative budget impact of the cohort was assessed each year up to 5 years. 
Patients enter the model in the “no complications” health state.  
 
Figure 1 Markov model structure.  
Patients enter the model in the “No complication” health state. Possible transitions are defined by the arrows. 
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In the base-case analysis, transition probabilities for thromboembolic and haemorrhagic 
complications and death were based on a systematic review and meta-analysis of 
individual patient data on self-monitoring of oral anticoagulation by Heneghan et al. (14). 
This study estimated the relative risks (RR) of thromboembolic and haemorrhagic 
complications and death between testing at anticoagulation centres and PST and/or PSM 
for all indications of OAT (Table 1). To assign transition probabilities for each testing 
strategy, baseline risks for patients visiting anticoagulation centres/clinics were also 
needed. Data on the number of thromboembolic and haemorrhagic complications and 
death, and duration of follow-up for this group were taken from studies by Menendez-
Jandula et al., Fitzmaurice et al., Matchar et al., and Siebenfofer et al. (Table 2 (19-22). 
These studies were selected because they were included in the study by Heneghan et al. 
and hence provide internal validity to our study (14). To estimate baseline risks of 
complications and death, we conducted a meta-analysis on the aforementioned studies in 
the statistical program R 3.0.2, using the “metafor” package (Table 1)(19-24). Because the 
study populations are not homogeneous across the studies and do not fit the assumption 
of a fixed-effect meta-analysis, a random-effect meta-analysis was applied.  
Annual risks of complications and death for the PST and/or PSM group were calculated by 
taking the product of the RRs reported by Heneghan et al. and the baseline risks estimated 
through a random-effect meta-analysis (Table 1)(14). In addition, age-specific background 
mortality rates for the Netherlands for 2012 were used to estimate transition from no 
complications to death (25). 
Cost parameters 
Costs associated with thromboembolic and haemorrhagic complications were collected 
from published Dutch studies. All costs were inflated to 2013 levels using the harmonised 
index for consumer product (HICP) for the health sector for the Netherlands (26). Costs for 
thromboembolic events were derived from costs of ischemic stroke (27), myocardial 
infarction (28), and pulmonary embolism (29) with contributions of 71.43%, 24.32%, and 
4.25%, respectively, to the overall estimate (30). Cerebral haemorrhage (31), 
gastrointestinal bleeding (32), and other bleedings (32) were assumed to represent 
10.66%, 30.46%, and 58.88% of the costs associated with haemorrhagic complications 
(30). For each complication, costs were differentiated between first and subsequent years 
in the analysis, given the differences in the nature of complications between these years. 
No subsequent year cost was assumed for pulmonary embolism and bleeding events 
though. Furthermore, death was not associated with any additional cost. The weighted 
costs of thromboembolic complications were €41,866 for the first year and €8,750 for 
subsequent years. For haemorrhagic complications, the weighted averages were €9,748 





Table 1 Annual risks of clinical events for use in the Markov model – base-case analysis. 
  Specialized Centre PST and/or PSM 
  Annual baseline riska, % Relative riskb Annual riskc, % 
Thromboembolic Event 3.22 (1.50-4.94) 0.44 (0.17-1.14) 1.42 (0.26-5.63) 
Haemorrhagic Event 2.84 (1.16-4.52)  0.91 (0.74-1.12) 2.58 (0.86-5.06) 
Death 2.87 (1.01-4.74) 0.82 (0.52-1.28) 2.35 (0.53-6.07) 
PST, patient self-testing; PSM, patient self-management. 
aEstimated through a random-effects meta-analysis of annual risks for patients using anticoagulation testing 
centre. 
bAdapted from the meta-analysis of individual patient data on self-monitoring of oral anticoagulation by 
Heneghan et al.(14). 
cEstimated by taking the product of the relative risks reported by Heneghan et al. (14) and the baseline annual 
risks estimated by the authors’ random-effects meta-analysis of annual risks for patients using anticoagulation 
testing centre. 
95% confidence intervals of risk estimates are showed in parentheses. 
Table 2 Studies used to estimate annual risks of complications for patients using testing centres. 







Spain Single-centre         
Thromboembolic 
events 
    20 363 0.055 0.012 
Haemorrhagic 
events 
    7 363 0.019 0.007 
Death     15 363 0.041 0.010 
Fitzmaurice (2005)(20)  UK Multi-centre         
Thromboembolic 
events 
    4 264 0.015 0.008 
Haemorrhagic 
events 
    3 264 0.011 0.007 
Death     1 264 0.004 0.004 
Matchar (2010)(21)  USA Multi-centre         
Thromboembolic 
events 
    101 4235 0.024 0.002 
Haemorrhagic 
events 
    199 4235 0.047 0.003 
Death     157 4235 0.037 0.003 
Siebenhofer (2008)(22)  Germany Multi-centre         
Thromboembolic 
events 
    13 290 0.045 0.012 
Haemorrhagic 
events 
    10 290 0.034 0.011 
Death     11 290 0.038 0.011 
RCT, randomised clinical trial; SE, standard error. 
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Table 3 Costs parameters applied in the model (€2013 per patient). 
  First Year  Subsequent Years 
Stroke(27) 50,828 11,800 
Myocardial infarction(28) 22.015 1.338 
Pulmonary embolism(29)a 5.244 0 
Weighted Average Thromboembolic Event b 41,866 8,750 
Cerebral haemorrhage(27)(31)c 38,417 11,800 
Gastrointestinal bleeding(32) 7,120 0 
Other major bleeding(32) 5,884 0 
Weighted Average Haemorrhagic eventd 9,748 1,263 
Testing strategy   
VKA(33) 16 16 
Specialized Centres 248 248 
Blood sampling & INR-measurements at centres(34)e 181 181 
Additional tariff for blood sampling at home(34)f 67 67 
PST and/or PSM 958 749 
Initial training & instruction(34) 396 0 
Monitoring & supervision (34)g 562 749 
Additional tariff for phone consultation for PST only (32)h 210 210 
VKA, vitamin K antagonists; PST, patient self-testing; PSM, patient self-management. 
aCost estimate of pulmonary embolism from the original source was corrected to exclude the cost of INR testing 
and coumarines. 
bOn the basis of the assumption that the cost of a thromboembolic event will be a composite of the costs related 
to stroke, myocardial infarction and pulmonary embolism with contributions of 71.4%, 24.3%, and 4.2%, 
respectively, to the overall estimate. 
cCost estimate of cerebral haemorrhage from the original source was corrected to exclude the costs of home 
help and private transportation costs. 
dOn the basis of the assumption that the cost of a haemorrhagic event will be a composite of the costs related to 
cerebral haemorrhage, gastrointestinal bleeding bleeding and other major bleeding with contributions of 10.7%, 
30.5%, and 58.9%, respectively, to the overall estimate. 
eAssuming 21.1 tests per year(2). 
fAssuming 8.6 home blood samplings per year(2). 
gAssuming 3 supervision sessions in the first year and 4 supervision sessions in the subsequent years. 
hAssuming 12 phone consultations on dosing per year for patients who only self-test. 
 
Acquisition cost of VKA and anticoagulation monitoring are presented in Table 3. Cost of 
VKA was estimated as a weighted average cost of acenocoumarol and phenprocoumon 
based on their usage in the Netherlands (i.e. 80%:20%, respectively). The annual cost of 
VKA was estimated at €16.06 (33). Anticoagulation testing at centres may involve blood 
sampling at the centres or at home. For blood sampling and measurement at testing 




8.6 home blood samplings per patient per year for the same patient group as those tested 
in the centre (2). The annual cost of monitoring at testing centres is the same for each 
year and estimated to be €248 (34).  
The first year cost of PST and/or PSM consisted of the costs of the device and one initial 
training session and 3 supervision sessions. Subsequent years of use required quarterly 
supervision sessions. The costs of the first and subsequent years were estimated to be 
€958 and €749, respectively (34). While these patients receive information for possible 
adjustments in their VKA dose by e-mail or specific software, no additional costs were 
added for dosing adjustments. 
Budget impact analysis 
In the analysis, a cohort population size was evaluated at 260,338. This cohort size 
represents an estimate of all patients requiring long-term anticoagulation testing for OAT 
for any indication on a national level for the Netherlands. Using estimates from the 
Federation of Dutch Thrombosis Services (“Federatie Nederlandse Trombosediensten”; 
FNT) Report 2012, the current share of PST and/or PSM among patients on long-term 
monitoring was assumed to be 15.4% (2). This current situation was evaluated against 
potential new market penetration scenarios of 50%, 75%, and 100% for PST and/or PSM. 
The BIA was evaluated for each year up to 5 years. Costs were not discounted as 
recommended by the ISPOR Task Force for BIAs (17). 
Sensitivity analysis 
To examine the impact of uncertainty in key model parameters (i.e. baseline and relative 
risks of complications and death and cost parameters) univariate sensitivity analyses were 
performed on the 5-year BIA results considering a market penetration scenario of 50% in 
Dutch patients on long-term OAT. Here each parameter was varied over the 95% 
confidence interval (CI) while holding all other parameters constant. Where CI or standard 
deviation (SD) was unavailable, the SD was assumed to be 25% of the mean. 
Scenario analyses 
Three scenario analyses were conducted to investigate the impact of increasing the 
market share of PST and/or PSM up to 50% under different decision analytic settings. The 
first scenario explored a linear increase in the uptake of PST and/or PSM from the current 
15.4% to the expected 50% in 5 years. In the second scenario, an increase in the market 
share of PST alone from the current 6.16% (i.e. 40% of all patients with PoC devices) to 
50% was explored. Here, transition probabilities for thromboembolic and haemorrhagic 
complications in the Markov model were based on the RRs of utilizing PST alone compared 
to testing at specialized centres as reported by Heneghan et al. while the baseline risks 
were estimated through a random-effect model (Table 4). The costs of PST alone were 
assumed to be associated with additional €210 per year, reflecting consultations for 
dosing regime adjustments. In the third scenario, the BIA of increasing the market share of 
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PST and/or PSM from the assumed 15.4% to 50% in patients with AF was explored in 
scenario 3. In this analysis, it was assumed that 62% of patients on long-term OAT are 
affected with AF, thus a cohort population size was evaluated at 161,410 patients. 
Transition probabilities in the Markov model were based on the RRs assessed in AF 
patients (Table 4). 
 
Table 4 Annual risks of clinical events for use in the Markov model – scenario analyses 
 Specialized 
centre 
PST  AF  
 Annual baseline 
riska 
Relative riskb Annual riskc Relative riskb Annual riskc 
Thromboembolic 
Event 
     
Mean 3.22% 0.74 2.38% 0.67 2.16% 
Low 95% CI 1.50% 0.3 0.45% 0.28 0.42% 
High 95% CI 4.94% 1.82 8.99% 1.57 7.76% 
Haemorrhagic 
Events 
          
Mean 2.84% 0.84 2.39% 1.04 2.95% 
Low 95% CI 1.16% 0.64 0.74% 0.81 0.94% 
High 95% CI 4.52% 1.12 5.06% 1.34 6.06% 
Death           
Mean 2.87% 0.91 2.61% 0.72 2.07% 
Low 95% CI 1.01% 0.75 0.76% 0.43 0.43% 
High 95% CI 4.74% 1.11 5.26% 1.2 5.69% 
PST, patient self-testing; AF, atrial fibrilation. 
aEstimated through a random-effects meta-analysis of annual risks for patients using anticoagulation testing 
centre. 
bAdapted from the meta-analysis of individual patient data on self-monitoring of oral anticoagulation by 
Heneghan et al.(14). 
cEstimated by taking the product of the relative risks reported by Heneghan et al. (14) and the baseline annual 
risks estimated by the authors’ random-effects meta-analysis of annual risks for patients using anticoagulation 
testing centre. 
95% confidence intervals of risk estimates are showed in parentheses. 
RESULTS 
Base-case results 
The estimation of total costs per patient associated with INR monitoring in specialized 
anticoagulation centres and with PoC-devices for a time horizon of one to five years is 
detailed in Table 5. Monitoring related costs were higher than event related costs only in 
the first year in patients conducting INR-testing with PoC-devices. Costs associated with 
thromboembolic and haemorrhagic events were responsible for the vast majority part of 
total costs with PoC-devices in the longer time horizons and in all time horizons in patients 




Dutch national cohort of 260,338 patients who are using long-term anticoagulation 
testing, a current situation of 15.4% using PST and/or PSM with PoC-devices resulted in 
cumulative costs of €486 million, €1.00 billion, €1.54 billion, €2.11 billion, and €2.70 billion 
in the first, second, third, fourth, and fifth year, respectively (Figure 2). Increasing the use 
of PST and/or PSM to 50% in the first year resulted in cost-saving of €8 million from the 
healthcare budget. The savings increased exponentially each year, reaching estimated 
savings of €184 million after the fifth year. Similarly, increasing PST and/or PSM market 
penetration to 75% and 100% produced correspondingly greater 5-year cumulative 
savings of €317 and €450 million, respectively. While it is not likely that PST and/or PSM 
will completely replace INR-testing at specialised anticoagulation centres, this latter 
scenario illustrates the potential maximum savings in long-term utilization.  
 
 
Figure 2 Budget impact analysis from year 1 to year 5 of current and new market share scenarios for 
PST and/or PSM (in millions). 
PST, patient self-testing; PSM, patient self-management.   
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Table 5 Cost allocation of overall medical costs associated with anticoagulation monitoring with PST 
and/or PSM and within specialized anticoagulation centres (€, per patient). Current situation. 
 PST/PSM Specialised centre 
Year Total Monitoring Events Total Monitoring Events 
1 1,796 951 845 1,881 256 1,628 
2 3,444 1,651 1,793 3,912 490 3,422 
3 5,140 2,306 2,834 6,071 703 5,368 
4 6,877 2,919 3,958 8,336 897 7,439 
5 8,647 3,492 5,155 10,690 1,073 9,617 
PST, Patient self-testing; PSM, patient self-management 
Sensitivity analysis 
The results of the univariate sensitivity analyses show the impact of uncertainty 
surrounding the key model parameters, illustrating that the relative and baseline risk of 
thromboembolic complications had the highest impact on the BIA results (Figure 3). 
Specifically, when the relative risk of thromboembolic complications would drop to the 
lower limit of the 95% CI, BIA results would indicate total health care expenditures of €302 
million. At risks increasing to the upper limits of 95% CIs, a cost-saving of €382 million 
would be observed. The univariate sensitivity analyses also showed the BIA results were 
sensitive to the uncertainty around the cost parameters. Yet, these results generally 
favored an increasing market penetration of PST and/or PSM. Notably, cost savings were 
robust over the whole range of variations except at the extreme for thromboembolic risk, 
reflecting a situation with this risk at its lower limit that is maximally unfavourable for our 
BIA. 
 
Figure 3 Tornado diagram illustrating results from sensitivity analyses for budget impact analysis in a 
5 year horizon considering a market penetration scenario of 50% for PST and/or PSM in a Dutch 
cohort of 260,338 patients (in millions). 
Grey bars denote influence of the low value of the 95% confidence interval range and black bars denote 
influence of the high value for parameters investigated. 





The results of scenario analyses are presented in Table 6. A linear increase in the uptake of 
PST and/or PSM from the current 15.4% to the expected 50% indicated savings from € 2 
million after the first year to €184 million cumulatively after the fifth year (scenario 1). 
Increasing the market share of PST alone from the current 6.16% to 50% resulted in 
expenditures from €57 million after the first year to €123 million cumulatively after the 
fifth year (scenario 2). Finally, increasing the market share of PST and/or PSM in a cohort 
of 161,410 AF patients indicated an expenditure of €15 million after the first year but 
resulted in cumulative savings of €2 million after 5 years (scenario 3). 
Table 6 Results of scenario analyses on uptake of PST and/or PSM (€, in millions) 
 New scenario Current scenario Difference 
Scenario 1: 260,338 patients and 15.4% PST and/or PSM 
1 485 486 -2 
2 983 1,000 -17 
3 1,493 1,543 -50 
4 2,007 2,112 -105 
5 2,517 2,701 -184 
Scenario 2: 260,338 patients and 6.16% PST 
1 555 497 57 
2 1,113 1,030 83 
3 1,697 1,595 102 
4 2,301 2,186 115 
5 2,923 2,800 123 
Scenario 3: 161,410 AF patients and 15.4% PST and/or PSM 
1 325 310 15 
2 652 638 15 
3 996 985 11 
4 1,354 1,348 6 
5 1,723 1,725 -2 
*values are rounded 
Scenario 1 explores a linear increase in the uptake of PST and/or PSM from the current 15.4% to the expected 
50% in 5 years. 
Scenario 2 explores an increase of market share of PST alone from 6.16% to 50%. 
Scenario 3 explores an increase of market share of PST and/or PSM in AF patients from 15.4% to 50%. 
DISCUSSION 
Our study presents a BIA of the current practice as well as new varying market penetration 
scenarios of anticoagulation monitoring with PST and/or PSM compared to monitoring at 
specialised anticoagulation centres in the Netherlands. Our findings in the base-case 
analysis indicated that increasing PST and/or PSM usage for anticoagulation testing from 
the current 15.4% to 50%, 75% and 100%, would lead to significant savings in all analysed 
scenarios. Even though INR testing is 3.9 times and 3.0 times more costly for PST and/or 
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PSM compared to specialised anticoagulation centres during the first year and subsequent 
years, cost-saving was still observed when considering total direct medical costs due to 
considerably higher event-related costs. This is due to the greater risk reductions of 
thromboembolic and haemorrhagic complications, associated with high medical costs. In 
fact, increasing the number of patients switching from conventional testing to PST and/or 
PSM by increasing market penetration, produced even greater savings in the time horizon 
of five years. For example, considering a national-level cohort population, potential 
maximum savings over the current situation of €450 million may be observed in 5 years. 
However, this is under the unlikely scenario of 100% adoption of PST and/or PSM. Yet, 
even if PST and/or PSM would be adopted by 50% of all patients requiring long-term INR 
testing – a figure that is quite attainable in the coming years – would result in a savings 
range from €8 million following the first year to €184 million after 5 years. These analyses 
clearly demonstrated the value of PST and/or PSM strategy with PoC-devices in the 
Netherlands. Univariate sensitivity analyses revealed the major impact of uncertainty in 
baseline thromboembolic risk on the BIA results. The impact of the uncertainty in the 
baseline thromboembolic risk can be directly attributed to its impact on the occurrence of 
stroke, myocardial infarction and pulmonary embolism events and their related costs of 
treatment reaching in the first year and follow-up years a weighted average cost of 
€41,866 and €8,750 per patient respectively. Overall, univariate sensitivity analysis 
showed robust cost savings, with the extreme of thromboembolic relative and absolute 
risk being maximally unfavourable for the BIA of PST and/or PSM at the relatively unlikely 
exception.  
Finally, this study observed potential unfavourable budget impact of increasing market 
shares of PST alone as well as increasing market shares of PST and/or PSM in AF patients 
on long-term OAT (scenarios 2 and 3). Greater expenditures associated with increasing 
market shares of PST alone in scenario 2 are due to not only the higher cost of PST 
strategy compared to PST and PSM combined but also costs associated with lower number 
of prevented complications in comparison to the base-case scenario. The findings in 
scenario 3 may be attributed to lower number of thromboembolic complications 
prevented in comparison to the base-case scenario with a corresponding greater number 
of haemorrhagic complications with PST and/or PSM compared to monitoring in 
specialized centers, which are associated with high costs.  
Comparison with other studies 
To our knowledge, published economic evaluations of PST and/or PSM compared to 
monitoring at specialised anticoagulation centres or to routine clinic-based care are all 
cost-effectiveness analyses (CEA). This hampers a direct comparison of our study findings 
with the ones from these other studies. Yet, there is a general agreement in the 
conclusions of the available CEAs with our study results regarding the preference for PST 




anticoagulation to be a more cost-effective alternative compared to physician-managed 
anticoagulation from the Canadian healthcare payer perspective in a 5-year time horizon 
with an incremental cost-effectiveness ratio (ICER) of CAD14,129 per quality-adjusted life 
year (QALY) (35). In the same study, when use of self-management was limited to a 1-year 
time horizon, an ICER of CAD236,667 per QALY was estimated (35). Furthermore, in the 
study by Lafata et al., self-testing in a US setting was found to be a cost-effective 
alternative to testing in anticoagulation clinics with an ICER of $24,818 per event avoided 
in a 5-year time horizon (36). Finally, Jowett et al. found PSM compared to routine clinic-
based monitoring unlikely to be cost-effective from the UK healthcare system perspective 
in a 1-year time horizon (i.e. ICER of £32,716 per QALY) (37). These findings may be mainly 
attributed to greater local costs of PST/PSM compared to alternative testing strategy and 
sources of effectiveness data. Across all the aforementioned studies, the cost of testing 
with PST and/or PSM outweighed the cost of alternative strategy. The costs associated 
with thromboembolic and haemorrhagic complications were greater with PST and/or PSM 
strategy compared to alternative testing. This was mainly driven by the effectiveness data 
used in those studies. In particular, Jowett et al. utilized patient-level data from a 
randomised clinical trial (RCT) by Fitzmaurice et al. which indicate greater number of 
thromboembolic and haemorrhagic events with PST and/or PSM compared to alternative 
testing strategy (20). In the studies by Regier et al. and  Lafata et al., the number of 
thromboembolic and haemorrhagic events was estimated based on the TTR achieved 
while using investigated testing strategies (i.e. 71.8% vs. 63.2% and 89% vs. 65%, 
respectively) and risk of those events conditional on the TTR. This estimation resulted in a 
relatively low number of events avoided with PST and/or PSM compared to alternative 
testing strategy. Regier et al. found only 0.72 thrombotic and 0.17 haemorrhagic events 
avoided per 100 patients with PST and/or PSM in the first year, and after five years this 
summed up to 3.5 and 0.79 events avoided, respectively. Similarly, Lafata et al. observed 
in total 4.9 events avoided per 100 patients with PST and/or PSM over a five year time 
horizon.  
Strengths and limitations 
Inferences drawn from BIAs are related to the quality of the evidence that goes into the 
model. One point of strength of the current analysis is that effectiveness inputs are based 
on a synthesis of evidence (14). In the hierarchy of evidence pyramid, evidence synthesis 
of multiple trials resides above evidence from a single RCT (38,39). Yet, it must be pointed 
out that no studies investigating the effectiveness of PST and/or PSM have been 
conducted in the Netherlands. In the present analysis, effectiveness measures were 
derived from studies investigating PST and/or PSM versus specialized testing centres for 
all OAT indications (19-22). Because of the heterogeneity between the studies, a random-
effect model was used to establish baseline risks for thromboembolic and haemorrhagic 
complications for patients using anticoagulation testing centres. To estimate risks of 
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complications for PST and/or PSM patients, relative risk reductions were applied as 
reported by Heneghan et al. (14). In addition to possibly providing some external validity, 
an advantage of this approach over relying on data from a single RCT is that all indications 
for OAT were considered. This reflects a more complete assessment of the impact of 
different strategies on costs of anticoagulation testing. Finally, we examined the impact of 
uncertainty surrounding the key model parameters on BIA results. 
Our study has several limitations. Firstly, only direct medical costs were considered in our 
analyses and no costs related to productivity loss were included. Costs related to 
productivity loss may be reduced for PST and/or PSM patients because they may spend 
less time away from work as a result of greater effectiveness in prevention of 
complications (Table 1). Also, testing at home with a PoC-device avoids work time lost 
because it eliminates the need for travel and waiting time at testing centres. Yet, one 
caveat in considering productivity loss among patients indicated for OAT is that many are 
elderly patients, such as those with AF, may already be retired. Notably, although the 
current estimates on cost-savings in the 5-year time horizon applied are substantial, they 
may still reflect an underestimation of the true savings in the patient groups where 
accounting for productivity loss is considered to be appropriate (i.e. patients <65 years of 
age). Secondly, our model design may also be a factor for underestimation. In this analysis, 
clinical events and associated costs were followed for a cohort of patients for up to 5 
years. An alternative approach is to dynamically add new patients each year as estimated 
by annual incidence rates (i.e. assume an open cohort). Such an approach would include 
more patients in the analysis because the incidence rates are expected to continue to rise 
in the coming decades (3). Thirdly, the recent introduction of novel oral anticoagulants 
(NOACs), such as dabigatran, rivaroxaban and apixaban, on the Dutch market for use in 
patients with some of the indications for OAT, was not accounted for in our study (40,41). 
Currently, such a comparison between NOACs and the VKAs managed with PST and/or 
PSM is hampered given the lack of RCTs between the two comparators as well as data on 
the current use of NOACs in clinical practice in the Netherlands. Fourthly, future uptake of 
PST and/or PSM strategy (i.e. 50, 75 and 100%) in this study was based on an assumption. 
Yet, it may be more informative to estimate this in relation to the factors influencing its 
current low market share, for example due to patients’ preferences. In particular, there 
are indications by some Dutch experts that some patients prefer to have more regular 
contact with hospitals/anticoagulation centres rather than to self-manage. Additionally, 
they indicate that an increase in the uptake of PoC strategies could be achieved if these 
strategies would be actively offered to patients as an alternative to management in the 
clinics what currently is not the case.  Finally, estimates of the baseline risks used in this 
study were not supported by local real-life data. Such information unavailable and is duly 




highly selected patient populations with characteristics that may deviate from the usual 
practice. 
In conclusion, compared to regular anticoagulation testing at specialised centres, PST 
and/or PSM with PoC-devices resulted in cost-savings. However, using PoC devices solely 
for PST resulted in greater expenditures compared to testing in anticoagulation clinics. 
Hence, this strategy may need to be disregarded. Additionally, our study indicated less 
favourable findings of using PST and/or PSM in patients with AF. Further research is 
needed to explore this strategy in other indications and confirm the aforementioned 
findings with local real-life data. 
Given the increasing number of patients with indications for OAT and high treatment costs 
of thromboembolic events, the choice of the optimal monitoring and managing strategy is 
of high importance, both regarding the costs considered here and the health effects as 
well. Further research should be directed to perform formal CEAs comparing the two 
strategies. This would provide the additional insights of both societal costs and long-term 
effects of those strategies on health, such as expressed in terms of QALYs.  
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Background: Stroke prevention is the main goal of treating patients with atrial fibrillation 
(AF). Vitamin-K antagonists (VKAs) present an effective treatment in stroke prevention, 
however, the risk of bleeding and the requirement for regular coagulation monitoring are 
limiting their use. Apixaban is a novel oral anticoagulant associated with significantly lower 
hazard rates for stroke, major bleedings and treatment discontinuations, compared to 
VKAs.  
Objective: To estimate the cost-effectiveness of apixaban compared to VKAs in non-
valvular AF patients in the Netherlands.  
Methods: The previously published lifetime Markov model using efficacy data from the 
ARISTOTLE and the AVERROES trial was modified to reflect the use of oral anticoagulants 
in the Netherlands. Dutch specific costs, baseline population stroke risk and coagulation 
monitoring levels were incorporated. Univariate, probabilistic sensitivity and scenario 
analyses on the impact of different coagulation monitoring levels were performed on the 
incremental cost-effectiveness ratio (ICER).  
Results: Treatment with apixaban compared to VKAs resulted in an ICER of €10,576 per 
quality adjusted life year (QALY). Those findings correspond with lower number of strokes 
and bleedings associated with the use of apixaban compared to VKAs. Univariate 
sensitivity analyses revealed model sensitivity to the absolute stroke risk with apixaban 
and treatment discontinuations risks with apixaban and VKAs. The probability that 
apixaban is cost-effective at a willingness-to-pay threshold of €20,000/QALY was 68%. 
Results of the scenario analyses on the impact of different coagulation monitoring levels 
were quite robust. 
Conclusions: In patients with non-valvular AF, apixaban is likely to be a cost-effective 
alternative to VKAs in the Netherlands. 
  
6 




Atrial fibrillation (AF) is a heart disease common among elderly people. In the Netherlands 
incidence rates increase with advancing age from approximately 1% among 55-year olds 
to 18% among 85-year olds and related relevant risks of ischemic stroke (IS) and other 
systemic thromboembolic events (1,2). In addition, patients with AF suffer not only from a 
greater activity impairment and lower quality of life (QoL) compared to the general 
population but also have a 50 – 90% increased risk of mortality (3,4). The majority of AF 
patients suffer from non-valvular AF. Strokes related to AF are often characterized by 
more severe disability and impairment of QoL in comparison to strokes due to other 
causes (5). As a result, stroke related morbidity, which is driven by high hospitalization and 
long-term maintenance costs, causes a high economic burden to the Dutch health care 
system. Specifically, the 6-month cost of usual care for stroke patients range from €16,000 
to €54,000 depending on severity (6). In parallel, the annual costs of treating patients with 
AF in the Netherlands were estimated to mount up to €2,328 with 70.1% of the resources 
allocated to the inpatient care and interventional procedures (7). Given the humanistic 
implications of both AF and stroke and economic considerations of their management, 
stroke prevention is the main focus of treatment strategies for patients with AF and could 
be expected to lead to both health and economic benefits. 
Until recently patients with AF and an estimated moderate to high risk of stroke (i.e. 
cardiac failure, hypertension, age, diabetes, stroke (doubled) [CHADS2] score ≥ 2) were 
recommended to receive vitamin-K antagonists (VKAs; e.g. warfarin, acenocoumarol or 
phenprocoumon) for stroke prevention (8). However, although VKAs present a highly 
effective treatment strategy in reducing the incidence of stroke, their optimal 
effectiveness and safety is crucially safeguarded with regular coagulation monitoring due 
to VKAs’ narrow therapeutic range (international normalized ratio [INR] limits of 2.0 and 
3.0)(9). Failure to achieve the anticoagulant effect inside the required INR therapeutic 
range increases the risk of IS and bleeding including haemorrhagic stroke (HS). The 
complexity of regular monitoring, which in the Dutch healthcare system is handled by 
thrombotic services, possibly followed by failure to achieve the safety range inside INR 
limits, accompanied with multiple drug and food interactions, might lead to underuse of 
VKAs or even result in an increase in medication-related hospital admissions as observed 
in the HARM study (8,10).  
Recently, a new class of anticoagulants became available (novel oral anticoagulant 
(NOAC)) that are at least as effective or superior in reducing the risk of stroke or systemic 
embolism (SE), have a better efficacy/safety profile and exclude the need for constant INR 
monitoring, compared to VKAs (11,12),(13). Accordingly, NOACs have been included in 
both international and national guidelines (8,14). One of them is apixaban, a NOAC of 




[ClinicalTrials.gov Identifier, NCT00412984]) or unsuitable (AVERROES trial 
[ClinicalTrials.gov Identifier, NCT00496769]) non-valvular AF patients with a high risk of 
stroke (11,15). In the AVERROES trial, apixaban was shown to prevent more stroke or SE 
events with no significant difference in the incidence of major bleedings (MBs) or 
intracranial haemorrhages (ICHs) compared to acetylsalicylic acid (ASA)(11,15). Similarly, 
in the ARISTOTLE trial, less stroke or SE events, less MBs and less fatal events related to 
any cause were observed in the treatment with apixaban when compared to the 
treatment with VKA (11,15). Despite obvious advantages of the NOACs, the choice of the 
optimal treatment strategy for AF-patients always needs to be made with respect to both 
health and economic consequences of the approach chosen, including a formal 
comparison of apixaban and VKAs as one element (16). 
The aim of this study is to evaluate the health and economic consequences of applying 
apixaban compared to VKAs for stroke prevention in non-valvular AF patients in the 
Netherlands. The health consequences associated with the use of apixaban and VKAs 
reflecting the likelihoods of having stroke, other thromboembolic or bleeding events, are 
mainly based on the data from the ARISTOTLE trial (11). The cost estimates of stroke and 
other AF-related complications as well as drug costs, reflect the Dutch situation from the 
healthcare payers’ perspective. 
METHODS 
Decision model 
The previously published lifetime Markov model was modified and updated to reflect the 
use of apixaban per defined daily dose and adjusted-dose warfarin in patients with non-
valvular AF in the Netherlands (17,18). The following health states were included in the 
model: baseline (non-valvular AF), IS, HS, SE, myocardial infarction (MI), other ICH, other 
MB and clinically-relevant non-major (CRNM) bleeding, other treatment discontinuation 
and death (Figure 1). Notably, other treatment discontinuations reflect discontinuations 
that are not directly related to having had a thrombotic or bleeding event. For the 
purposes of this study, warfarin, studied versus apixaban in the ARISTOTLE trial (11), was 
used as a comparator, as the Dutch reimbursement authorities presume the efficacy and 
safety profile of warfarin and acenocoumarol/phenprocoumon (also VKAs) to be 
interchangeable(19). 
Base-case analysis followed a hypothetical cohort of 1,000 patients with non-valvular AF 
whose characteristics were comparable to those in the ARISTOTLE trial. Specifically, 
patients were predominantly male, aged 70 years, with an average CHADS2 score of 2.3 
and a history of previous VKA use (Table 1) (11,20,21). The progression of patients with 
non-valvular AF through the Markov model is detailed elsewhere (17,18). Briefly, patients 
remained in the baseline state until a fatal or non-fatal event or treatment discontinuation 
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occurred, or they died due to other, non-cardiovascular related, causes. In order to reflect 
daily life more closely, a distinction between different levels of IS and HS severity was 
made in the model, i.e. mild, moderate, severe and fatal. The model allows one recurrent 
stroke event to occur. The annual risk of recurrent stroke event was based on the 10-year 
cumulative risk of recurrence derived from a population based study using the South 
London stroke registry (22). Health states for thromboembolic events other than stroke 
(i.e. SE and MI) were considered to be absorbing (i.e. patients remain there until death). 
The probability of patient being in a particular health state was assessed every 6-weeks 
which was the cycle length of the model. 
Certain assumptions on the treatment following thromboembolic or bleeding events were 
made. Firstly, upon the occurrence of IS or SE, patients surviving were assumed to stay on 
the initially assigned anticoagulant treatment while those surviving HS and MI were 
assumed only to receive long-term disease-specific maintenance treatment. Secondly, 
patients experiencing other ICH, MB and CRNM bleeding were allocated between an 
option to stay on the initially assigned treatment and an option to switch to ASA. Details 
on the allocation of patients between the two treatment options are provided in 
previously published studies (17,18). Patients staying on the initially assigned 
anticoagulant treatment after an ICH that was not a HS, were additionally assumed to 
have a six-week drug holiday. Finally, patients discontinuing the initial treatment for 
reasons unrelated to stroke, SE and bleeding were assumed to switch to ASA. 
The final outcome of the decision model is the incremental cost-effectiveness ratio (ICER) 
of apixaban compared to VKA. As a measure of effectiveness, quality-adjusted life-years 
(QALYs) and life years (LYs) gained were estimated. All relevant costs incorporated in the 
model reflect the health care payer’s perspective and were inflated to price year 2013 
using the Dutch consumer price index (23). Future costs and health effects were 
discounted by 4% and 1.5% annually after the first year, according to the Dutch guidelines 
for pharmacoeconomic research (24). 
Table 1 Baseline characteristics of the patients included in the model. 
Characteristic Value Range Reference 
Age 70 63-77 (11) 
Gender (female, %) 35.3 34.1-36.5 (11) 
CHADS2 (% of patients)    
1 7 5.4-8.8 (20) 
2 27 21.3-33.1 (20) 
3 25 19.7-30.7 (20) 
4 20 15.7-24.7 (20) 
5 12 9.3-15 (20) 
6 7 5.4-8.8 (20) 
7 2 1.5-2.5 (20) 
Average TTR in the Netherlands (%) 72.48 Fixed (21) 





Figure 1 Model for the non-valvular AF population. 
Depicted in the diagram are the chance nodes (circles) and terminal nodes (triangles). Branches for apixaban and 
VKA are identical except numerical risks. Patients that discontinue the initial anticoagulant treatment re-enter 
the model with identical Markov branches but under the assumption of switching their treatment to 
acetylsalicylic acid.  
NVAF, non-valvular atrial fibrillation; ASA, acetylsalicylic acid; IS, ischemic stroke; HS, haemorrhagic stroke; SE, 
systemic embolism; MI, myocardial infarction; ICH, intracranial haemorrhage; CRNM, clinically-relevant non-
major; MB, major bleeding; Tmt, treatment. 
Transition probabilities 
Data from the ARISTOTLE and the AVERROES trial were the main sources used to estimate 
the transition probabilities between the health states in the model for patients receiving 
apixaban, VKA and ASA (11,15,17,18). Specifically, the rates of IS, MI, SE, ICH, other MB 
and CRNM bleeding and other treatment discontinuations from the aforementioned trials, 
were applied for deriving the transition probabilities between the health states similarly to 
the previously published Markov models (Table 2)(17,18). Additionally, trial rates of IS, 
ICH, other MB and CRNM bleeding were adjusted for the average level of risk dependent 
on the level of INR control in the Netherlands represented by mean time in therapeutic 
range (TTR) (i.e. 72.48%(21),(25)).  
ICHs were further differentiated into HSs and other ICHs; other MBs were differentiated to 
those that were or were not gastrointestinal (GI) by location. Details on the number of 
patients experiencing one of the two types of ICHs, specific fatality rates after stroke, MI, 
SE, ICH and other MB and the factors of age-related increasing risk of stroke, bleeding (i.e. 
ICH, other MB and CRNM bleedings) and MI are provided elsewhere (17,18)(29). 
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Table 2 Rates of events while on apixaban, VKA and ASA used in estimating the transition 
probabilities in the model. 
Parameter Apixaban VKA ASA Reference 
IS rate by CHADS2 score     
1 0.52 0.46  (11,15,17,19) 
2 0.52 0.46  (11,15,17,19) 
3 0.95 0.93  (11,15,17,19) 
4 1.53 1.94  (11,15,17,19) 
5 1.53 1.94  (11,15,17,19) 
6 1.53 1.94  (11,15,17,19) 
7 1.53 1.94  (11,15,17,19) 
IS HR by cTTR     
cTTR < 52.38% 0.92 1.54  (11,15,17,19) 
52.38% ≤ cTTR < 66.02% 1.00 1.00  (11,15,17,19) 
66.02% ≤ cTTR < 76.51% 0.69 0.84  (11,15,17,19) 
cTTR ≥ 76.51% 0.56 0.72  (11,15,17,19) 
Rate of IS (per 100 patient years)   3.45 (11,15,17,19) 
Rate of ICH (per 100 patient years) 0.33 0.80 0.32 (11,15,17,19) 
ICH HR by cTTR     
cTTR < 52.38% 0.58 1.05  (11,15,17,19) 
52.38% ≤ cTTR < 66.02% 1.00 1.00  (11,15,17,19) 
66.02% ≤ cTTR < 76.51% 0.69 0.68  (11,15,17,19) 
cTTR ≥ 76.51% 0.36 0.78  (11,15,17,19) 
Rate of other MBs (per 100 patient years) 1.79 2.27 0.89 (11,15,17,19) 
Other MBs HR by cTTR     
cTTR < 52.38% 0.72 0.84  (11,15,17,19) 
52.38% ≤ cTTR < 66.02% 1.00 1.00  (11,15,17,19) 
66.02% ≤ cTTR < 76.51% 1.69 1.13  (11,15,17,19) 
cTTR ≥ 76.51% 1.77 1.37  (11,15,17,19) 
Rate of CRNMBs (per 100 patient years) 2.08 2.99 2.94 (11,15,17,19) 
CRNMBs HR by cTTR     
cTTR < 52.38% 0.71 0.99  (11,15,17,19) 
52.38% ≤ cTTR < 66.02% 1.00 1.00  (11,15,17,19) 
66.02% ≤ cTTR < 76.51% 1.25 1.26  (11,15,17,19) 
cTTR ≥ 76.51% 1.70 1.27  (11,15,17,19) 
Rate of myocardial infarction (per 100 patient years) 0.53 0.61 1.11 (11,15,17,19) 
Rate of other treatment discontinuations (unrelated to 




Rate of systemic embolism (per 100 patient years) 0.09 0.10 0.4 (11,15,17,19) 
Death rate during trial period (per 100 patient years) 3.08 3.34 3.59 (11,15,17,19) 
Background mortality after trial period  Age- and gender-adjusted 
non-CVD mortality 
(26-28) 
VKA, vitamin K-antagonist; ASA, acetylsalicylic acid; IS, ischemic stroke; HR, hazard ratio; cTTR, clinic time in 






The average risk of IS in patients receiving apixaban and VKA, was estimated as the joint 
probability of having an event associated with a specific baseline population stroke risk 
represented by CHADS2 score corrected for the average level of risk dependent on INR 
control, and the probability of having an event associated with the level of INR control in 
the Netherlands (Table 1)(21),(25). Baseline population stroke risk represented by CHADS2 
score was determined by weighting the risk for each categorization of CHADS2 score by 
the proportion of patients within each group of CHADS2 score in the Netherlands (20). 
Published population based registries were used to estimate the transition probabilities 
for recurrence of events (22). The annual risks for recurrent stroke events of 2.97 and 2.17 
were assigned to patients surviving first IS and HS, respectively (22). The distribution of 
stroke severity for recurrent stroke events was assumed to be the same as that of the first 
stroke events in patients treated with apixaban.  
Mortality due to causes other than cardiovascular while on apixaban and VKA, for the trial 
period, were based on data from the ARISTOTLE trial (11). Beyond the duration of the trial 
period (1.8 years), age- and gender-adjusted mortality due to causes other than 
cardiovascular, was obtained from Statistics Netherlands (26-28). In addition to the 
mortality due to causes other than cardiovascular, an increase in mortality rates 
associated with AF, strokes by severity level, MI and SE, was incorporated as in the 
previously published Markov models (17,18).  
Utilities 
A utility score specific for patients with AF was applied to all patients in the baseline 
health state of the model (Table 3)(30). Upon the occurrence of stroke, MI or SE, utility 
scores were adjusted to account for the level of utility for AF and comorbid 
thromboembolic event jointly (30),(31). Utility decrements following the occurrence of a 
certain bleeding event were applied additively for a specific time interval (32). Finally, 
utility decrements reflecting the use of VKA (warfarin), apixaban and ASA were applied 
(32)(33). 
Costs 
Prices of apixaban, defined as price per defined daily dose (2x 5 mg), VKAs and ASA (100 
mg) were taken from the official Dutch price list (Z-index) (Table 4)(35). Cost of VKA was 
estimated as a weighted average cost of acenocumarol and fenprocoumon based on their 
usage in the Netherlands (80%:20%, respectively)(36). In addition to anticoagulants’ costs, 
routine care cost representing medical specialist fee was added to all treatment 
alternatives and cost due to INR testing was added to treatment with VKAs (24).  
Acute care costs associated with clinical events (IS and HS with different levels of severity, 
other ICH, other MB and CRNM bleedings, SE, MI) were adopted from previous costing 
studies conducted in the Netherlands and updated to the year 2013 using the Dutch 
6 
Economic evaluation of apixaban for the prevention of stroke in non-valvular atrial fibrillation 
 
149 
inflation index (Table 4)(6,37,38)(23)(23). Patients surviving acute stroke and MI were 
assigned with long-term maintenance costs (39). 
Sensitivity analyses 
Univariate sensitivity analyses were conducted in order to inspect the effects of the 
uncertainty in key input parameters and assumptions on the uncertainty in the final cost-
effectiveness outcome. Furthermore, a probabilistic sensitivity analysis (PSA) was 
performed in order to simultaneously incorporate the uncertainty around all parameters 
in the CE analysis. Key input parameters in the deterministic analysis that were assumed 
random variables in the PSA were: event rates, utilities and costs. A gamma distribution 
was assigned to event rates, a beta distribution to utilities and a log-normal distribution to 
cost estimates. Results from the PSA were plotted on a CE plane and transformed into CE-
acceptability curves (CEACs). 
Finally, in order to investigate the impact of different levels of INR control on the 
estimated ICER, as is the case in the various Dutch thrombotic centres, scenario analyses 
were conducted. Four different scenarios were investigated. Specifically, one scenario 
assumed patients were equally distributed across centers with different cTTR, similarly to 
the patient allocation in the ARISTOTLE trial. Other scenarios assumed the allocation of all 
patients to the one of specific cTTR range (i.e. cTTR< 52.38%, 52.38% ≤ cTTR<66.02% and 
cTTR ≥ 76.51%) that was different from the range in the base-case analysis (i.e. 
cTTR=72.48%). 
 
Table 3 Utility parameters applied in the model. 
Parameter Mean Range* Reference 
   Baseline Utility for AF 0.6980 0.5532-0.8250 (30) 
   Stroke mild 0.6704 0.5330-0.7944 (31) 
   Stroke moderate 0.6165 0.4925-0.7333 (31) 
   Stroke severe 0.4416 0.3561-0.5289 (31) 
   SE 0.5769 0.4622-0.6876 (30) 
   MI 0.5328 0.4279-0.6363 (30) 
Disutility of other ICH (6 weeks) 0.1385 0.1125-0.1667 (32) 
Disutility of other MBs (14 days) 0.1385 0.1125-0.1667 (32) 
Disutility of CRNM bleedings (2 days) 0.06 0.0488-0.0723 (32) 
Disutility of anticoagulation with VKA 0.013 0.0106-0.0157 (33) 
Disutility of anticoagulation with ASA 0.002 0.0016-0.0024 (32) 
Disutility of anticoagulation with apixaban 0.002 0.0016-0.0024 (32) 
AF, atrial fibrillation; SE, systemic embolism; MI, myocardial infarction; ICH, intracranial haemorrhage; MB, major 
bleeding; CRNM, clinically relevant non-major; VKA, vitamin K-antagonist; ASA, acetylsalicylic acid. 
*Utility estimates that were available only as single point estimates, were assumed to follow a beta distribution 
with a 10% standard deviation of the mean. 





Table 4 Cost parameters applied in the model. 
Parameter Mean Range‡ Reference 
Apixaban (daily) € 2.28 Fixed (35) 
VKA (daily)§ € 0.03 Fixed (35) 
ASA (daily) € 0.15 Fixed (35) 
Monitoring visit (per year) € 224 163-308 (35) 
Routine care (per visit) € 78.97 62-117 (24) 
Stroke¶    
   Mild 0-6 months  € 16,097 11,712-22,124 (6) 
   Mild 7-12 months  € 4,470 3,252-6,144 (6) 
   Mild 13 -19 months men € 1,174 854-1,614 (6) 
   Mild 13 -19 months women € 1,174 854-1,614 (6) 
   Moderate 0-6 months  € 44,640 32,479-61,354 (6) 
   Moderate 7-12 months  € 21,146 15,385-29,063 (6) 
   Moderate 13 -19 months men € 7,115 5,177-9,779 (6) 
   Moderate 13 -19 months women € 11,745 8,545-16,142 (6) 
   Severe 0-6 months  € 54,678 39,783-75,150 (6) 
   Severe 7-12 months  € 26,711 19,43-36,712 (6) 
   Severe 13 -19 months men € 9,055 6,588-12,445 (6) 
   Severe 13 -19 months women € 15,069 10,964-20,711 (6) 
Fatal stroke € 2,988 2,876-3,102 (39) 
SE acute care (per episode)* € 4,995 3,634-6,865 (38) 
Other ICH# € 20,326 14,789-27,937 Assumption 
GI bleeds € 4,995 3,635-6,866 (38) 
Non ICH and non-GI bleeds¥  € 4,995 3,635-6,866 Assumption 
CRNMB (assume a visit to GP) € 30.71 22-42 (24) 
MI acute care (per episode) € 5,021 4,936-5,106 (37) 
MI maintenance (per month) € 196 183-206 (39) 
VKA, vitamin K-antagonist; ASA, acetylsalicylic acid; SE, systemic embolism; ICH, intracranial haemorrhage; GI, 
gastrointestinal; CRNMB, clinically relevant non-major bleeding; GP, general practitioner; MI, myocardial 
infarction. 
‡ Cost estimates that were available only as single point estimates, were assumed to follow a log-normal 
distribution with a coefficient of variation equal to 0.25.  
§ Cost of VKA was estimated as a weighted average cost of acenocumarol and fenprocoumon based on their 
usage in the Netherlands (35) 
¶ Stroke related costs were adjusted to fit the design of a decision model. Specifically, acute and long-term one-
month maintenance costs were estimated.  
*Assumed to be equal to the cost of pulmonary embolism.  
# Assumed to be the same as cost of acute mild stroke 
¥ Assumed to be the same as cost of GI bleeds 
RESULTS 
The number of events associated with the use of VKAs and apixaban in a cohort of 1,000 
patients with non-valvular AF, as well as the costs related to those events and the 
anticoagulant treatment, are presented in Table 5. Specifically, the incremental difference 
in the number of events observed over a lifetime horizon in the apixaban treatment 
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scenario compared to the VKA treatment scenario was: ten less stroke or SE events 
(including first and recurrent IS and HS), nine less other ICHs, 12 more other MBs, three 
less MIs and 58 less CRNM bleedings. A comparable number of other treatment 
discontinuations was observed in both apixaban and VKA treatment scenarios (648 and 
652 respectively). Finally, treatment with apixaban was estimated to provide an additional 
0.18 QALYs or 0.18 LYs compared to treatment with VKA over a lifetime horizon (Table 6). 
Costs associated with handling stroke and thromboembolic events were lower in the 
apixaban treatment scenario compared to the VKA treatment scenario (€14,113 vs. 
€14,904)(Table 5). However, the overall anticoagulant treatment costs including the drug 
acquisition costs, costs of routine care and INR monitoring were higher with apixaban 
compared VKA (€6,092 vs. €3,449)(Table 5). Accounting for all the aforementioned costs 
resulted in an additional cost of €1,852, associated with the use of apixaban compared to 
VKA. 
Finally, the summarized lifetime health and economic consequences of applying apixaban 
compared to VKA in 70-year old patients in the Netherlands yielded a base-case ICER of 
€10,576 per QALY gained or €10,529 per LY gained (Table 6).  
Sensitivity analyses 
Figure 2 presents a tornado diagram illustrating the impact of varying each of key input 
parameters on the ICER while holding all the other model parameters fixed. The 
uncertainty around the absolute stroke risk under apixaban, the risks of treatment 
discontinuations under both apixaban and VKA and the risk of ICH under VKA, showed the 
highest impact on uncertainty in the estimated ICERs. In particular, when the absolute 
stroke risk or treatment discontinuations risk under apixaban would reach the upper limit 
of the 95% confidence interval (CI), ICERs would be €33,426 and €27,103 per QALY gained, 
respectively. At risks dropping to lower limits of 95% CIs, ICERs would fall to €4,268 or 
€5,086 per QALY gained, respectively. The uncertainty around the risks of treatment 
discontinuations under VKA led to comparable variation in estimated ICERs ranging from 
€4,236 to €25,811 per QALY gained. 
The results of 2,000 iterations in PSA are presented through an incremental CE plane in 
Figure 3. The ellipsoid shape of this incremental CE plane indicated a negative correlation 
between incremental costs and incremental effects. Transforming the results of a CE plane 
to CEACs shows that apixaban was cost-effective at alternative willingness to pay (WTP) 
thresholds of €20,000/QALY and €30,000/QALY in 68% and 72% of simulations 
respectively (Figure 4). Accordingly, VKA was estimated to be the preferred alternative 
over apixaban at the aforementioned WTP thresholds in 32% and 28% of simulations 
respectively. 
The impact of different levels of INR control on the estimated ICER was explored through 




rates of IS, ICH, other MB and CRNM bleeding and therefore can have an indirect impact 
on the estimated ICER. Across the scenarios investigated, the majority of the 
aforementioned rates was estimated to be lower with apixaban compared to VKA. IS rate 
with apixaban was estimated to be higher than with VKA (i.e. 1.316 and 1.159, 
respectively) only in the scenario assuming allocation of patients in the range 52.38% ≤ 
cTTR< 66.02%. Finally, the estimated ICER was in range from €27 to €12,662/QALY or from 
€22 to €12,905/LY across the scenarios explored (Table 7).  
 
Table 5 Stroke and other thromboembolic and bleeding complications and related costs within a 
hypothetical patient population of 1,000 subjects receiving apixaban and VKA over a lifetime 
horizon. 



















Ischemic stroke       
Mild, non-fatal 96.32 € 1,429  € 638  93.01 € 1,379  € 614  
Moderate, non-fatal 83.62 € 3,285  € 2,612  89.30 € 3,563  € 2,921  
Severe, non-fatal 32.86 € 1,586  € 643  34.31 € 1,675  € 699  
Fatal 30.36 € 67   29.05 € 64   
Sum 243.15 € 10,259   245.67 € 10,915   
Recurrent ischemic 
stroke 
      
Mild, non-fatal 10.63 € 149  € 38  10.81 € 152  € 37  
Moderate, non-fatal 4.21 € 161  € 225  4.28 € 165  € 244  
Severe, non-fatal 1.61 € 75  € 49  1.63 € 77  € 52  
Fatal 3.61 € 7   3.67 € 8   
Sum 20.06 € 705   20.40 € 735   
Haemorrhagic stroke       
Mild, non-fatal 4.86 € 79  € 41  5.64 € 93  € 49  
Moderate, non-fatal 7.78 € 339  € 333  5.70 € 247  € 241  
Severe, non-fatal 4.47 € 226  € 105  5.67 € 295  € 147  
Fatal 10.88 € 25   17.68 € 42   
Sum 27.99 € 1,147   34.69 € 1,115   
Recurrent haemorrhagic 
stroke 
      
Mild, non-fatal 0.29 € 4  € 1  0.29 € 4  € 1  
Moderate, non-fatal 0.40 € 16  € 18  0.40 € 16  € 16  
Severe, non-fatal 0.13 € 6  € 5  0.13 € 6  € 6  
Fatal 0.44 € 1   0.44 € 1   
Sum 1.25 € 51   1.25 € 51   
Systemic embolism       
Non-fatal 24.10 € 86  24.60 € 88  
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Fatal 2.50 € 0  2.55 € 0  
Sum 26.60 € 86  27.14 € 88  
Other ICH       
Non-fatal 11.72 € 176  19.20 € 303  
Fatal 1.75 € 0  2.87 € 0  
Sum 13.47 € 176  22.07 € 303  
Other major bleedings       
Non-fatal GI 
bleedings 
78.14 € 306   69.49 € 274   
Non-fatal Non ICH or 
Non GI related major 
bleedings 
126.23 € 496   123.45 € 490   
Fatal 4.17 € 0  3.94 € 0  
Sum 208.54 € 802   196.88 € 764   
Clinically relevant non-
major bleeding 
314.94 € 7  372.69 € 9  
Myocardial infarction       
Non-fatal 76.39 € 283  € 596  78.85 € 295  € 630  
Fatal 14.34   14.79   
Sum 90.73 € 879   93.64 € 925   
Other treatment 
discontinuation 
647.58   652.08   
       
Cost of anticoagulants  € 3,870   € 365  
Cost of routine care  € 2,120   € 2,067  
Cost of INR monitoring  € 102   € 1,018  
     
Total costs  € 20,205  € 18,353 
VKA, vitamin K-antagonist; p.p., per patient; ICH, intracranial hemorrhage; GI, gastrointestinal; INR, international 
normalized ratio. 
 
Table 6 Incremental costs, QALYs and ICER for patients with non-valvular atrial fibrillation receiving 
anticoagulation therapy. 
Treatment Costs (€) QALYs LYs Δ Cost  (€) Δ QALY Δ LYs ICER 
(€/QALY) 
ICER (€/ LYs) 
VKA 18,353 7.00 10.26 1,852 0.18 0.18 10,576 10,529 
Apixaban 20,205 7.18 10.44      






Figure 2 Tornado diagram illustrating results from sensitivity analyses for apixaban vs. vitamin-K 
antagonists. 
Black bars denote influence of the high value of the 95% confidence interval range and grey bars denote 
influence of the low value for parameters investigated. 
ICER, incremental cost-effectiveness ratio; QALY, quality adjusted life year; ICH, intracranial hemorrhage; AF, 
atrial fibrillation; MI, myocardial infarction; MB, major bleeding. 
 
 
Figure 3 Incremental cost-effectiveness plane. 
Incremental cost-effectiveness plane presents the incremental cost-effectiveness ratios of apixaban compared to 
vitamin-K antagonists in patients with non-valvular atrial fibrillation, obtained through a probabilistic sensitivity 
analysis. Points below the diagonal dotted and the full line represent simulations in which apixaban was a cost-
effective alternative at a threshold of €30,000/QALY and €20,000/QALY, respectively. 
QALY, quality adjusted life year; VKA, vitamin-K antagonists 
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Figure 4 Cost-effectiveness acceptability curves for the treatment with apixaban and VKA in non-
valvular atrial fibrillation. 
The cost-effectiveness acceptability curve assesses the probability that the estimated incremental 
cost-effectiveness ratio is under a certain willingness to pay threshold. 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































This economic evaluation estimated the CE of apixaban compared to VKA for prevention 
of stroke and other thromboembolic events in patients with non-valvular AF in the 
Netherlands. Apixaban was shown to be a cost-effective alternative to treatment with VKA 
with an ICER of €10,576/QALY or €10,529/LY. Notwithstanding that both the Dutch-
specific level of INR monitoring (TTR=72.48%) and a weighted level of baseline CHADS2 
stroke risk were incorporated in this analysis, the specific long-term health and economic 
benefits of treatment with apixaban are evident. Those benefits correspond with a lower 
number of stroke and thromboembolic events as well as a generally better safety profile 
(i.e. less ICH and CRNM bleeding events) that is associated with the use of apixaban when 
compared to VKA. However, the number of other MBs was higher in the apixaban 
treatment scenario compared to VKA scenario. This finding can be explained by a 
relatively small difference in risks of MBs between the two comparators and a higher 
number of survivors in each model cycle that would be exposed to those risks in the 
apixaban treatment scenario.  
Yet, the base-case ICER was found to be below the Dutch informal WTP threshold of 
€20,000/QALY in 68% of PSA simulations mainly reflecting the uncertainty in the apixaban 
absolute stroke risk and the risks of treatment discontinuations under both comparators. 
The major impact of uncertainty in those risks on both incremental effects and 
incremental costs was visualized in univariate sensitivity analyses’ tornado diagram (Figure 
2) and PSA’s incremental CE plane (Figure 3). Specifically, the estimated ICERs in univariate 
and probabilistic sensitivity analyses, the specific shape of incremental CE plane and the 
overall number of simulated ICERs below a certain WTP threshold are mainly driven by the 
uncertainty in absolute stroke risk and treatment discontinuations risk. Notably, the 
relevance of the uncertainty in the apixaban absolute stroke risk can be directly attributed 
to its impact on the occurrence of stroke events and their related costs of treatment and 
reduced quality of life. In particular, the influence of the risk of treatment discontinuations 
can be indirectly explained by the choice of a second-line treatment that would follow 
after those discontinuations. In this analysis ASA was chosen to be a second-line 
treatment even though it provides less protection from various thromboembolic and 
bleeding events. Therefore, uncertainty in the risk of treatment discontinuations would in 
the case of a higher level of risk, lead to more patients being treated with ASA and 
consequently to a higher number of stroke and thromboembolic events.  
Finally, the results of the scenario analyses examining the impact of different levels of INR 





Comparison with other studies 
Findings of this analysis regarding the long-term health effects and economic 
consequences of using apixaban compared to VKA are similar to the results of other 
analyses studying apixaban in the US setting (40-42). Harrington et al. evaluated the use of 
NOACs compared to warfarin and estimated an ICER of $15,026/QALY for apixaban (40). 
Furthermore, the use of apixaban was reported to be a cost-effective alternative with 
$11,400/QALY compared to warfarin in the study of Kamel et al (41). Finally, Lee et al. 
found apixaban to be a cost-saving option compared to warfarin (42). Differences in the 
observed ICERs might be explained by different modelling assumptions and inputs that 
were used. Also differences in economic consequences associated with the use of 
anticoagulants could be attributed to the variability in country-specific cost estimates and 
the choice of study perspective (e.g. societal (41,42)). Finally, differences in the underlying 
patients’ characteristics, modes of INR control and various modelling assumptions such as 
inclusion of multiple recurrent events (42) or different comorbid health states (e.g. 
transient ischemic attack (41)) could additionally hinder comparability between the study 
results. 
Strengths and limitations 
Our study examines the potential use of apixaban for the prevention of stroke and other 
thromboembolic events in patients with non-valvular AF in the Dutch setting. Country-
specific cost estimates, nation-specific background mortality and conjoint influence of the 
level of INR control and the allocation of baseline CHADS2 stroke risk in Dutch population 
on the events rates were implemented in this analysis. Furthermore, the impact of 
different levels of INR control was examined in this study. Comparable to similar CE 
studies, the health states of IS, SE, ICH, MI and CRNM bleedings were incorporated in this 
analysis. Finally, unlike other aforementioned analysis, utility estimates of stroke, MI and 
SE were estimated to reflect the level of utility for joint health states, using specific 
methodologies (34).  
Our analysis has several limitations that may restrict the interpretation of results in a 
broader context. One limitation might be that the event rates incorporated in the decision 
model were assumed to be constant through life even though they were based on 
ARISTOTLE trial with an average follow-up of 1.8 years. This assumption, however, was 
partly corrected by applying event-specific rates that account for age-related increase in 
risk. In addition, multiple thromboembolic events were not incorporated in the decision 
model due to the lack of epidemiological evidence. Incorporating multiple 
thromboembolic events could nevertheless lead to a more favourable ICER which makes 
our analysis more conservative. A further potential limitation in our analysis is the 
assumption that a certain number of patients who experience ICH or other MB as well as 
all patients that discontinue treatment for reasons other than thromboembolic events, 
switch to a treatment with ASA. Noticeably, second-line treatment with ASA will provide a 
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different level of protection from stroke and thromboembolic events when compared to 
initially assigned anticoagulants. In a real-life setting, patients might alternatively be 
switched to other NOACs or VKAs. However, current guidelines have no clear 
recommendations for the treatment following bleeding events or treatment 
discontinuations. Finally, our analysis does not reflect a societal perspective. In patients 
with non-valvular AF younger than 65 years, incorporating a societal perspective is of 
major importance given that this patient population encounters a significant productivity 
loss. Accounting for the productivity loss in the aforementioned patient population, would 
lead to even more favourable ICERs.   
Implications for practice and future research 
Our findings showed apixaban to be a cost-effective alternative to VKAs in the Dutch 
setting with 68% of chances if a willingness-to-pay threshold is set to €20,000/QALY. 
Having in mind the high cost of illness due to AF and associated comorbid events, applying 
an effective and safe treatment in patients is of high importance. In the ARISTOTLE and 
AVERROES trials apixaban was shown to be a valuable alternative to VKAs and ASA 
regarding the effectiveness and safety issues. However “real life” long-term benefits of the 
use of apixaban as well as other NOACs still need to be proven, primarily regarding the 
patients’ adherence to them (43). Additionally, the regulations regarding the choice of a 
second-line treatment in the case of adverse drug reactions need to be more clearly 
specified. 
Apixaban is a NOAC which was recently approved for use in Europe, just after two other 
NOACs, rivaroxaban and dabigatran, were introduced. Further investigation should be 
directed to estimating comparative effectiveness and CE among the individual NOACs in 
the Dutch setting. 
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Background: Dabigatran was proven to have similar effect on the recurrence of venous 
thromboembolism (VTE) and a lower risk of bleeding compared to vitamin K antagonists 
(VKA). The aim of this study is to assess the cost-effectiveness (CE) of dabigatran for the 
treatment and secondary prevention in high risk patients of VTE compared to VKAs in the 
Dutch setting. 
Methods: The previously published Markov model was modified and updated to assess 
the CE of dabigatran and VKAs for the treatment and secondary prevention in high risk 
patients of VTE from a societal perspective in the base-case analysis. The model was 
populated with efficacy and safety data from major dabigatran trials (i.e. RE-COVER, 
RECOVER II, RE-MEDY and RE-SONATE), Dutch specific costs, and utilities derived from 
dabigatran trials or other published literature. Univariate, probabilistic sensitivity and a 
number of scenario analyses on the impact of various decision-analytic settings (e.g. the 
perspective of analysis, use of anticoagulants only for treatment or only for secondary 
prevention) were tested on the incremental cost-effectiveness ratio (ICER). 
Results: In the base-case analysis, patients on dabigatran gained an additional 0.583 
discounted quality adjusted life years (QALYs) over a lifetime and savings of €1,996. 
Results of univariate sensitivity analysis were quite robust. The probability that dabigatran 
is cost-effective at a willingness-to-pay threshold of €20,000/QALY was 100%.  
Except for the scenario comparing the use of dabigatran and VKAs from the healthcare 
provider perspective and the one comparing dabigatran to placebo for the prevention of 
recurrent VTE in patients who are at equipoise for anticoagulation treatment where the 
ICERs for dabigatran compared to VKAs of €1,005 and €33,305 per QALY gained, 
respectively were estimated, other scenarios showed dabigatran was cost-saving. 
Conclusion: From a societal perspective, dabigatran is likely to be a cost-effective or even 








Venous thromboembolism (VTE) can manifest as deep vein thrombosis (DVT) and/or 
pulmonary embolism (PE)(1). The health burden associated with VTE is mostly determined 
with the risk of a fatal PE and risk of considerable late morbidity associated with the 
development of post thrombotic syndrome (PTS) or chronic thromboembolic pulmonary 
hypertension (CTEPH). Moreover, recurrent DVT (rDVT) occurs in approximately 7% of 
patients per year and reaches to about one quarter to one third of patients within 8 years 
(2)(3). The health related quality of life (HRQoL) in VTE patients is also affected. For 
example, a Dutch study found distinctly lower HRQoL scores measured with SF-36 
questionnaire in patients with PE compared to the general population on the subscales: 
social functioning, role emotional, general health, role physical and vitality (4).  
In the Netherlands, the DVT incidence was estimated to approximately 16,000 to 20,000 
cases per year (5). Though, the overall incidence of PE in the Netherlands is unknown, a 
survey among Dutch pulmonologists/internists indicated the incidence of suspected PE 
was 2.6 per 1,000 patients per year (2), while in general practice, 0.2 PEs per 1,000 
patients were reported (6). 
Both national and international guidelines recommend anticoagulation therapy as an 
effective measure to prevent thrombus propagation and recurrence in VTE patients (1,2). 
For the initial treatment phase of VTE, low-molecular-weight heparins (LMWHs) for at 
least 5 days combined with subsequent administration of vitamin K antagonists (VKAs; e.g. 
warfarin, acenocoumarol or phenprocoumon), or rivaroxaban are recommend. For the 
maintenance phase, the use of VKAs or rivaroxaban is recommended for at least three 
months (1,7). The need to continue anticoagulation should be re-assessed in patients 
based on individual patient risk-benefit balance every three months as there is no strong 
distinction between treatment and prevention phase (1,7). 
VKAs present a highly effective anticoagulation treatment which use is limited by a narrow 
therapeutic range (international normalised ratio (INR) limits of 2.0 and 3.0) and several 
interactions with other drugs and food. To achieve the anticoagulant effect inside the 
required INR range, regular monitoring and dose-adjustment is required for treatment 
with VKAs. In the Dutch healthcare system, INR-monitoring is handled by thrombotic 
services or patient self-management. Though it is considered highly effective in the 
Netherlands, INR-monitoring also affects expenditures from both healthcare provider and 
societal perspective. In particular, next to the costs of material, labour, nurse visits, 
training and material for self-management that affect healthcare providers, there are 
various out-of-the pocket expenses (e.g. travel costs of patients) and productivity loss 
costs associated with monitoring visits that have an impact on a societal economic burden. 
Recently, in the RE-COVER and RE-COVER II trials, dabigatran, a novel oral anticoagulant 




relevant non-major bleeding (CRNMB) and for any bleeding compared to VKA (8,9). When 
administered for the extended treatment in patients with VTE who had completed at least 
three months of initial therapy, dabigatran was non-inferior in preventing rVTE events and 
showed a better safety profile than VKA (the RE-MEDY trial), but a significantly better 
efficacy in preventing rVTE and higher risk of bleedings than placebo (the RE-SONATE trial) 
(10). 
Importantly, both health and economic consequences associated with the use of 
dabigatran compared to VKAs need to be considered when choosing the optimal 
treatment strategy. A formal pharmacoeconomic comparison of the two anticoagulant 
treatments should be conducted to account for all the relevant health consequences such 
as likelihood of rVTE, bleedings, PTS, CTEPH, death and other adverse events, as well as all 
relevant cost parameters including the costs of drugs, administration, INR-monitoring, 
event-related costs and various indirect costs.  
The aim of this study is to assess the cost-effectiveness (CE) of dabigatran (300mg per day) 
for the treatment and secondary prevention in high risk patients of DVT and PE compared 
to VKAs for the Dutch situation. 
METHODS 
Decision model 
The previously published Markov model was modified and updated to assess the CE of 
dabigatran and VKAs for the treatment and secondary prevention of DVT and PE in the 
Dutch setting. The health states included in the model were: index VTE, rVTE, major or 
clinically relevant bleeding (MCRB), CTEPH, PTS, other adverse events (i.e. myocardial 
infarction (MI), unstable angina (UA) and dyspepsia), off-treatment and death from other 
causes (Figure 1). 
In the base-case, the use of dabigatran was compared to VKAs for up to 6 months of 
treatment followed by up to 18 months of secondary prevention in high risk patients. The 
flow of patients with an index VTE event through the Markov model is detailed elsewhere 
(11). Shortly, at the start of the simulation, a hypothetical cohort of 10,000 adult patients 
(mean age 54.7 years) for whom at least 6 months of anticoagulant therapy was 
considered appropriate entered the model following an index VTE (i.e. index DVT or index 
PE) event and received initial treatment with LMWHs followed by either dabigatran or 
VKAs. The duration of treatment with LMWHs was assumed to be 5 days in dabigatran 
treatment arm to follow the summaries of product characteristics (SCPs) for dabigatran, 
and 9 days in VKAs arm to simulate the treatment in RE-COVER trials. Patients in the index 
VTE state were exposed to the risk of rVTE, MCRB, CTEPH, PTS, other adverse events, 
treatment discontinuation and death from other causes. After the initial 6 months of 
treatment, patients who remained in the index health state were simulated to receive up 
7 
Economic evaluation of dabigatran for the treatment and prevention of venous thromboembolism 
 
169 
to 18 months of anticoagulants for the secondary prevention, reflecting patient profiles 
from the RE-MEDY trial (10).  
rVTE could occur in any model cycle, however, the model was restricted to a maximum of 
two rVTEs (12).  Furthermore, a distinction was made between different forms of rVTE (i.e. 
a fatal VTE, non-fatal PE, proximal DVT and distal DVT). After a first rVTE, patients from 
both treatment arms were assumed to stop the initial treatment and initiate or reinitiate a 
6 months standard treatment course of LMWHs followed by VKAs.  
For patients experiencing a MCRB, a distinction was made between an intracranial 
haemorrhage (ICH), other major bleed (MB), and a CRNMB. If ICH occurred, it could lead 
to permanent disability, death, or recovery. MBs were modelled to lead to death or 
recovery. Furthermore, it was assumed that patients can experience up to two major 
bleeds (ICH or MB) during the entire time they may spend on anticoagulation; one event 
could be experienced during treatment phase with study medication and one event during 
LMWHs/VKAs re-treatment (12). CRNMB could occur at every model cycle while on 
anticoagulation (12). After a MB or ICH, all patients were assumed to discontinue 
treatment altogether having no further risk of bleeding, but continuing to be exposed to a 
risk of rVTE.  
In the model, all patients who experienced a first or recurrent PE (rPE) were at risk to 
develop CTEPH, while those with an index or rDVT were at risk of PTS.  
Other adverse events of anticoagulant therapy captured by the model are UA, MI and 
dyspepsia. Patients with a non-fatal MI or UA could suffer from chronic ischemic heart 
disease (IHD), or recover.  
During treatment or secondary prevention phases, all patients could discontinue 
treatment prior to reaching the maximum planned duration of treatment due to reasons 
other than rVTE or ICH/MB. If discontinuation occurs, patients move to off-treatment state 
where they continue to experience a risk of rVTE, but no further risk of bleeds. Finally, 
patients in any of the health states were at risk to die from other causes. Patient 
movement between health states was modeled using 1-month cycles for 60 years or until 
death.  
The final outcome of the decision model is the incremental cost-effectiveness ratio (ICER) 
of dabigatran compared to VKAs. Quality-adjusted life-years (QALYs) and life-years (LYs) 
gained were estimated as a measure of effectiveness. All relevant costs reflect a societal 
perspective in the base-case analysis and are inflated, if necessary, to price year 2013 
using the Dutch consumer price index (13). Future costs and health effects were 
discounted by 4% and 1.5% annually after the first year, according to the Dutch guidelines 
for pharmacoeconomic research (14). 
Transition probabilities 
In the base-case, to estimate the transition probabilities between the health states in the 




the RE-COVER and RE-COVER II trials (8)(9) and the RE-MEDY trial (10), respectively were 
used, similarly to the previously published Markov model (11). 
In particular, the baseline probabilities of rVTE and MCRB were calculated from the 
observed incidence in VKA arm of the aforementioned trials. For the treatment phase, the 
incidences of rVTE and MCRB were log transformed with respect to time, to better reflect 
the occurrence pattern of these events in the trials. For the secondary prevention phase, 
the incidences were not varied with time. To calculate the probabilities of events while on 
dabigatran, the estimated treatment effect (hazard ratio (HR)) for each trial endpoint was 
applied to the risk in the VKA arm (Table 1).  
Furthermore, the probabilities of having a fatal VTE, non-fatal PE, proximal DVT, or distal 
DVT, were based on the incidences of these events in the aforementioned trials, and they 
were modelled to be conditional on having a VTE event. Similarly, the probabilities of 
having an ICH, other MB, fatal MB (including ICH) or CRNMB were conditional on having a 
MCRB. The proportion of ICH leading to permanent disability was assumed to be 65.3% 
(15). 
Beyond the duration of the anticoagulant treatment, the lifetime probability of rVTE was 
calculated from the assumed 10-year cumulative incidence of 39.9% (16), assuming a 
constant hazard. The risk of bleeding after treatment discontinuation was assumed at 
zero.  
Probabilities of MI, UA and dyspepsia were estimated from the dabigatran trials (8)(9)(10). 
For the treatment followed by secondary prevention, probabilities of MI, fatal MI and UA 
were calculated as the sum of probabilities in the treatment and secondary prevention 
trials. Events were assumed to occur at a constant rate during the trial follow-up. For 
simplicity, events were assigned to occur at the midpoint (i.e., three months). Additionally, 
we assumed 14% of MIs and UAs would lead to IHD (17). 
CTEPH rate for all patients in index PE was estimated to be 3.8% for two years (18). For 
patients experiencing non-fatal rPE events, the risk of CTEPH was applied monthly up to 2 
years (18). 
Published evidence suggests that mild PTS has little detrimental effect on HRQoL(6), 
therefore, the model included only severe PTS. For all patients in index DVT, the 5-year 
rate of PTS was estimated to be 8.1% at model start (19). A monthly probability of PTS 
subsequent to non-fatal rDVT events was applied up to 5 years (19). Finally, the 
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Table 1 Distribution and parameter limits for the transition probabilities in the model as used in the 
probabilistic sensitivity analysis. 
Clinical variable Value CI (95%) Distribution Reference 
Incidence of rVTE (baseline risk), 
treatment 
2.43% - Beta (α=62, β=2492) (8,9) 
Incidence of MCRB (baseline risk), 
treatment 
7.68% - Beta (α=189, β=2273) (8,9) 
Treatment effects     
Treatment phase     
rVTE, dabigatran vs VKA (HR) 1.09 0.77 – 1.54 Normal (log scale) (8,9) 
MCRB, dabigatran vs VKA (HR) 0.56 0.45 – 0.71 Normal (log scale) (8,9) 
Secondary prevention     
rVTE, dabigatran vs VKA (HR) 1.44 0.78 – 2.64 Normal (log scale) (10) 
rVTE, dabigatran vs placebo (HR) 0.08 0.02 – 0.25 Normal (log scale) (10)  
MCRB, dabigatran vs VKA (HR) 0.55 0.41 – 0.72 Normal (log scale) (10) 
MCRB, dabigatran vs placebo (HR) 2.69 1.43 – 5.07 Normal (log scale) (10) 
Type of recurrent VTE events     
Treatment phase     
Dabigatran     
Non-fatal PE 33.8%  Beta (α=23, β=45) (8,9) 
Proximal DVT 63.2%  Beta (α=43, β=25) (8,9) 
VTE-related death 2.9%  Beta (α=2, β=66) (8,9) 
Distal DVT 0.0%  n/a  
VKA     
Non-fatal PE 33.9%  Beta (α=21, β= 41) (8,9) 
Proximal DVT 61.3%  Beta (α=38, β=24) (8,9) 
VTE-related death 4.8%  Beta (α=3, β=59) (8,9) 
Distal DVT 0.0%  n/a  
Secondary prevention     
Dabigatran (RE-MEDY trial)     
Non-fatal PE 34.6%  Beta (α=9, β=17) (10) 
Proximal DVT 61.5%  Beta (α=16, β=10) (10)  
VTE-related death 3.8%  Beta (α=1, β=25) (10) 
Distal DVT 0.0%  n/a  
Dabigatran (RE-SONATE trial)     
Non-fatal PE 33.3%  Beta (α=1, β=2) (10) 
Proximal DVT 66.7%  Beta (α=2, β=1) (10)  
VTE-related death 0.0%  Beta (α=0.5, β=4) (10) 
Distal DVT 0.0%  Fixed  
VKA     
Non-fatal PE 22.2%  Beta (α=4, β=14) (10) 
Proximal DVT 72.2%  Beta (α=13, β=5) (10)  
VTE-related death 5.6%  n/a  
Distal DVT 0.0%  Beta (α=1, β=17) (10) 
After therapy discontinuation     




Clinical variable Value CI (95%) Distribution Reference 
Proximal DVT 65.1%  Beta (α=243, β=130) (16) 
VTE-related death 11.5%  Beta (α=43, β=330) (16) 
Distal DVT 0.0%  n/a  
Type of bleeding events     
Treatment phase     
Dabigatran      
ICH 1.8%  Beta (α=2, β=107) (8,9) 
Other MB 20.2%  Beta (α=22, β=87) (8,9) 
Fatal MB 4.2%  Beta (α=1, β=23) (8,9) 
CRNMB 78.0%  Beta (α=85, β=24) (8,9) 
VKA     
ICH 2.1%  Beta (α=4, β=185) (8,9) 
Other MB 19.0%  Beta (α=36, β=153) (8,9) 
Fatal MB 5.0%  Beta (α=2, β=38) (8,9) 
CRNMB 78.8%  Beta (α=149, β=40) (8,9) 
Secondary prevention     
Dabigatran (RE-MEDY)     
ICH 2.5%  Beta (α=2, β=78) (10) 
Other MB 13.8%  Beta (α=11, β=69) (10)  
Fatal MB 0.0%  Fixed (10) 
CRNMB 83.8%  Beta (α=67, β=13) (10) 
Dabigatran (RE-SONATE)     
ICH 0.0%  Fixed (10) 
Other MBE 5.6%  Beta (α=2, β=34) (10)  
Fatal MBE 0.0%  Fixed (10) 
CRNMB 94.4%  n/a (10) 
VKA     
ICH 2.8%  Beta (α=4, β=141) (10) 
Other MB 14.5%  Beta (α=21, β=124) (10)  
Fatal MB 4.0%  Beta (α=1, β=24) (10) 
CRNMB 82.8%  Beta (α=120, β=25) (10) 
Other probabilities     
Disabled from ICH 65.3%  Beta (α=90.8, β=48.2) (15) 
Probability of IHD after MI and UA 14%  Beta (α=19, β=116) (17) 
Cumulative incidence of CTEPH at 2 
years in PE patients 
3.8%  Beta (α=7, β=184) (18) 
Probability of CTEPH (per cycle) 0.16%   (18) 
5 years cumulative incidence of 
severe PTS 
8.1%  Beta (α=43, β=485) (19) 
Probability of severe PTS (per 
cycle) 
0.14%   (19) 
rVTE after therapy discontinuation 39.90% 35.40% - 44.40% Normal (SE=0.02) (16) 
Discontinuation probabilities (per 
cycle) 
    
Treatment phase     
Dabigatran 2.09%  Fixed (8,9) 
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Clinical variable Value CI (95%) Distribution Reference 
VKA 1.91%  Fixed (8,9) 
Secondary Prevention     
Dabigatran 1.00%  Fixed (10) 
VKA 0.97%  Fixed (10) 
CI, confidence interval; r VTE, recurrent venous thromboembolism; MCRB, major or clinically relevant bleeding; 
VKA, vitamin K antagonists; HR, hazard ratio; DVT, deep vein thrombosis; PE, pulmonary embolism; 
CRNMB = clinically relevant non-major bleed event; ICH = intracranial haemorrhage; MB = major bleed; 
MI = myocardial infarction; UA, unstable angina; CTEPH = chronic thromboembolic pulmonary hypertension; 
PTS = post thrombotic syndrome. 
 
Table 2 Utility parameters applied in the model. 
 
Parameter Value Distribution Reference 
Baseline utilities    
Age 18-24 years (weight for males, females) 0.976, 0.925 Fixed (20) 
Age 25-34 years (weight for males, females) 0.945, 0.907 Fixed (20) 
Age 35-44 years (weight for males, females) 0.953, 0.917 Fixed (20) 
Age 45-54 years (weight for males, females) 0.902, 0.877 Fixed (20) 
Age 55-64 years (weight for males, females) 0.913, 0.866 Fixed (20) 
Age 65-74 years (weight for males, females) 0.878, 0.894 Fixed (20)  
Age ≥ 75 years (weight for males, females) 0.910, 0.787 Fixed (20) 
Disutility during active VKA treatment e 0.012  Gamma (α=28.66, β=0.0004) (25) 
Disutility of index and recurrent DVT c  0.250 Normal (SE=0.0054)a (11) 
Disutility of index and recurrent PE c  0.250 Normal (SE=0.0152)a (11) 
Disutility of ICH or other MB d 0.130 Gamma (α=100, β=0.001) (11) 
Disutility of disabled from ICH f 0.380 Gamma (α=16, β=0.024)b (21) 
Disutility of CRNMB d 0.040 Gamma (α=100, β=0.0004)  (11) 
Disutility of MI d 0.063 Gamma (α=22.57, β=0.003)  (22) 
Disutility of Angina d 0.085 Gamma (α=40.40, β=0.002) (22) 
Disutility of Dyspepsia e 0.040 Gamma (α=16, β=0.003) b (23) 
Disutility of CTEPH d 0.440 Gamma (α=16, β=0.028) b (24) 
Disutility of severe PTS f 0.070  Gamma (α=39.22, β=0.002) (6) 
CRNMB = clinically relevant non-major bleed event; DVT = deep vein thrombosis; ICH = intracranial haemorrhage; 
MB = major bleed; MI = myocardial infarction; PE = pulmonary embolism; CTEPH = chronic thromboembolic 
pulmonary hypertension; PTS = post thrombotic syndrome. 
a Change in mean from baseline to 3 months. In the probabilistic analysis, the mean baseline and 3-month value 
were individually sampled from normal distributions defined by the mean and standard error (standard error was 
calculated from the standard deviation and N) and the difference calculated for each simulation. 
b Variance was not reported; the standard error is assumed to be 25% of the mean. 
c The duration of disutility was assumed to be 6 weeks similarly to the previously published study.  
d A disutility is applied in the month of the event. Specifically, the duration of the impact of UA and MI on HRQoL 
was assumed to be 3 months. 
e The disutility applied is assumed to last for the duration of treatment. 





Table 2 summarises the utilities used in the model. Patients were assigned baseline age- 
and gender-specific utilities derived from the general Dutch population (20). These 
estimates formed the baseline from which the utility decrements associated with VTE, 
bleeding and other adverse events were subtracted.  
Utility decrements associated index and rVTE, MB and CRNMB were based on a meta-
analysis of EQ-5D data collected in the RE-COVER and RE-COVER II trials and applied in the 
model similarly to the previously published study (11). 
Utility decrements following the occurrence of other adverse events (i.e. MI, UA, 
dyspepsia, disabled from ICH, CTEPH, and severe PTS) were derived from the published 
studies and applied additively for a specific time interval in the model (21)(22)(23)(6)(24). 
Finally, utility decrements reflecting the use of VKA were applied (25).  
Costs 
In the base-case analysis, all costs were collected from a societal perspective, therefore, 
both direct (inside and outside healthcare) and indirect costs were included (Table 3). 
Direct costs inside healthcare included the costs related to: drugs, visits to general 
practitioner (GP), administration, INR-monitoring, event-related resources. Costs of 
dabigatran, defined as price per defined daily dose (2x 150mg), VKAs and LMWHs were 
taken from the official Dutch price list (Z-index) (26). Importantly, the price of dabigatran 
extracted from Z-index is established for other registered indications of dabigatran in the 
Netherlands (i.e. prevention of VTE in patients who have undergone elective total hip 
replacement surgery or total knee replacement surgery, and prevention of stroke and 
systemic embolism in non-valvular atrial fibrillation). Acenocumarol and phenprocoumon 
are the only VKAs registered in the Netherlands, therefore, the cost of VKAs was 
estimated as a weighted average cost of those drugs based on their usage in the 
Netherlands (80%:20%, respectively)(27). The cost of LMWHs was assumed as a weighted 
average cost of enoxaparin, dalteparin, tinzaparin and nadroparin (26). All treatment 
alternatives were assumed to have a cost of one initial GP visit in the first month and one 
follow up visit in the 4th month of a treatment. 
The cost of administration of LMWHs was estimated to reflect the costs of administration 
in hospital and at home. For patients receiving LMWHs in hospital, the costs of 
administration was adjusted for the percentage of patients and time they spent being 
hospitalized for DVT and for PE (28). The costs of administration at home accounted for 
the costs of self-injection and costs for patients requiring a nurse visit for injection (Table 
3)(28,29).   
The costs of INR-monitoring reflected the costs of monitoring handled by thrombotic 
services and costs for patient self-management (Table 3). In the Netherlands, self-
management is applied by 14.9% of patients on treatment with VKAs. Therefore, the costs 
of initial training for self-management and monthly follow up costs associated with the 
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rental of equipment were applied for this patient population (Table 3). Resource use 
associated with INR-monitoring at thrombotic services (i.e. number of visits) was based on 
the data from the RECOVER trials (8)(9). In particular, in the first month of a treatment, 
the cost of INR-monitoring by thrombotic services reflected the costs of 4.3 visits to 
thrombotic services. In follow up months (2nd until 6th month), the cost of 1.9 visits per 
month was assumed (8)(9). For the application of VKAs longer than 6 months (i.e. 
secondary prevention phase), the costs of INR-monitoring by thrombotic services reflected 
the cost of 1.5 visits per month (8)(9). Moreover, direct costs outside healthcare (i.e. 
travel costs) were attributed to the nurse visits for injection of LMWHs. Acute care costs 
associated with clinical events (e.g. DVT, PE, ICH, other MB, CRNMB, PTS, CTEPH, MI, UA, 
and dyspepsia) were adopted from previous costing studies conducted in the Netherlands. 
Patients surviving acute ICH, MI, PTS and CTEPH were assigned with long-term 
maintenance costs. 
Indirect costs outside healthcare included: productivity loss costs, caregiver time costs for 
patients experiencing ICH and travel costs for the visits of patients to thrombotic services. 
A 2-hour productivity loss costs were assumed for all INR-monitoring visits to thrombotic 
services and all GP-related visits. Additionally, productivity loss costs associated with 
hospitalizations due to DVT (0.63 days), PE (7 days) and MI (5.6 days) were included. The 
number of productivity loss hours for each of the aforementioned hospitalizations was 
estimated in order to account for regular working hours (8 hours per day) and was 
corrected for the weekends (14,30). 
Table 3 Cost parameters applied in the model.  
Cost parameters Average cost 
(2013, €) 
Rangea Reference 
Medication, administration and monitoring costs 
VKA (daily)  0.04  0.03-0.05   (26) 
Dabigatran (daily) 2.30 Fixed (26) 
LMWH (daily) 10.65  7.99-13.31   (26) 
LMWH at home, self-injection (one-off training) 16.77  9.59-25.93 (29) 
LMWH at home, nurse injection (per day after 
discharge) 
17.50  10.00-27.05   (29) 
LMWH, administration in clinic (per day after 
discharge) incl. travel costs 
16.54  9.45-25.57   (29) 
LMWH at home, self-injection (domiciliary care) 6.74  3.85-10.43   (29) 
GP visit 30.54  17.46-47.22   (14) 
INR-control self-management initial monthly 
cost 
90.46  51.71-139.88   (14,31) 
INR-control cost incl. travel costs (per visit) b  12.54  7.17-19.38   (14,31) 
INR-control self-management (monthly) 12.29  7.03-19.01   (14,31) 




Cost parameters Average cost 
(2013, €) 
Rangea Reference 
DVT 1,187.23  679-1,836  (30) 
PE 4,221.01  2,413-6,527   (30) 
ER visit 167.28  96-259  (30) 
Chest x-ray 156.15  89-241  (30) 
Electrocardiogram 30  17-46  (30) 
Acute ICH 32,754  18,722-50,646   (21) 
ICH direct mild (annually) 2,367.97  1,354-3,662   (21) 
ICH direct moderate (annually) 18,268  10,442-28,247  (21) 
ICH direct severe (annually) 23,353  13,348-36,110   (21) 
MB  4,969  2,840-7,683   (30) 
CRNMB c 31 17-47  (14) 
PTS (year 1) 25,073  14,331-38,769   (30) 
PTS (year 2) d 61 35-94  (14) 
MI acute  5,021  4,936-   5,106 (32) 
MI follow up (monthly) 97  55-150  (33) 
UA 5,351  5,236-5,467   (34) 
Dyspepsia e 0.69  0.39-1.07  (26) 
CTEPH acute f  7,121  4,070-11,011   (35) 
CTEPH follow up (monthly)  84  48-130  (35) 
Indirect costs    
Productivity loss age group 55-60 (per hour) g 31  17-47  (14) 
Productivity loss age group 60-65 (per hour) g 23  13-36  (14) 
ICH informal care mild (annually) 12,369  7,070-15,462   (36) 
ICH informal care moderate (annually) 16,345  9,343-25,274   (36) 
ICH informal care severe (annually) 20,322  11,616-31,422   (36) 
VKA, vitamin K antagonists; LMWH, low molecular weight heparins; INR, international normalised ratio; MCRB, 
major or clinically relevant bleeding; DVT, deep vein thrombosis; PE, pulmonary embolism; CRNMB = clinically 
relevant non-major bleed event; ICH = intracranial haemorrhage; MB = major bleed; MI = myocardial infarction; 
UA, unstable angina; CTEPH = chronic thromboembolic pulmonary hypertension; PTS = post thrombotic 
syndrome GP, general practitioner. 
a Cost estimates that were available only as single point estimates, were assumed to follow a log-normal 
distribution with a coefficient of variation equal to 0.25.  
b Travel costs of patients included only in the base-case. 
c Assumed to be equal to the cost of a GP visit. 
d Assumed to be equal to the cost of two GP visit. 
e Assumed the cost of Omeprazol 20mg. 
f Based on the study by Mayer et al, pulmonary endarterectomy is applied to 56.8% of cases. 
g One hour of productivity loss costs was estimated as a weighted average cost for employed and non-employed 
population in the Netherlands in the specific age group. 
 
Sensitivity analyses 
Univariate sensitivity analyses were performed to identify the key determinants of CE by 
varying parameters individually over the ranges derived from their 95% confidence 
intervals. Where confidence intervals and standard deviations of parameters were 
unavailable, the standard error was assumed to be 25% of the mean. The exceptions were 
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made when varying discount rates which were varied between 0 and 5%, and the number 
of days on treatment with LMWHs which were varied between 5 and 9 days. The results 
were defined in terms of incremental cost per QALY and are presented diagrammatically 
in the form of a tornado diagram. 
Additionally, a probabilistic sensitivity analysis (PSA) was performed to assess the 
robustness of the findings by performing 1,000 simulations to generate ICERs in which 
event risks and HRs, costs and utilities were simultaneously varied randomly within their 
ranges. HRs were sampled from a normal distribution on the log scale, probabilities were 
sampled from a beta distribution, and costs were sampled from a gamma distribution. For 
utilities, a gamma distribution was used, except for utilities assigned to DVT and PE, for 
which a normal distribution was used. Results from the PSA were plotted on a CE plane. 
Scenario analyses 
To investigate the impact of applying dabigatran under different decision making settings 
four scenario analyses were conducted. First scenario compared the use of dabigatran and 
VKAs for treatment and secondary prevention in high risk patients from the healthcare 
provider perspective. Second scenario compared the use of dabigatran to VKAs for up to 6 
months of treatment only. Third scenario assessed the use of anticoagulants for up to 18 
months of secondary prevention only (not considering the preceding treatment duration). 
In the fourth scenario, the use of dabigatran for up to 6 months of secondary prevention 
(not considering the preceding treatment duration) was compared to placebo. Here, study 
population simulated the profile of the patients in the RE-SONATE trial (i.e. patients for 
whom the need for secondary prevention is at equipoise (10)). Data from the RE-SONATE 
trial were the main sources used to estimate the transition probabilities between the 





Figure 1 Markov model  
VTE, venous thromboembolism; DVT, deep vein thrombosis; PE, pulmonary embolism; r, recurrent; LMWH, low 
molecular weight heparin; CRNMB = clinically relevant non-major bleed event; ICH = intracranial haemorrhage; 
MB = major bleed; MI = myocardial infarction; CTEPH = chronic thromboembolic pulmonary hypertension; 
PTS = post thrombotic syndrome; UA, unstable angina; IHD, ischemic heart disease. 
RESULTS 
Under base-case conditions, in a hypothetical cohort of 10,000 patients with VTE event 
followed over their lifetime starting at age 54.7 years, dabigatran averted 720 MCRBs 
compared with VKAs but resulted in an additional 86 rVTEs, and 65 MIs (Table 4). A 
comparable number of PTS, CTEPH and UA was observed in both dabigatran and VKAs 
treatment arms. Dabigatran was associated with a projected discounted quality-adjusted 
life expectancy of 19.187 QALYs compared with 19.129 QALYs for patients receiving VKAs.  
Costs allocation across different categories indicated that costs associated with handling 
rVTE, bleeding and other adverse events were the greatest contributors to the total 
expenditures. In VKAs treatment arm, these costs were higher compared to dabigatran 
arm (€12,409 vs €11,072). Expenditures for event-related costs were followed by 
monitoring and administration costs which were higher with VKAs compared to 
dabigatran (€3,730 vs. €1,242), and the total drug costs that were higher with dabigatran 
than VKAs (€1,549 vs. €298). Finally, accounting for all the aforementioned cost categories 
resulted in the total lifetime costs varied from €12,254 per person for VKAs to €10,258 per 
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person for dabigatran at a discount rate of 4%. In total, the savings of €1,996 and an 
additional 0.0583 discounted QALYs per patient where observed when applying 
dabigatran compared to VKAs (Table 5). 
Sensitivity analyses 
The results of univariate sensitivity analyses for the top 15 parameters by the order of 
influence they have to the ICERs are presented in the form of a tornado diagram (Figure 
2). Specifically, the ICER was mostly influenced by variations in the probability of VTE-
related death, productivity loss costs in the age group 55-60, probability of MCRBs-related 
and probability of ICH. 
The results of 1,000 iterations in PSA are presented through an incremental CE plane in 
Figure 3. The probability that dabigatran is cost-effective at a willingness-to-pay (WTP) 
threshold of €20,000/QALY was 100%. 
Scenario analyses 
The results of the scenario analyses are presented in Table 5. In the scenario comparing 
dabigatran to VKAs for the treatment, and in the one comparing them for the secondary 
prevention in high-risk patients, dabigatran remained cost-saving. In the scenario 
comparing dabigatran to VKAs for treatment and secondary prevention from the 
healthcare provider perspective dabigatran was cost-effective with an ICER of €1,005 per 
QALY gained. Finally, the scenario examining the prevention of recurrent VTE in patients 
who are at equipoise for anticoagulation treatment with dabigatran compared to placebo, 




Table 4 Recurrent VTE, bleeding complications and other adverse events and related costs within a 
hypothetical patient population of 10,000 subjects receiving dabigatran and VKA over a lifetime 
horizon. 
 Dabigatran  VKA  









Index VTE 10,000 €2,142 10,000 €2,142 
All recurrent VTE 13,471   13,384   
Recurrent non-fatal VTE  11,959   11,871   
Non-fatal DVT 8,761  €1,071 8,713  €1,065 
Non-fatal PE 3,198  €1,592 3,158  €1,570 
VTE-related death 1,512  €0 1,513  €0 
All MCRBs 1,351   2,071   
Non-fatal MCRBs 1,342   2,052   
ICH 28  €1,876 47  €3,262 
Other MBs 230  €118 339  €177 
CRNMBs 1,084  €9 1,665  €14 
Deaths from bleeding 9  €0 19  €0 
MI 86 €93 21 €23 
UA 23 €23 23 €23 
Dyspepsia 682 €0.05 112  €0.01 
PTS 1,294  €3,482 1,290  €3,471 
CTEPH  243  €667 242  €662 
Medication     
Investigational treatment  €1,315  €24 
LMWHs, index event  €71  €110 
Re-treatment recurrent event, VKA  €12  €12 
Re-treatment recurrent event, LMWHs  €152  €152 
Monitoring and administration     
INR-monitoring, GP visits, administration 
and productivity loss 
 €167  €2,622 
Index event: Administration of LMWHs  €43  €81 
Re-treatment with VKA for recurrent 
event: INR-monitoring, GP visits, 
administration and productivity loss 
 €901  €896 
Re-treatment recurrent event: 
Administration of LMWHs 
 €131  €130 
VKA, vitamin K antagonists; VTE, venous thromboembolism; DVT, deep vein thrombosis; PE, pulmonary 
embolism; r, recurrent; LMWH, low molecular weight heparin; CRNMB = clinically relevant non-major bleed 
event; ICH = intracranial haemorrhage; MB = major bleed; MI = myocardial infarction; CTEPH = chronic 
thromboembolic pulmonary hypertension; PTS = post thrombotic syndrome; UA, unstable angina; INR, 
international normalised ratio. 
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Table 5 Results of the base-case and scenario analyses. 
Base-case: 6 months treatment + 18 months secondary prevention (societal perspective) 
  Dabigatran  VKA  Difference 
Discounted LYs  22.053 22.025 0.0282 
Discounted QALYs  19.187 19.129 0.0583 
Costs (€) undiscounted  13,865 16,437 -2,571 
Costs (€) discounted  10,258 12,254 -1,996 
ICER (€/ LYs) Cost-saving   
ICER (€/ QALYs) Cost-saving   
Scenario 1: 6 months treatment + 18 months secondary prevention (healthcare provider perspective) 
Discounted LYs  22.053 22.025 0.0282 
Discounted QALYs  19.187 19.129 0.0583 
Costs (€) undiscounted  12,140 12,346 -206 
Costs (€) discounted  9,067 9,008 59 
ICER (€/ LYs) 2,078   
ICER (€/ QALYs) 1,005   
Scenario 2: 6-months treatment (societal perspective) 
Discounted LYs  21.924 21.907 0.0170 
Discounted QALYs  19.083 19.056 0.0266 
Costs (€) undiscounted  12,219 13,461 -1,241 
Costs (€) discounted  9,000 10,010 -1,010 
ICER (€/ LYs) Cost-saving   
ICER (€/ QALYs) Cost-saving   
Scenario 3: 18-months secondary prevention in high-risk patients (societal perspective) 
Discounted LYs  22.044 22.030 0.0144 
Discounted QALYs  19.248 19.212 0.0368 
Costs (€) undiscounted  10,297 11,755 -1,458 
Costs (€) discounted  6,692 7,758 -1,066 
ICER (€/ LYs) Cost-saving   
ICER (€/ QALYs) Cost-saving   
Scenario 4: 6-months secondary prevention with placebo in patients for whom the need for secondary 
prevention is at equipoise (societal perspective) 
Discounted LYs  21.950 21.950 0.0003 
Discounted QALYs  19.169 19.165 0.0035 
Costs (€) undiscounted  7,971 7,873 98 
Costs (€) discounted  4,940 4,823 117 
ICER (€/ LYs) 428,158   
ICER (€/ QALYs) 33,305   






Figure 2 Tornado diagram illustrating ICERs from sensitivity analyses for dabigatran vs. vitamin-K 
antagonists. 
Figure 2 presents a tornado diagram illustrating the impact of varying each of input parameters on the ICER while 
holding all the other model parameters fixed. Light grey bars denote influence of the high limit and dark grey 
bars denote influence of the low limit of the input parameters investigated on the ICER. The solid vertical line 
represents the base case incremental costs per QALY for dabigatran compared to VKA. Horizontal bars indicate 
the range of incremental costs per QALY obtained by setting each variable to the values shown while holding all 
other values constant. 
ICER, incremental cost-effectiveness ratio; QALY, quality adjusted life year; VKA, vitamin K antagonists; VTE, 
venous thromboembolism; r, recurrent; ICH = intracranial haemorrhage; MBE = major bleeding event; HR, hazard 
ratio. 
 
Figure 3 Incremental cost-effectiveness plane. 
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Our base-case decision analysis demonstrated dabigatran may be a cost–saving 
alternative to VKAs for the treatment and secondary prevention of VTE from societal 
perspective. Patients on dabigatran gained an additional 0.583 discounted QALYs over a 
lifetime and savings of €1,996. The key drivers of the CE of dabigatran relative to trial-
based VKA are based on its ability to reduce MCRBs as found in RECOVER trials. 
Particularly, the use of dabigatran resulted in 710 less MCRB events (i.e. 19 ICHs, 109 
other MBs and 582 CRNMBs) in a cohort of 10,000 patients. 
Results were sensitive to the probability of VTE-related death, productivity loss costs, 
probability of MCRBs-related death and probability of ICH, yet, they all indicated 
dabigatran to be cost-saving compared to VKAs. Moreover, the PSA showed that the 
likelihood of dabigatran being cost-effective at WTP threshold of €20,000 per QALY was 
100%. 
The results of the scenario analyses comparing dabigatran to VKAs for the treatment, 
secondary prevention in high-risk patients, were quite robust, all indicating dabigatran 
may be cost-saving alternative to VKAs. However, in the scenario examining the CE of 
anticoagulants for the treatment and secondary prevention from the healthcare provider 
perspective, dabigatran was shown to be a cost-effective alternative to VKAs with an ICER 
of €1,005 per QALY gained. Interestingly, although the variability in productivity loss costs 
showed an impact on the estimated ICER in the univariate sensitivity analyses, excluding 
these costs together with other indirect costs still led to highly cost-effective findings in 
the aforementioned scenario. Finally, in the scenario examining the prevention of 
recurrent VTE in patients who are at equipoise for anticoagulation treatment, unlikely to 
be treated with anticoagulants in clinical practice, dabigatran was found to be cost-
effective compared to placebo with an ICER of €33,305 per QALY gained. This finding 
reflects the higher total costs associated with greater number of MCRBs and drug costs in 
dabigatran treatment arm compared to placebo arm.   
To our knowledge, this is the first study that examined the use of dabigatran compared to 
VKAs for the treatment and prevention of VTE in the Dutch setting. In terms of the 
economic consequences of using dabigatran compared to VKAs, our findings are similar to 
the ones by Braidy et al (37). A cost-minimisation analysis by Braidy et al. investigated the 
use of NOACs and VKAs for the prevention of VTE and stroke in patients with atrial 
fibrillation from the third-party payer perspective in Australian setting (37). They found 
dabigatran to be dominant over VKA (∆c≈$AUS40) in terms of cost of drug administration 
and therapeutic monitoring. Notably, a direct comparability between the two studies is 
hampered due to differences in the underlying patients’ characteristics, safety and 




Our study is confronted with several potential limitations. One limitation might be that the 
duration of initial treatment with LMWHs was assumed to be different in dabigatran and 
VKAs treatment arms in the base-case analysis (i.e. 5 and 9 days respectively). However, 
the duration of treatment with LMWHs was assumed to have no impact on the 
effectiveness of the follow up use of dabigatran and VKAs. To cope with this limitation, we 
varied the duration of LMWHs treatment between 5 and 9 days for both treatment 
alternatives in univariate sensitivity analyses. The results remained robust to variability in 
the duration of LMWHs use. Furthermore, this study simulated the occurrences of all 
MCRBs further subdivided into ICHs, other MBs and CRNMBs, however, the meta-analysis 
of the RE-COVER trials indicated that there was only a marginally significant reduction of 
MBs observed in the double-dummy period in dabigatran arm compared to VKA. 
Therefore, simulating the occurrences of MBs might overestimate the benefits in the 
dabigatran arm compared to VKA. Similarly, acute coronary syndromes (i.e. MIs and UAs) 
were modelled in this study although their incidence was only numerically higher with 
dabigatran compared to VKAs. A further potential limitation in our study concerns the 
assumption that patients in both treatment arms who experience a first recurrent VTE 
event would switch to a 6-months standard treatment course of LMWH followed by VKAs. 
This may not always be the case and patients might alternatively be switched to other 
NOACs. However, there are currently no available efficacy and safety data that could 
characterize such a switch. Furthermore, a maximum of two rVTEs over the lifetime of the 
patients and two MBs during the anticoagulation treatment were modelled. This 
assumption may be considered conservative given that a better safety profile of 
dabigatran treatment would be associated with a lower number of MBs and consequent 
lower costs compared to treatment with VKAs. Another limitation concerns treatment 
discontinuation that was assumed for patients who experience a MB or ICH. In a real-life 
setting such a decision would likely be based on individual patient characteristics. Finally, 
given the lack of specific treatment recommendations for patients experiencing CRNMBs, 
the discontinuation of treatment due to CRNMB was not modelled. Notably, in daily 
practice, patients may discontinue with the treatment after a certain number of 
consequent CRNMBs. 
In conclusion, from a societal perspective, this modelling study suggests that the use of 
dabigatran for treatment and secondary prevention of VTE is maximally likely to be a cost-
effective alternative to VKAs at a WTP threshold €20,000 per QALY in the Dutch setting. 
Importantly, even when the comparison between dabigatran and VKAs was assessed from 
the healthcare provider perspective, dabigatran remained highly cost-effective with an 
ICER of €1,005 per QALY gained.  
In addition to some established advantages of dabigatran (e.g. better safety profile than 
VKAs; excludes the need for INR-monitoring), our study estimated the long-term economic 
benefits associated with its use. Yet, it must be acknowledged that such benefits in a “real 
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life” setting are still to be proven. Notably, given that dabigatran is the second NOAC 
registered in Europe for the treatment and secondary prevention of VTE, further 
investigation is needed to estimate comparative effectiveness and CE among the 
individual NOACs. 
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In the last decades, a decline in cardiovascular diseases (CVD) mortality was observed 
across most of the developed countries (1). This can likely be attributed to a broad 
application of prevention strategies (2). In clinical practice, CVD prevention strategies aim 
at identifying individuals at high CVD risk followed by enhancing risk factor(s) modification 
(e.g. lifestyle changes and/or pharmacological interventions). This approach was shown to 
successfully reduce the risk of CVD (3). However, the rate of CVD-related hospital 
admission and mortality, as well as CVD attributable costs of acute treatment, long-term 
management and rehabilitation care, all indicate that further spread of CVD prevention 
approaches and interventions have the potential to be beneficial and further reduce the 
disease burden (1)(4).  
Pharmacological innovations open new opportunities to prevent or delay the onset of 
CVD. Yet, innovative interventions often come at a higher cost what may be seen as a 
burden to the healthcare budget and possibly a limitation to patient access. Because of 
healthcare budget constraints, the decisions to implement innovative interventions in 
clinical practice have to be made with respect to both health and economic consequences 
associated with their use.  
This thesis deals with pharmacoeconomic issues that relate to pharmacological preventive 
interventions in CVD. In particular, it addresses challenges in simulating and synthesizing 
pharmacoeconomic evidence in (primary) CVD prevention, and proposes potential 
solutions to those challenges. Moreover, it derives pharmacoeconomic evidence on the 
use of oral anticoagulants (i.e. vitamin K antagonists (VKAs) and novel oral anticoagulants 
(NOACs)) for secondary CVD prevention. This chapter summarizes and discusses the main 
results, findings, and ideas described in the previous chapters, including some future 
perspectives. Lastly, to assess the main implications of this thesis, this chapter discusses 
methods for providing robust pharmacoeconomic evidence in CVD prevention, and direct 
implications of pharmacoeconomic evidence on the use of VKAs and NOACs for current 
practice. 
PRINCIPLE FINDINGS AND FUTURE PERSPECTIVES 
Part I: Simulating and synthesizing health and economic evidence in (primary) 
cardiovascular disease prevention 
Part I of this thesis examined some of the challenging issues on simulating and 
synthesizing health and economic evidence in (primary) CVD prevention. In Chapter 2, a 
systematic literature review on the application of CVD risk prediction models in 
pharmacoeconomic studies for primary CVD prevention in high income countries was 
described. This review aimed at understanding the extent that methods for incorporating 
CVD risk models in pharmacoeconomic studies are being used and assesses their quality. 
Through a systematic search, 12 eligible pharmacoeconomic studies were identified. The 




the intended population(s) of the risk model, frequent disagreement between risk model- 
and study time horizons and a general lack of proper consideration of the uncertainty 
surrounding risk predictions. Based on the findings in Chapter 2, it was concluded that 
projecting intermediate effectiveness/efficacy evidence to long-term health and economic 
benefits is possible and useful but careful characterization of the uncertainty should be 
pursued as well as the limitations of this approach should be acknowledged. To assist in 
the design of future pharmacoeconomic studies, Chapter 2 proposed a set of 
recommendations for the appropriate use of a CVD risk model in pharmacoeconomic 
analysis.  
The knowledge and recommendations from Chapter 2 were utilized for designing a 
pharmacoeconomic model in Chapter 3. This model explored the cost-effectiveness of 
primary CVD prevention with antihypertensive treatment compared to no treatment in 
patients with mild hypertension, ineligible for treatment according to the Dutch 
guidelines. Surrogate endpoints on lowering systolic blood pressure (SBP) were projected 
to hard CVD endpoints with the use of the modified SCORE CVD risk model. It was shown 
that, the cost-effectiveness of antihypertensive treatment was highly influenced by the 
model’s time horizon. In a lifetime horizon, significant health and economic benefits were 
observed in all scenarios for both genders and ages when SBP reduction was assumed to 
be achieved with the use of hydrochlorothiazide (HCT) 25 mg. However, in a 10-year 
horizon, SBP reductions were more favourable when targeted to older patients and more 
in men than in women. In scenarios assuming fixed-dose combination HCT 12.5 
mg/Losartan 50 mg, long-term health and economic benefits were even more favourable 
in both time horizons investigated. In the same chapter, a 10-year treatment with HCT 25 
mg vs. no treatment was examined in male and female smokers. This analysis indicated 
more favourable cost-effectiveness for applying antihypertensive treatment compared to 
no treatment in smokers than the ones estimated for patients with comparable age-, 
gender- characteristics but with the average prevalence of smoking as representative the 
for Dutch population. This was due to the higher levels of CVD risk estimated for male and 
female smokers as well as the greater benefits of risk reduction in this patient population. 
The aforementioned findings suggest more aggressive SBP reductions in patients with mild 
hypertension and in smokers, however, uncertainty in the results should be noted. 
Notably, a relatively large overall uncertainty was observed surrounding the estimated 
values in the analysis regardless of the applied time horizon. As expected from our 
previous work, the largest contribution to the overall uncertainty came from the 
uncertainty surrounding the risk prediction. 
The model in Chapter 3 was informed with various published Dutch cost estimates such as 
cost of heart failure (HF), angina, stroke, etc. Given the major changes in the clinical 
practice and treatment of HF in the last decade, and the fact that hospitalization costs 





aimed to provide up-to-date information on the characteristics and use of hospital care 
resources associated with HF in the Netherlands. Notably, given that HF hospitalizations 
might occur due to the new onset of HF (‘de novo’) or deterioration of chronic HF with 
symptoms that warrant hospitalization, these are labelled acute heart failure (AHF) 
hospitalizations. This study identified 31,248 HF hospitalizations in the 2011 Dutch 
National Medical Registration (LMR) data. Based on the hospital resource use associated 
with the hospitalisations in 2011 and under the assumption that the resource use of 
inpatient care was associated only with the costs of stay in general hospital wards, the 
minimum total hospital costs were estimated to be €3,902 and €4,044 for women and 
men, respectively. When the cost of stay in emergency wards was assumed to plausibly 
significantly contribute as well to the cost of inpatient care, the aforementioned total cost 
estimates almost doubled. Due to the limitations of the LMR data to provide information 
on medication use, further analysis should be directed to linking the available LMR data 
with hospital claims data which could indicate the cost of medication use and, therefore, 
provide more comprehensive AHF cost estimates. 
Chapter 4 describes an evidence synthesis (a multivariate meta-analysis) of instrument-
specific preference-based health-related quality of life (HRQoL) values in coronary heart 
disease (CHD) and its underlying disease-forms (i.e. stable angina, post-acute coronary 
syndrome (post-ACS)) in developed countries. The study explicitly accounted for study-
level characteristics and relevant correlations between those values. Using a systematic 
literature search, 40 studies were identified. In post-ACS, HRQoL estimates ranged from 
0.64 (Quality-of-Well-Being) to 0.92 (EQ-5D European ”tariff”); in stable angina, HRQoL 
ranged from 0.64 (SF-6D) to 0.89 (standard gamble) while in overall CHD the range of 
values was comparable to the aforementioned (i.e. from 0.60 (HALex) to 0.89 (standard 
gamble)). Chapter 4 indicated inequality in HRQoL values, both within and between the 
instrument-specific values, potentially explained by both observed and unobserved 
methodological differences across instruments and underlying study-level characteristics. 
Current economic models in CHD generally ignore the between-study study heterogeneity 
in HRQoL. Therefore, Chapter 4 suggests that multivariate meta-analysis should be applied 
for quantifying this uncertainty to improve estimates used in cost-utility analyses. 
Part II: Pharmacoeconomic findings in secondary cardiovascular disease prevention; 
Focus on oral anticoagulation 
Part II of this thesis described a number of pharmacoeconomic findings in secondary CVD 
prevention. Specifically, the health and economic findings associated with the use of oral 
anticoagulants - VKAs and NOACs such as apixaban and dabigatran - for the prevention of 
CVD in the Dutch setting were presented.  
In Dutch clinical practice, VKAs are still the most commonly applied anticoagulants in 




(VTE)(5). Yet, their use comes with a narrow therapeutic range of international normalised 
ratio (INR) limits of 2.0 and 3.0, calling for regular monitoring. In the Netherlands, INR-
monitoring is mostly performed at specialised anticoagulation testing centres. An 
alternative is patient self-testing and patient self-management (PST and/or PSM) that was 
internationally shown to lead to better coagulation care compared to monitoring in 
specialized anticoagulation centres (6,7). Chapter 5 explored the budget impact of 
increasing market-share scenarios of PST and/or PSM in patients on long-term 
anticoagulation with VKAs. The occurrence of thromboembolic and haemorrhagic 
complications in the aforementioned patient population was assessed in a Markov model 
that incorporated Dutch specific costs and effectiveness data derived from a meta-analysis 
on self-monitoring of oral anticoagulation. Chapter 5 indicated that increasing PST and/or 
PSM in anticoagulation monitoring from the current 15.4% to 50%, 75% and 100%, would 
lead to significant savings in one to five year time horizons. This is driven mainly by 
considerably lowered complications-related costs associated with PST and/or PSM 
compared to conventional monitoring centres. Due to a lack of RCTs to compare the VKAs 
managed with PST and/or PSM with NOACs, the use of NOACs was not accounted for in 
this study. Further research should account for the potential increasing market share of 
NOACs as well as provide a formal cost-effectiveness analysis comparing the two VKA 
monitoring strategies.   
Chapter 6 presents the cost-effectiveness analysis of using apixaban compared to VKAs for 
the prevention of stroke in non-valvular AF in the Netherlands. Using a previously 
developed Markov model (8,9), updated with the most recent Dutch costs and 
epidemiological data, the incremental cost-effectiveness ratio (ICER) of using apixaban 
compared to VKAs was €10,576 per quality adjusted life year (QALY). These results from 
the healthcare provider’s perspective require confirmation from the studies on “real life” 
long-term benefits of the use of apixaban, primarily regarding the patients’ adherence, 
and extension to aspects relevant within broader societal perspective inclusive production 
losses (10). 
For the VTE indication, NOACs are not yet included in the Dutch reimbursement system. 
To support any further future decision-making on reimbursement, a formal 
pharmacoeconomic comparison of NOACs and standard treatment (i.e. VKAs) was needed. 
Thus, Chapter 7 explored the cost-effectiveness of dabigatran, another NOAC, for 
treatment and secondary prevention of VTE. In contrast to Chapters 3, 5 and 6, in which 
the economic analyses were performed from a healthcare provider’s perspective, the 
base-case analysis in this study considered the societal perspective. This perspective is 
preferred by the Dutch authorities. The base-case findings indicated that patients on 
dabigatran would gain an additional 0.585 discounted QALYs over a lifetime time horizon 
and savings of €1,996 per patient. Chapter 7 explored various scenarios comparing 





patients. All scenarios consistently showed dabigatran to be a cost-saving alternative to 
VKAs. Finally, scenarios comparing the use of dabigatran and VKAs from the healthcare 
provider perspective and comparing dabigatran to placebo for the prevention of recurrent 
VTE in patients who are at equipoise for anticoagulation treatment, indicated the ICERs for 
dabigatran compared to VKAs of €1,005 and €33,305 per QALY gained, respectively. 
PROVIDING ROBUST PHARMACOECONOMIC EVIDENCE IN CARDIOVASCULAR 
DISEASES (PRIMARY) PREVENTION 
Healthcare decision making bodies recognize and/or require pharmacoeconomic evidence 
to guide or assist in allocating healthcare resources in many developed countries (11). In 
particular, decisions to reimburse pharmacological innovations for prevention of CVD 
often need to be firmly grounded on both the evidence of added therapeutic value in 
comparison to standard or usual intervention, and pharmacoeconomic evidence. 
Moreover, if local health and economic parameters change, pharmacoeconomic evidence 
is needed to guide changes in policy or reimbursement. Therefore, due to the health and 
economic implications of health policy and reimbursement decisions, the most robust 
evidence is needed nowadays. In that respect health technology assessment (HTA) has 
rapidly evolved in the recent decades. 
Various country-specific and international guidelines for conducting pharmacoeconomic 
analyses assist analysts in providing sound and valid evidence. Some of the matters 
addressed by guidelines concern: the quality of health and economic inputs, modelling, 
sensitivity analyses, discounting future health effects and costs, etc. In assessing 
pharmacoeconomic evidence on interventions in CVD prevention, analysts can apply 
general methodological standards and criteria addressed in aforementioned guidelines. 
Yet, in Chapter 1 of this thesis, it was suggested that the standards or solutions to some 
potential challenges in analyses on interventions in (primary) CVD prevention are still to 
be faced. 
One challenge relates to the common preference of the healthcare decision making 
bodies to assess the effectiveness of interventions with respect to their impact on life 
expectancy and quality of life rather than intermediate (surrogate) outcomes. Specifically, 
this can be a major issue in analyses on interventions in primary CVD prevention. Here, 
preventive interventions are indicated in patients with no medical history of hard clinical 
CVD events. Commonly, only short-term treatment effectiveness evidence (e.g. 
modification of CVD risk factor levels) is measured in clinical trials on pharmacological 
interventions for primary CVD prevention. For short-term effectiveness evidence to be 
incorporated into a pharmacoeconomic analysis, surrogates need to be projected to long-
term hard clinical endpoints (e.g. fatal or non-fatal CVD events). In various studies, the use 
of CVD risk prediction models has already been established to provide the aforementioned 




analyses incorporating CVD risk prediction models (Chapter 2) indicated a lack of 
standardisation and quality consideration as well as failure to exactly report the 
implications of incorporating these models with their specific methodologies. To provide 
robust pharmacoeconomic evidence in analyses incorporating CVD risk prediction models, 
it may be beneficial to specify and expand methodological criteria and considerations (12). 
For example, a risk model can actually only be applied after the compatibility of the risk 
model and the study populations has been thoroughly investigated and assessed. 
Furthermore, to enhance the transparency of methods applied, the study should report 
the method used for the translation of cumulative risks to short-term probabilities and 
should clearly describe the method behind extrapolating this risk to longer time horizons, 
if applicable. Finally, the uncertainty surrounding risk predictions should be incorporated 
in a transparent way in the estimation of the overall uncertainty of the 
pharmacoeconomic model. Thus, by examining current practices and identifying areas for 
improvement in selecting and utilizing CVD risk prediction models in pharmacoeconomic 
analyses, we specified and proposed methods for enhancing the robustness of such 
studies. Moreover, we used these caveats and recommendations when conducting and 
interpreting the findings of the pharmacoeconomic analysis in Chapter 3. In this analysis, 
we used the modified SCORE CVD risk model to project surrogate endpoints on lowering 
SBP to hard CVD endpoints. This model was selected due to the similarity between the risk 
model’s and study’s populations characteristics, and its established validity in the Dutch 
population. Furthermore, the methods used for translating cumulative 10-year risk to 
short-term probabilities and extrapolating those risks to a lifetime horizon were explicitly 
reported. Finally, the uncertainty surrounding risk predictions was provided in such a form 
that could be incorporated in the overall probabilistic analysis.  
Another challenging issue in conducting pharmacoeconomic analyses, in particular cost-
utility analyses, on interventions in CVD prevention and/or treatment relates to the 
robustness of evidence on the HRQoL values used. When multiple HRQoL values are 
available in literature, analysts often select a value assessed in a setting and using a 
patient population that is comparable to their study/country. This seems highly 
reasonable, but still may not be fully robust. Solid methods for evidence-synthesis can be 
considered here as a potential tool for optimizing strategies confronting this challenge 
(14-16). Importantly, not only may evidence-synthesis provide summary data that is 
considered as the evidence of highest level in the hierarchy of evidence, but it can also 
indicate the level of heterogeneity in the HRQoL values assessed across the studies (17). In 
fact, the main finding of our evidence synthesis of HRQoL values in stable angina, post-ACS 
and, in general CHD (Chapter 4) was the indication of large heterogeneity within and 
between the instrument-specific values and inherent uncertainty if applied within cost-
utility analysis. This finding was despite the fact that this evidence-synthesis was 





correlation between the instrument-specific values and a number of study-level 
covariates. Heterogeneity detected between the instrument-specific values may be partly 
explained by underlying methodological differences across the HRQoL instruments used. 
Still, the unobserved patients’ characteristics (e.g. socio-economic, ethnical, religious 
characteristics, etc.) are potentially of even greater concern as crucially contributing to the 
overall heterogeneity. Thus, evidence-synthesis may be considered as a relevant tool to, 
where appropriate, synthesize HRQoL values in specific CVD disorders as well as to 
indicate the level of heterogeneity and possibly its sources across the studies. In this 
manner, robustness of HRQoL values used to inform cost-utility analyses on interventions 
in CVD prevention and/or treatment can be further enhanced. 
In general, we conclude that conducting pharmacoeconomic analyses on interventions in 
CVD prevention can be confronted with challenges, with solutions not yet specified in 
pharmacoeconomic guidelines. Addressing these challenges could benefit from further 
standardization ideally with a consensus on methodological requirements and 
recommendations across pharmacoeconomic guidelines (18). In this thesis, we tackled 
some of the challenging issues and provided recommendations that could assist in 
providing more robust pharmacoeconomic evidence on interventions in CVD prevention. 
In fact, the expected benefit of standardizing methodological requirements and 
recommendations for conducting and reporting pharmacoeconomic analyses including the 
ones proposed in this thesis is to enhance the quality and validity of pharmacoeconomic 
analyses as well as reduce possible bias (19).  
DIRECT IMPLICATIONS FOR CURRENT PRACTICE: VITAMIN K ANTAGONISTS OR 
NOVEL ORAL ANTICOAGULANTS IN THE DUTCH SETTING? 
The work in the thesis may have some direct societal relevance and impact. During the last 
60 years, VKAs have been established as highly effective anticoagulant treatment, shown 
to reduce the risks of thromboembolic events in a number of clinical situations (20). Yet, 
their position has recently been challenged when the European Medicines Agency granted 
market authorizations to NOACs (e.g. dabigatran, rivaroxaban, apixaban) for prevention of 
stroke in AF, and treatment of VTE. Notably, for NOACs to compete for the market share 
of VKAs, reimbursement approval is essential. In the Netherlands, health authorities 
require pharmacoeconomic evidence in reimbursement submissions. This evidence should 
indicate whether there is an economic rationale next to added value of innovative 
treatment (i.e. NOACs) compared to standard treatment (i.e. VKAs). Moreover, the health 
and economic consequences associated with possible improvements in the quality of 
standard care should be assessed. 
In the Dutch healthcare system, the quality of anticoagulation care performed by 
specialised anticoagulation testing centres is measured with the percentage of patients on 




Notably, the estimate of approximately 80% for quality of anticoagulation care in the 
Dutch setting may be considered high (5). This suggests that further investments into 
optimizing the standard anticoagulant care with VKAs may be considered as an alternative 
to switching to NOACs. INR monitoring with PST and/or PSM may be considered as an 
alternative approach to optimizing the standard anticoagulant care with VKAs. This 
monitoring alternative was shown to be associated with lower occurrence of 
thromboembolic and haemorrhagic complications in patients on long-term indication for 
anticoagulation with VKAs, when compared to monitoring in specialized anticoagulation 
centres (21-24). Although PST and/or PSM is more costly than monitoring in Dutch 
specialized anticoagulation centres, Chapter 5 showed that increasing its market share 
would lead to overall cost-savings due to lower total direct medical costs driven by lower 
complication-related costs. However, using point-of-care devices solely for PST resulted in 
greater expenditures compared to testing in anticoagulation centres. Additionally, this 
study indicated less favourable findings of using PST and/or PSM in patients with atrial 
fibrillation. 
Furthermore, anticoagulant treatment with NOACs was proven to be superior or at least 
non-inferior to VKAs for thromboprophylaxis, but also free from the need for regular INR-
monitoring (25,26)(27,28). Yet, some concerns of clinicians and decision makers regarding 
the use of NOACs are still unresolved. These reflect the scarcity of antidotes for treatment 
with NOACs (29), real-world adherence to NOACs and finally the economic consequences 
in different treatment indications. In this thesis, to tackle some of the concerning issues 
regarding the use of NOACs, we examined the health and economic consequences 
associated with the use of apixaban for the prevention of stroke in non-valvular AF 
(Chapter 6) and the use of dabigatran for treatment and prevention of VTE in the Dutch 
setting (Chapter 7). Both apixaban and dabigatran were found to be favourable 
alternatives to treatment with VKAs. Both studies importantly contributed to discussions 
on reimbursement of NOACs in the Netherlands. Notably, the one on dabigatran was part 
of the formal submission to the Dutch authorities by the manufacturer. Importantly, given 
that these findings were based on RCTs evidence where drug adherence is usually up to 
100%, further analyses are needed to examine the pharmacoeconomic findings that 
reflect real-world adherence. Moreover, future research should also allow for comparison 
between the VKAs managed with PST and/or PSM and NOACs. This was currently 
hampered due to the lack of RCTs comparing VKAs managed with PST and/or PSM and 
NOACs. 
We can conclude that in the Dutch setting, NOACs may present a valuable alternative to 
VKAs for thromboprophylaxis, supported by various other studies (30-32)(33). Still, fine-
tuning of recommendations for the most optimal anticoagulant treatments in the 
Netherlands will require continuous confirmation and adaptation based on real-world 
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Cardiovascular diseases (CVD) account for a major share of overall morbidity and 
mortality worldwide and significantly strain healthcare budgets. In reducing some of 
this burden, pharmacological interventions for preventing CVD can be considered. 
Notably, the decisions to implement pharmacological interventions in clinical practice 
have to be made with respect to both health and economic consequences associated 
with their use. 
In this thesis, some of the methodological challenges in simulating and synthesizing 
pharmacoeconomic evidence in CVD prevention were assessed and potential 
solutions to those challenges were proposed. This includes a set of recommendations 
for enhancing the robustness of pharmacoeconomic analyses that apply CVD risk 
prediction models. The application of these recommendations was also explored in a 
simplified model of primary CVD prevention with antihypertensives. Another 
challenging issue relates to the robustness of evidence on the health-related quality 
of life (HRQoL) values used in pharmacoeconomic analyses. Here, evidence-synthesis 
was suggested as a relevant approach to, where appropriate, synthesize HRQoL 
values in specific CVD disorders as well as to indicate the level of heterogeneity 
across those values and possibly its sources. As an example, evidence-synthesis of 
instrument-specific HRQoL values in coronary heart disease and its underlying 
disease-forms was explored. In this study large heterogeneity within and between 
the instrument-specific values and inherent uncertainty if applied within 
pharmacoeconomic analysis, were found. 
This thesis also derives pharmacoeconomic evidence on the use of oral 
anticoagulants (i.e. vitamin K antagonists (VKAs) and novel oral anticoagulants 
(NOACs) e.g. apixaban, dabigatran) for secondary CVD prevention that may have 
direct societal relevance and implications in the Dutch setting. Firstly, optimizing the 
standard anticoagulant care with VKAs was explored. Secondly, the health and 
economic consequences associated with the use of apixaban for the prevention of 
stroke in non-valvular atrial fibrillation, and dabigatran for treatment and prevention 
of venous thromboembolism indicated that both apixaban and dabigatran were 
favourable alternatives to treatment with VKAs. 
In conclusion, several studies in this thesis emphasize that standardizing 
methodological requirements and recommendations for conducting and reporting 
pharmacoeconomic studies in CVD prevention including the ones proposed in this 
thesis may enhance the quality and validity of pharmacoeconomic evidence and 
reduce possible bias. Furthermore, this thesis provides pharmacoeconomic evidence 







Cardiovasculaire ziekten (CVZ) zijn verantwoordelijk voor een belangrijk deel van de 
algehele morbiditeit en mortaliteit wereldwijd en hebben daarmee een significante 
invloed op de gezondheidszorgbudgetten. Om deze last enigszins te reduceren, kan 
farmacologische interventie voor preventie van CVZ worden overwogen. In het 
bijzonder moeten de beslissingen om farmacologische interventies te implementeren 
in de klinische praktijk worden gemaakt tegen de achtergrond van zowel de 
consequenties voor de gezondheid als de economische consequenties van het 
gebruik ervan. 
In dit proefschrift zijn een aantal methodologische uitdagingen in het simuleren en 
synthetiseren van farmaco-economisch evidence in CVZ-preventie vastgesteld en zijn 
potentiële oplossingen aangedragen. Deze bevatten een aantal aanbevelingen voor 
het verbeteren van de robuustheid van farmaco-economische analyse waarin CVZ-
risicoschattingsmodellen worden toegepast. Het toepassen van de aanbevelingen is 
ook verkend in een vereenvoudigd model voor CVZ-preventie door middel van het 
gebruik van antihypertensiva. Een andere uitdaging wordt gevormd door de 
robuustheid van de in farmaco-economische analyses gebruikte waarden voor health 
related quality of life (HRQoL). Hier wordt evidence-synthese voorgesteld als een 
relevante aanpak om, waar toepasbaar, HRQoL-waarden in specifieke CVZ-
stoornissen te synthetiseren alsmede om het niveau van heterogeniteit tussen deze 
waarden en mogelijk haar oorsprong aan te duiden. Bij wijze van voorbeeld zijn 
evidence-synthese van instrumentspecifieke HRQoL-waarden in coronaire hartziekte 
en haar onderliggende ziektevormen verkend. In deze studie werden een hoge 
heterogeniteit binnen en tussen de instrumentspecifieke waarden en inherente 
onzekerheid wanneer toegepast in farmaco-economische analyse gevonden. 
In dit proefschrift wordt ook farmaco-economische evidence voor het gebruik van 
orale anticoagulantia afgeleid voor secundaire CVZ-preventie die directe 
maatschappelijke relevantie en implicaties kunnen hebben in de Nederlandse 
situatie. De beschouwde anticoagulantia zijn vitamine-K antagonisten (VKAs) en 
nieuwe orale anticoagulantia (NOACs), zoals bijvoorbeeld apixaban en dabigatran. 
In de eerste plaats is de optimalisatie van de standaard trombosedienst met VKAs 
onderzocht. In de tweede plaats zijn het de economische en 
gezondheidsconsequenties gekoppeld aan het gebruik van apixaban voor de 
preventie van beroerten in niet-valvulaire atriumfibrillatie en dabigatran voor de 
behandeling en preventie van veneuze trombo-embolie die laten zien dat zowel 
apixaban als dabigatran te prefereren alternatieven zijn voor behandeling met VKAs. 
Concluderend kan worden gesteld dat verscheidene studies in dit proefschrift 




aanbevelingen voor het uitvoeren en rapporteren van farmaco-economische studies 
in CVZ-preventie, waaronder de in dit proefschrift voorgestelde, de kwaliteit en 
geldigheid van farmaco-economisch bewijs verbeteren alsmede de mogelijke bias 
verkleinen. Voorts verschaft dit proefschrift farmaco-economische evidence dat 
NOACs een waardevol alternatief kunnen zijn voor VKAs voor tromboprofylaxe in de 
Nederlandse situatie. 
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